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General introduction and outline of the thesis 
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Chapter 1 
Focal segmental glomerulosclerosis (FSGS) is a disease entity defined by findings on kidney 
biopsy. The classical lesion of focal segmental glomerulosclerosis (FSGS), as first described 
by Rich in 1957, is characterized by the presence of a scarring lesion in a portion (segment) 
of some (focal), but not all glomeruli.1;2 The scar comprises increased mesangial matrix with 
collapsed glomerular capillaries, an adhesion between the tuft and Bowman’s capsule, and 
hyaline deposits. The glomerular scar can be accompanied by features such as mesangial 
hypercellularity and foam cells. Progressive lesions are characterized by periglomerular and 
tubulo-interstitial fibrosis. In immunofluorescence deposits of IgM and C3 are often found in 
the sclerotic areas, a result of non-specific trapping of these proteins and not evidence of an 
immunologic process. It is important to realize that FSGS is a histologic diagnosis and not a 
single disease entity.3 FSGS can be idiopathic (primary; unknown cause) or secondary (with 
underlying cause; table 1). 
Etiology and pathogenesis of FSGS 
Idiopathic FSGS 
For most patients with FSGS the pathogenesis is largely unknown. However, there is strong 
evidence that idiopathic FSGS may be the result of a circulating factor or factors that alter 
the permeability of glomeruli.4-6 The best evidence supporting the presence of a circulating 
permeability factor comes from recurrent FSGS after renal transplantation. Proteinuria may 
develop within a few days after transplantation, and plasma exchange instituted early in the 
course of recurrent disease removes the putative factor and results in a remission of 
proteinuria.7 In addition, rats infused with serum from patients with recurrent FSGS develop 
proteinuria.8;9 More recent data paint a more complicated picture, suggesting that the 
increased permeability may be due to the absence or the loss of an inhibitor for the 
permeability factor.10 Studies using isolated perfused glomeruli show that addition of normal 
serum abrogates the permeability activity of FSGS serum.11
Damage to the podocyte plays an important role in the development of FSGS (as discussed 
below). In addition, animal models resembling idiopathic FSGS and studies in humans 
suggest that injury to the parietal cells (PECs) also contributes to the development of 
idiopathic FSGS.12;13 In these studies proliferating cells in Bowman’s capsule were derived  
from the parietal epithelium. It is hypothesized that the PECs start to proliferate secondary to 
injury of the podocyte aimed at replacing damaged or injured podocytes.14
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Table 1. Etiologic classification of FSGS (adapted from D’Agati et al.15 ) 
Idiopathic (primary) FSGS 
Secondary FSGS 
 1. Familial 
A. Mutations in Į-actinin 4 
B. Mutations in nephrin 
C. Mutations in podocin 
D. Mutations in WT-1 
E. Mutations in CD2-associated protein 
F. Mutations in TRPC 6 
G. Mitochondrial cytopathies 
 2. Virus associated 
A. HIV-associated nephropathy  
B. Parvovirus B19 
 3. Medication 
A. Heroin-nephropathy 
B. Interferon-Į
C. Lithium 
D. Pamidronate / Alendronate 
 4. Adaptive structural-functional responses likely mediated by glomerular hypertrophy or hyperfiltration 
  4.1 Reduced renal mass 
   A. Oligomeganephronia 
   B. Unilateral renal agenesis 
   C. renal dysplasia 
   D. Cortical necrosis 
   E. Reflux nephropathy 
   F. Surgical renal ablation 
G. Chronic allograft nephropathy 
H. Any advanced renal disease with reduction in functioning nephrons 
 . 4.2 Initially normal renal mass  
   A. Diabetes mellitus 
   B. Hypertension 
   C. Obesity 
   D. Cyanotic congenital heart disease 
   E. Sickle cell anemia 
 5. Malignancy (lymphoma) 
Nonspecific pattern of FSGS caused by renal scarring in glomerular disease 
  A. Focal proliferative glomerulonephritis (IgA nephropathy, lupus nephritis, pauci-immune focal  
   necrotizing and crescentic glomerulonephritis) 
B. Hereditary nephritis (Alport syndrome) 
C. Membranous glomerulopathy 
D. Thrombotic microangiopathy 
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Secondary FSGS 
With our increase in knowledge, the number of secondary causes has steadily grown (table 
1). Secondary forms of FSGS were generally considered to result from maladaptive 
responses that occurred due to the loss of functioning nephrons, hyperfiltration or increased 
glomerular pressure. 
Based on studies in experimental animal models such as the remnant kidney model in the rat, 
Kriz et al. demonstrated that loss of podocytes was pivotal in FSGS resulting from these 
maladaptive responses.16 Of note, all animal models used, had evidence of glomerular 
hyperfiltration, hypertrophy or increased glomerular pressure. Based on these studies, Kriz 
proposed that the following sequence of events results in FSGS (figure 1): which starts with 
injury to the podocyte. The damaged podocytes detach from the glomerular basement 
membrane (GBM), ultimately followed by loss of the entire cell into Bowman’s space. 
Because podocytes are incapable of regenerative replication, loss of podocytes cannot be 
replaced, which leads to areas of “bare” GBM. Next, parietal epithelial cells covering 
Bowman’s capsule attach to the bare GBM, leading to the formation of an adhesion between 
the capillary tuft and Bowman’s capsule. At the site of the adhesion a gap in the parietal 
epithelium comes into existence. 
Figure 1. Schematic to show the development of focal segmental glomerulosclerosis secondary to 
maladaptive responses. (A) Normal glomerulus with vascular and urinary poles. Podocytes are shown 
in blue, parietal epithelial cells in red. The GBM is shown in black, the parietal basement membrane in 
yellow, tubular epithelia are shown in white. (B) A dilated and podocyte-denuded capillary is attached 
to Bowman's capsule. The attachment is accomplished by the affixation of parietal cells to the naked 
GBM. Thereby a gap in the parietal epithelium has come into existence, permitting filtration/exudation 
towards the cortical interstitium (arrow). (C) The adhesion has spread to neighboring capillaries 
resulting in either the collapse or in hyalinosis (shown in a dark grey pattern) of the involved 
capillaries. Podocytes at the flanks of the adhesion degenerate. The parietal epithelium may either 
appose those podocytes (arrowhead) or attach directly to the GBM at the flanks of the adhesion. Fluid 
leakage from perfused capillaries inside the adhesion has created a paraglomerular space (shown in 
yellow) that contains the sclerotic tuft remnants (that is, collapsed or hyalinized GBM formations). 
Towards the cortical interstitium this paraglomerular space has become separated by a layer of sheet-
like fibroblast processes (shown in green). (D) Via the vascular pole the sclerotic process has reached a 
further lobule. A small "intact" tuft remnant protrudes into the urinary space still covered by the 
parietal epithelium. The sclerotic tuft remnants are located outside the parietal epithelium in the 
paraglomerular space that is separated from the cortical interstitium by a complete layer of cortical 
fibroblasts. Even in those late stages of injury perfused capillaries are regularly found within the 
sclerotic regions, probably accounting for the further expansion of the paraglomerular space that may 
extend onto the proximal tubule. In even later stages fibroblasts will invade the sclerotic area, resulting 
in fibrous organization. Reprinted with permission.16
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If the attached capillary is still functioning, fluid leaks into the gap in the parietal epithelium 
(misdirected filtration), leading to the formation of a fluid-rich periglomerular space. Then 
fibroblasts are stimulated which results in periglomerular and tubulointerstitial fibrosis. The 
continuing misdirected filtration and podocyte loss results in a further expansion of the 
adhesion. Inside an adhesion eventually capillaries collapse or become occluded either by 
deposition of hyaline material or microthrombosis. 
In recent years the list of secondary causes has steadily grown and now also includes FSGS 
not related to glomerular hyperfiltration (table 1). FSGS may result from direct injury to the 
podocytes due to viral infections (HIV) or the use of drugs (pamidronate/alendronate).17;18
Familial FSGS and FSGS secondary to sporadic mutations 
The podocyte also plays an important role in familial forms of FSGS. The podocyte is a 
terminally differentiated cell that contains a contractile system composed of actin, myosin II, 
Į-actinin-4, talin and vinculin (figure 2).19 The actin filament bundles form arches between 
foot processes of the same podocyte.20 Foot processes are anchored to the underlying GBM 
via Į3ȕ1 integrin complexes and dystroglycans.21;22 Neighboring foot processes are 
connected by cell-cell junctions, the glomerular slit diaphragm, which constitutes the main 
size selectivity filter barrier in the kidney.23;24 Important slit diaphragm proteins are nephrin, 
an adhesion and signaling protein that bridges the slit between foot processes; podocin, 
which targets nephrin into lipid raft microdomains and facilitates nephrin signaling and 
CD2AP which interacts with nephrin and podocin.25-30 A recent discovered slit protein is 
TRPC6, a non-selective cation channel.31 TRPC6 colocalizes to the slit diaphragm with 
nephrin, podocin, and CD2AP; in addition, alterations in TRPC6 calcium currents appear to 
be central to the ability of the podocyte to regulate intracellular and cytoskeletal behaviour.32
During recent years, several mutations in genes encoding for these structural proteins in the 
podocyte and slit diaphragm have been identified in familial forms of FSGS. 
Mutations in nephrin cause a severe type of nephrotic syndrome in newborns (Finnish type 
congenital nephrotic syndrome).33 These infants are born prematurely, edema is present at 
birth or appears within a few days. End-stage renal disease develops most often within 3-8 
years. Podocin mutations were first described in children with familial steroid-resistant 
nephrotic syndrome.34 These patients show rapid progression to ESRD. Podocin mutations 
have also been reported in a few familial cases of FSGS with adolescent or adult onset.35
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autosomal dominant form of FSGS.37 These patients tend to present in the teenage years or 
later. FSGS caused by Į-actinin-4 mutations runs a more slowly progressive course 
compared to FSGS caused by mutations in nephrin and podocin.40 A mutation in TRPC 6, a 
nonselective calcium channel expressed on podocytes, has recently been identified as a cause 
of autosomal dominant FSGS.38 The exact mechanism resulting in FSGS is not known.41
Proteinuria usually develops between the age of 20 and 50 years and the duration from onset 
to ESRD averages 10 years.32;38
A special form of inheritable FSGS is caused by podocytic mitochondrial DNA mutations.42
The mutation has been associated with the MELAS syndrome and more recently with 
maternally inherited hearing loss, diabetes mellitus, cardiomyopathy and progressive 
opthalmoplegia.43-46 However, FSGS can be the only clinical feature.42
Sporadic (non-familial) mutations in adults with FSGS are rare, with a reported prevalence 
of 1.5-5%.47-49 He et al. screened 78 adult patients with non-familial FSGS (15 steroid-
sensitive and 63 steroid-resistant) for known mutations in the podocin gene. Compound 
heterozygous mutations were detected in only one patient with steroid-sensitive FSGS, no 
homozygous mutations were found. These results are consistent with the findings of Caridi et
al, who found only 3 heterozygous mutations in a cohort of 64 patients with steroid-resistant 
nephrotic syndrome.48 The study by He et al. also identified 8 patients with heterozygous 
R229Q. The allele frequency of this variant did not differ from normal controls. The 
significance of the heterozygous R229Q variant as a disease causing mutation in FSGS is 
currently unknown.50 Sporadic mutations in the gene encoding Į-actinin-4 are also rare. 
Aucella et al. found no Į-actinin-4 gene mutations in 33 adults with non-familial FSGS.49
Pathological classification of FSGS 
Over the years, the pathologic description of FSGS has evolved, and in addition to the 
classical form other variants have been described. Recently a group of pathologists proposed 
a new pathological classification for FSGS based on an assessment of glomerular light 
microscopic features (Columbia classification; table 2; figures 3-7). This classification 
presumes exclusion of FSGS caused by glomerular scarring in the course of other idiopathic 
glomerular diseases (table 1).15 The classification defines five main light microscopic 
variants: FSGS not otherwise specified (NOS), tip variant, perihilar variant, cellular variant, 
and collapsing variant. It is important to notice that the presence of sclerosis is no longer  
14
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obligatory for the diagnosis of FSGS, since in particular in the tip-variant and the collapsing 
variant, sclerosis is often absent.  
Although the different variants may reflect different diseases (with different causes and 
differences in pathogenesis), this is not proven. The different variants may be just a 
reflection of a different stage of FSGS, dependent on the activity and time of onset of the 
disease.
Some pathological variants are more likely to occur in relation to certain causes. The 
perihilar variant of FSGS is associated with hyperfiltration, whereas HIV typically results in 
collapsing FSGS.51 However, there is a clear overlap, and patients with idiopathic FSGS may 
present with either variant. Studies that have assessed the clinical relevance of the histologic 
variants are few and conflicting.52;53
Table 2. Morphological variants of FSGS 
Subtype Characteristics Exclusion criteria
NOS variant At least one glomerulus with segmental increase in matrix 
 obliterating the capillary lumen. 
There may be segmental glomerular basement membrane 
 collapse without overlying podocyte hyperplasia 
Exclude perihilar, 
cellular, tip and 
collapsing variant  
Perihilar
variant 
At least one glomerulus with perihilar hyalinosis, with or 
 or without sclerosis  
> 50% of glomeruli with segmental lesions must have 
 perihilar sclerosis and/or hyalinosis 
Exclude cellular, tip 
and collapsing variant 
Cellular 
variant 
At least one glomerulus with segmental endocapillary 
 hypercellularity occluding lumina, with or without 
 foam cells and karyorrhexis 
Exclude tip and 
collapsing variant 
Tip variant At least one segmental lesion involving the tip domain 
 (outer 25% of tuft next to origin of proximal tubule) 
The tubular pole must be identified in the defining lesion 
The lesion must have either an adhesion or confluence of 
 podocytes with parietal or tubular cells at the tubular  
 lumen or neck  
The tip lesion may be cellular or sclerosing 
Exclude collapsing 
variant 
Collapsing 
variant 
At least one glomerulus with segmental or global collapse 
 and overlying podocyte hyperplasia  
None
Adapted from D’Agati et al.15
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Clinical presentation and prognosis 
The data on the clinical characteristics and natural history of patients with FSGS are biased 
by variable inclusion criteria used in the reported studies. Patients with secondary FSGS due 
to hyperfiltration injury will not be biopsied and are often not included in these studies. 
Search for etiological causes has been limited especially in the older studies. In most studies 
patients with idiopathic FSGS will predominate. 
Clinical presentation 
FSGS can occur at any age. In adults the mean age at onset varies between 40-50 years.52;54;55
The number of affected males and females is roughly similar with a male to female ratio of 
1:1. Patients with idiopathic FSGS and patients with FSGS secondary to infections, 
medication or genetic mutations typically present with a nephrotic syndrome.56 By 
comparison, patients with FSGS secondary to adaptive structural-functional responses 
(hyperfiltration associated FSGS) usually present with a more indolent course without 
hypoalbuminemia or edema, even when proteinuria exceeds 3-4 g/day.56;57 In addition to 
proteinuria, microscopic hematuria and hypertension are common presenting features of both 
idiopathic and secondary FSGS.  
Prognosis 
Both the amount of proteinuria and the level of plasma creatinine are of prognostic 
significance. Patients with a serum creatinine concentration below 115 ȝmol/l at presentation 
have a better renal survival rate than those with higher serum concentrations.58;59 Prognosis is 
excellent in patients with non-nephrotic proteinuria, whereas patients with a proteinuria > 3 
g/day have a 50% change of reaching ESRD within 5-10 years.60 Renal survival is even 
worse if proteinuria exceeds 10 g/day, with the majority of patients reaching ESRD within 5 
years after presentation. In contrast, attainment of a partial or complete remission of 
proteinuria (either spontaneous or after steroid treatment) heralds a favorable prognosis, with 
respectively less than 15% and 2% of such patients developing ESRD.61
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Recurrent FSGS after renal transplantation 
FSGS can recur after renal transplantation.62 The reported recurrence rate varies between 20-
50%.63-65 Recurrence rate is especially high in patients younger than 20 years of age, in 
patients with a rapid clinical course of their original disease with development of ESRD 
within 3 years and also in patients with evidence of mesangial proliferation in their native 
kidney.65-67 It is very likely, that the majority of patients with recurrent disease have 
idiopathic FSGS. Analysis of our own data showed that FSGS mainly recurred in patients 
with idiopathic FSGS defined by strict clinical criteria.68 These patients had a recurrence rate 
of 61%. We did not observe a recurrence in patients with secondary FSGS, except for one 
patient (7%) with a family history of FSGS. Although one might expect that patients with 
genetic mutations would not develop recurrent FSGS in the renal transplant, multiple reports 
have described recurrent disease in patients with mutations in nephrin and podocin.69-72
Recurrence of proteinuria has been described in 20% of children with a congenital nephrotic 
syndrome (nephrin mutation). The recurrence seems to be mediated by the development of 
anti-nephrin antibodies.69 In the absence of nephrin, the fetus does not develop tolerance 
against the protein. Following renal transplantation, the patient develops an immune response 
to nephrin, expressed on the renal graft. 
Recurrent disease has also been reported in approximately 8% of patients with homozygous 
or compound heterozygous podocin mutations.73 The recurrence of proteinuria in these 
patients was initially attributed to other mechanisms than circulating permeability factors. As 
observed in patients with the congenital nephrotic syndrome, the development of 
autoantibodies against the unmutated protein of the transplanted kidney seemed a convincing 
alternative explanation. However, so far, no antipodocin antibodies were detected in affected 
patients.70;72 A study by Carraro et al. suggests that the permeability factor may  also play a 
role in patients with podocin mutations.74 Using an in vitro assay, these authors demonstrated 
the presence of the permeability factor in two patients with a heterozygous podocin 
mutations. These patients also responded to treatment with plasma exchange, which 
strengthens the hypothesis that possibly both genetic and endogenous factors are involved in 
the recurrence of FSGS. Without treatment prognosis is poor in patients with a recurrence of 
FSGS after renal transplantation, and approximately half of the patients will loose their graft  
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within 5 years.64;66 Treatment with plasma exchange can induce a remission of proteinuria, 
however long-term effects of plasma exchange are less well known.7
Outline of the Thesis 
Despite our current knowledge, FSGS remains an enigmatic disease. The aim of this thesis 
was to gain more insight into FSGS, and to better define risk factors and outcome. This 
knowledge should allow better treatment of individual patients.  
The first two chapters are dedicated to clinical parameters that can predict response to 
therapy and remission in idiopathic FSGS. In chapter 2 we studied the clinical course of 
idiopathic FSGS in initially untreated patients. In this group of patients we have tried to 
define clinical parameters that allow to predict a spontaneous remission and renal prognosis. 
Important parameters were serum albumin and selectivity of proteinuria. Previous data 
suggest that fractional excretion of IgG (FE IgG) may predict remission of proteinuria and 
could also be helpful in the identification of patient at risk for development of ESRD. In 
chapter 3 we evaluated the usefulness of urinary proteins to predict remission rate, response 
to therapy and renal outcome of patients with idiopathic FSGS.  
The next two chapters examine the prognostic value of FSGS lesions. A new histologic 
classification of FSGS has been described that distinguishes 5 mutually exclusive FSGS 
variants on light microscopy. Recognition of these variants may have prognostic value. In 
chapter 4 we have studied the characteristics and renal outcome of FSGS variants in an adult 
Dutch population and evaluated the predictive value of the FSGS variants in comparison to 
other known risk factors for renal failure.  
FSGS lesions can also develop secondary to other glomerular diseases. In membranous 
nephropathy, the existence of FSGS lesions has been associated with a worse renal 
prognosis. In chapter 5, we have evaluated the prognostic significance of FSGS lesions in 
idiopathic membranous nephropathy. In addition, we performed a meta-analysis of studies 
that also evaluated FSGS as prognostic marker in idiopathic membranous nephropathy.  
Differentiating between idiopathic and secondary FSGS is important as misdiagnosis can 
lead to inappropriate treatment with steroids and cytotoxic agents that are not effective in 
secondary forms of FSGS. However, in daily practice distinguishing between idiopathic and 
secondary FSGS can be difficult. We have performed a morphometric study of podocyte foot 
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processes in patients with idiopathic FSGS and FSGS secondary to maladaptive responses. 
The degree of foot process effacement, estimated by foot process width, in these patients was 
compared to foot process effacement in minimal change nephrotic syndrome and normal 
kidneys. We tried to define a cut-off value for foot process width that could predict 
idiopathic or secondary FSGS with a high sensitivity and specificity (chapter 6).
Recurrence of FSGS after renal transplantation is associated with poor graft survival. Plasma 
exchange can reduce proteinuria and can even induce a remission. However, limited 
information is available on the long-term prognosis after treatment with plasma exchange. In 
chapter 7 we describe the follow-up of patients treated with plasma exchange after 
recurrence of FSGS in the renal graft. These patients were compared with a group of 
historical controls, consisting of patients with recurrent FSGS not treated with plasma 
exchange. Although many patients can be successfully treated with plasma exchange, several 
patients require prolonged or repeated courses of plasma exchange because of persistent 
recurrences. Prednisone may be essential in patients with plasma exchange dependent FSGS. 
The role of prednisone in plasma exchange dependent FSGS is discussed in chapter 8.
Rituximab, a chimeric murine/human antibody against the CD20 antigen expressed on 
immature and mature B-cells may be another option in plasma exchange dependent FSGS. In 
children, this treatment induced a remission of proteinuria. In chapter 9 we describe the 
effect of rituximab in a patient with plasma exchange dependent FSGS after a second renal 
transplantation.   
Based on the studies discussed in this thesis and a review of the literature, we provide  
guidelines on diagnosis and treatment of focal segmental glomerulosclerosis in chapter 10.   
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Abstract
Background: Patients with focal segmental glomerulosclerosis (FSGS) are considered to 
have a poor prognosis and spontaneous remissions are seldom reported. However, FSGS is 
not a single disease entity. Our aim was to describe the clinical course in initially untreated 
patients with recently diagnosed idiopathic FSGS.  
Methods: This was a retrospective study of patients with a diagnosis of FSGS by histology, 
who fulfilled the following criteria: proteinuria >3.5 g/day, normal renal function, duration of 
proteinuria or hypertension of less than one year, normal-sized kidneys, no underlying renal 
disease, and a negative family history. Renal biopsies were reviewed without knowledge of 
the clinical course. 
Results: Twenty patients (13 male, 7 female) fulfilled the study criteria. Median age was 
49.3 (range 21.8 to 73.0) years, serum creatinine 90 ± 20 ȝmol/l, proteinuria 10.0 ± 5.5 g/day 
and serum albumin 24 ± 6 g/l. After a median follow-up of 9.4 (2.1-18.6) years, 13 patients 
(65%) were in remission of proteinuria. Renal function deterioration occurred in seven 
patients, and prompted treatment in four of them. The ten-year death-censored renal survival 
was 89%. Renal function deterioration and remission rate could be predicted by selectivity 
index, serum albumin at three months after renal biopsy and the percentage of glomeruli with 
segmental sclerosis.  
Conclusion: Focal glomerulosclerosis is not a single disease. Case definition using strict 
clinical criteria identifies a subgroup of patients with idiopathic FSGS who have a good 
prognosis. In the majority of these patients immunosuppressive therapy is not warranted.
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Introduction  
In recent years focal segmental glomerulosclerosis (FSGS) has become an increasingly 
important cause of the nephrotic syndrome in adults.1,2 In general, prognosis is considered to 
be poor in patients with FSGS and a nephrotic syndrome with up to 50% of patients 
proceeding to end-stage renal disease (ESRD) within five years.3,4 Spontaneous remissions 
are reported to be rare, occurring in less than 6% of untreated patients.4-7 Retrospective 
studies have suggested that complete remissions may develop in up to 60% of patients after 
prolonged treatment with immunosuppressive drugs.6,8 Therefore, a trial of steroid therapy is 
recommended in all nephrotic patients with primary FSGS.3 Attainment of a complete 
remission heralds a favourable prognosis with less than 15% of such patients developing 
ESRD. However, the literature data on prognosis and outcome of patients with FSGS must 
be interpreted with caution since FSGS is a descriptive, histological diagnosis and not a 
single disease entity.9,10
Secondary forms of FSGS occur frequently, and may result from nephron loss (hypoplastic 
kidney, reflux nephropathy), other underlying renal diseases, longstanding hypertension, or 
obesity. If no underlying causes are identified, FSGS is classified as primary, idiopathic 
FSGS. In recent years it has become evident that in some of these patients the disease may be 
caused by mutations in podocyte proteins such as Į-actinin-4 and podocin.11,12
Discrepancies between studies may thus be explained by differences in the distribution of the 
various types of FSGS in the studied populations. For example, in a recent study that 
described the natural history of patients with FSGS, the mean serum albumin of the patients 
was 37 g/l, which strongly suggests that patients with secondary forms of FSGS were 
included.13
We retrospectively studied the outcome in a subgroup of patients with idiopathic FSGS. To 
avoid bias caused by including patients with other types of FSGS as far as possible, we 
applied a set of strictly defined clinical exclusion criteria. Because it was our policy to 
withhold immunosuppressive treatment in the majority of patients with FSGS without renal 
function deterioration, we were able to determine the outcome of FSGS in a cohort of 
untreated patients. 
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Materials and methods 
We identified all patients diagnosed with FSGS between 1980 and 1996 from the pathology 
registry at the Radboud University Nijmegen Medical Centre and affiliated hospitals. Since 
the aim of this study was to assess the clinical course in adult patients with recent-onset 
idiopathic FSGS, we included adult patients (18 years at biopsy) with a proteinuria 3.5 
g/day and a serum creatinine 135 ȝmol/l in the study. To avoid bias by including patients 
with hereditary or secondary forms of FSGS or patients with longstanding disease, the 
following exclusion criteria were used: evidence of hypoplastic kidney, renal agenesia, prior 
nephrectomy, underlying renal disease, obesity (BMI >32 kg/m2), longstanding proteinuria 
(>12 months) or hypertension (>12 months), family history of renal disease, underlying 
malignancy, intravenous drug abuse, evidence of human immunodeficiency virus (HIV) 
infection or renal insufficiency (serum creatinine >135 ȝmol/l). During the study period most 
nephrologists in the participating hospitals considered FSGS to be prednisone resistant, 
based on the available data that short-term prednisone therapy was mostly unsuccessful. 
More intensive immunosuppressive therapy was used in patients with evidence of renal 
function deterioration (increase in serum creatinine >50%).  
All renal biopsies of the patients who were included in our study were reviewed by two renal 
pathologists (KA and ES), who were unaware of patient outcome. A diagnosis of FSGS was 
made using the criteria recently described by D’Agati et al.14 Based on these criteria we 
discerned five light microscopic patterns of FSGS: FSGS not otherwise specified (NOS), 
perihilar variant, cellular variant, tip variant and collapsing variant.  
For quantitative analysis all available glomerular cross-sections were numbered. Twenty-five 
glomerular profiles were selected at random by one of us and these profiles were evaluated 
by the renal pathologist (KA) for the presence of sclerosis, synechia, hyalinosis, collapse of 
the glomerular tuft, podocyte hypertrophy and foam cells. 
Definitions 
End-stage renal disease (ESRD) was defined as a serum creatinine of >450 ȝmol/l or the 
need for renal replacement therapy. Nephrotic syndrome was defined as a proteinuria of >3 
g/day together with a serum albumin of <30 g/l and massive proteinuria was defined as 
proteinuria >10 g/day. Patients with a systolic blood pressure >140 mmHg or a diastolic 
blood pressure >90 mmHg were considered hypertensive. A complete remission was defined  
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as proteinuria <0.2 g/day with a stable serum creatinine <135 ȝmol/l and a partial remission 
was defined as proteinuria between 0.2 g/day and 2.0 g/day with a stable serum creatinine 
<135 ȝmol/l. A relapse was defined as a proteinuria >3.0 g/day after prior reduction of the  
proteinuria to less than 2.0 g/day. Protein selectivity index was calculated as the clearance of 
IgG divided by the clearance of transferrin.15 Proteinuria was considered selective if the 
selectivity index was below 0.2. 
Statistical analysis 
Values are given as means ± SD or median (range) when appropriate. For comparison 
between groups, unpaired T-test or Mann-Whitney U test were used for continuous 
data and Fisher’s exact test was used for categorical data. Cumulative renal survival and 
cumulative remission rates were calculated with Kaplan-Meier survival curves. A p-value of 
0.05 was considered to be the level of statistical significance. 
Results
In the period 1980 to 1996 a diagnosis of FSGS was made in 104 patients. Based on strict 
clinical criteria, 37 of these 104 patients were considered to have recent-onset idiopathic 
FSGS (figure 1). On revision of the renal biopsies a diagnosis of FSGS was confirmed in 28 
patients. FSGS lesions were not present in the biopsies of nine patients. The renal biopsies of 
these patients showed early lesions consisting of hyalinosis and/or foam cells and/or collapse 
of the glomerular tuft and/or glomerular epithelial cell hypertrophy and/or mesangial 
hypercellularity. Twenty patients were initially not treated, and they form the basis of this 
study. Thirteen out of these 20 patients received an angiotensin-converting enzyme inhibitor 
(ACEi), which was standard therapy for patients with proteinuria after 1988. Patient 
characteristics at biopsy of the 20 patients are presented in table 1.
For comparison we have also provided the characteristics of the patients (n=8) who were 
treated with prednisone within a few months after the renal biopsy. Twenty-seven patients 
were Caucasian and one patient was Indonesian. A nephrotic syndrome was present in all 
patients, except for one patient who had a serum albumin of 43 g/l at biopsy. Proteinuria >10 
g/day was present in ten patients. The findings on renal biopsy are presented in table 2. Most 
patients were classified as tip variant; only three patients had FSGS-NOS. All patients 
studied had evidence of diffuse foot process effacement. 
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Figure 1. Flow chart of selection of patients with idiopathic focal glomerulosclerosis.
104 patients diagnosed as 
having FSGS 
80 patients 
24 patients excluded 
x duration of proteinuria > 1 yr n =18 
x proteinuria < 3.5 g/day n = 2 
x hypertension > 1 yr n = 4 
     
30 patients with secondary FSGS 
x hypoplasia/ chronic pyelonephritis n = 12 
x glomerulonephritis n = 7 
x malignancy n = 4  
x familial FSGS n = 3 
x other  n = 4 
50 patients with 
primary FSGS 
13 patients with renal insufficiency 
28 patients with primary FSGS 
fulfilling the inclusion criteria 
   
9 patients without FSGS after 
 revision of the renal biopsy  
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Table 1.  Patient characteristics at biopsy.  
 Initially untreated  Treated  
(n=20) (n=8)
Sex (M/F)  13/7 5/3
Age at biopsy (years)  49.3 (21.8-73.0) 42.4 (19.5-67.4) 
Serum albumin (g/l)  24 ± 6 18 ± 5*
Serum creatinine (ȝmol/l)  90 ± 20 81 ± 17  
Creatinine clearance (ml/min; n=22)  101 ± 34 123 ± 35    
Serum cholesterol (mmol/l; n=23)  11.3 ± 2.3 11.6 ± 2.9   
Proteinuria (g/day)  10.0 ± 5.5 9.8 ± 3.1  
Proteinuria > 10 g/day (n)  7 (35%) 3 (38%)  
Selectivity index (n=23)  0.21 ± 0.09 0.15 ± 0.05  
Hypertension (n)   16 (80%) 4 (50%)  
Systolic blood pressure (mmHg)  155 ± 16 146 ± 13  
Diastolic blood pressure (mmHg)  91 ± 9 82 ± 8*   
Interval presentation-biopsy (months)  2.1 (0.7-10.6) 4.5 (0.7-7.6)  
Follow-up (years)  9.4 (2.1-18.6) 9.2 (4.0-11.2) 
Values are given as means (±SD) or median (range). * p< 0.05 for comparison between treated and untreated 
patients.  
Table 2. Findings in renal biopsies of treated and untreated patients.
 Initially untreated Treated  
(n=20) (n=8) 
Number of glomeruli per biopsy  26 (4-87) 13 (4-62) 
Light microscopy 
 Number of patients with NOS variant   3   2
 Number of patients with tip variant   13 6
 Number of patients with collapsing variant  2    0
 Number of patients with perihilar variant  2    0
Fluorescence microscopy (n=26)*
Number of patients with segmental  17  6                     
Number of patients without depositions      2   1
n = number of patients; * fluorescence microscopy was not available in two patients.
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Outcome of untreated patients 
As mentioned above, 20 patients were initially left untreated. Fourteen of these 20 patients 
developed a spontaneous partial remission. The nephrotic syndrome persisted in six patients. 
Time between biopsy and partial remission varied between 1.4 and 36.7 months, with a 
median of 9.9 months.  
Cumulative incidence of partial remission at one, three and five years after biopsy was 40%, 
73% and 73% respectively. Two patients with a partial response have relapsed, one patient 
had a sustained partial remission, whereas 11 patients developed a persistent complete 
remission of proteinuria. Serum creatinine increased more than 50% in all six patients with a 
persistent nephrotic syndrome and in one patient who relapsed after a partial remission. Four 
of these seven patients were treated with immunosuppressive drugs, either prednisone 
monotherapy (n=1) or prednisone combined with cyclophosphamide (n=3). Patients received 
prednisone at a dose 60 mg/day for an average of 2.5 ± 0.9 months; Thereafter the 
prednisone dose was progressively tapered. Cyclophosphamide was given in a dose of 150 
mg/day for three months. Treatment resulted in a partial remission in one patient, and 
nephrotic range proteinuria persisted in two patients; however, renal function improved in 
both patients and remained stable until the end of follow-up, and one patient progressed to 
ESRD. In the three patients with declining renal function who did not receive 
immunosuppressive drugs, one patient progressed to ESRD, one patient had persistent 
nephrotic proteinuria and one patient had persistent non-nephrotic proteinuria. Renal 
function deteriorated progressively in both patients with persistent proteinuria. Treatment 
with an ACEi was not different between patients who achieved a complete remission (7 out 
of 11) and patients with deterioration in renal function (4 out of 7). 
Table 3. Clinical status at the end of follow-up in treated and untreated patients 
Initially untreated    Treated  
(n=20) (n=8)
Complete remission  11 (55%)  1 (12.5%) 
Partial remission  2 (10%)   1 (12.5%) 
Persistent proteinuria  4 (20%)   2 (25%) 
ESRD* 2 (10%)   1 (12.5%) 
Deceased 1 (5%)   3 (37.5%) 
* End stage renal disease 
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Clinical status at the end of follow-up is given in table 3. One patient (5%) with persistent 
proteinuria died due to a myocardial infarction, 2.3 years after diagnosis. Renal survival was 
100, 84 and 84% at one, five and ten years after biopsy, respectively. Renal survival 
censored for death at one, five and ten years after biopsy was 100%, 89% and 89%. For 
comparison, clinical status at the end of follow-up is also presented for the treated patients 
(table 3).
In this group of initially untreated patients we tried to define the characteristics that would 
allow us to predict prognosis. The following parameters were evaluated: serum albumin, 
proteinuria and protein selectivity index (all measured at the time of biopsy), serum albumin, 
proteinuria and a combination of increased levels of proteinuria or decreased concentrations 
of serum albumin (all measured at three months after biopsy), histological variants of FSGS 
and the percentage of glomerular profiles with sclerosis, synechia or hyalinosis on renal 
biopsy. A higher percentage (>25%) of sclerosis in the glomeruli, nonselective proteinuria at 
the time of biopsy and decreased concentrations of serum albumin at three months after renal 
biopsy were associated with a higher rate of renal failure (table 4).
Table 4.  Predictors of deterioration of renal function in initially untreated patients.  
 Deterioration of renal function* p-value†
Yes No 
 (n=7) (n=13)
Selectivity index‡   
d 0.2 0 8  p<0.01
 > 0.2 7 2
Serum albumin at three months  
 < 20 g/l   4 0 p<0.01
t 20 g/l   3 13
Sclerosis    
 < 25% of glomerular profiles 2 13 p<0.01
t 25% of glomerular profiles 5   0 
* Deterioration of renal function was defined as an increase in serum creatinine of > 50%. 
† P-values were calculated by Fisher’s Exact Test.  
‡ The selectivity index of three patients was not available.
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Discussion
We aimed to study the outcome in a well-defined subgroup of patients with a nephrotic 
syndrome due to idiopathic FSGS. Therefore, we selected patients with FSGS who fulfilled 
strict criteria i.e. normal-sized kidneys, absence of underlying glomerular disorders, negative 
family history of renal disease, no longstanding proteinuria or hypertension, no morbid 
obesity and normal renal function. We observed that more than half of the untreated patients 
showed a spontaneous partial or complete remission of proteinuria, clearly different from 
previous studies in patients with FSGS that report spontaneous remission rates of 6 to 7%.4-
6,16 We feel that our study underlines that FSGS is not a single disease entity, but rather a 
common phenotypic expression (on histology) of various diseases that differ in pathogenesis, 
prognosis and response to therapy.10 This is supported by the fact that literature data on the 
prognosis and outcome of treatment in patients with FSGS are quite diverse. In contrast to 
our study, many studies that report low remission rates have included patients with decreased 
renal function at presentation or at the time of renal biopsy,4,6,17 patients with non-nephrotic 
proteinuria, 16 patients with longstanding proteinuria16,18 and patients with normal serum 
albumin.13 Furthermore, many studies do not mention the specific criteria that were used to  
select patients.  
In recent years it has become evident that FSGS can result from mutations in podocytic 
proteins such as nephrin, Į-actinin-4 and podocin.11,12 Mutations may not only be present in 
patients with familial forms of FSGS but also in some patients with sporadic forms of 
FSGS.19,20 In our patients DNA typing was not performed. 
However, because of our exclusion criteria (family history of renal disease, age <18 years, 
longstanding proteinuria) it is unlikely that patients with mutations were included. Although 
our study is retrospective in nature, we tried to avoid potential bias as far as possible. First, 
we have included all patients derived from the pathology registry. In addition, the 
composition of the study population was based on predefined clinical criteria without 
knowledge of the outcome. Finally, all renal biopsies were revised and only patients with 
typical lesions of FSGS were included. In the period between 1980 and 1996 not all 
physicians adhered to the same treatment strategy. Thus eight patients were initially treated. 
Nevertheless, if untreated and treated patients are grouped together, still 12 out of 28 patients 
with a normal renal function have a persistent spontaneous remission of proteinuria.  
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Four of the initially untreated patients received immunosuppressive therapy after 
deterioration of the renal function. In some of these patients treatment was successful, and 
renal function improved in three out of four patients. Results might have been even better if 
we had used immunosuppressive therapy for a longer period of time, as has been suggested 
by recent studies.4,8,21 If spontaneous remissions occur frequently, it is important to be able to 
predict outcome at an early stage to allow tailor-made treatment. In our patients, nonselective 
proteinuria, a higher percentage of sclerotic lesions on renal biopsy and low levels of serum 
albumin at three months after renal biopsy predicted prognosis. Because of the small number 
of patients in our study we could not define the most predictive variable.  
Recent studies suggest that the occurrence of the ‘tip lesion’ variant of FSGS identifies a 
group of patients with a better prognosis. 22,23 Due to the small number of patients with FSGS 
variants other than the tip lesion we were unable to determine whether the histological 
variant of FSGS can predict the occurrence of a spontaneous remission. However, in 
agreement with our findings, these studies have also demonstrated that a higher percentage 
of sclerotic lesions predicts a worse prognosis.22,23 In a recent study Bazzi et al. concluded 
that the fractional excretion of IgG (FE IgG) predicted prognosis in patients with FSGS.15 
These authors measured FE IgG in 29 patients with FSGS and normal renal function of 
whom 27 were treated. FE IgG could predict remission in 91% and progression to ESRD in 
71% of patients, respectively. This confirms our findings that qualitative markers of 
proteinuria such as FE IgG and selectivity index are important predictive variables.  
In conclusion, clinical criteria allow us to identify a group of patients with recent-onset 
idiopathic FSGS that have a favourable prognosis. Many of these patients will develop a 
spontaneous remission of proteinuria. In these patients immunosuppressive therapy is not 
warranted unless renal function deteriorates. Future studies should allow identification of 
laboratory parameters and histological criteria that predict outcome with high sensitivity and 
specificity.
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Abstract
Aims: Predicting prognosis in patients with a nephrotic syndrome due to primary FSGS 
remains difficult. Recently, it was suggested that the fractional excretion (FE) of IgG 
(threshold 0.14%) predicts remission, progression to renal failure and response to therapy in 
FSGS. In the present study, we evaluated the usefulness of FE IgG to guide treatment of 
patients with primary FSGS in clinical practice. 
Methods: From 1995 onward, FE of IgG was measured in 32 adult patients with biopsy-
proven primary FSGS. In addition, we quantified 24-hour proteinuria, selectivity index (SI) 
and FE of albumin, IgG, transferrin and ȕ2-microglobulin (ȕ2m). We evaluated outcome in 
patients with FE IgG above and below 0.14%. Receiver-operating curves were used to 
determine the best cut-off values for other urinary proteins in predicting remission, response 
to therapy and renal survival. 
Results: Mean age was 45 ± 17 years, serum creatinine 128 ± 58 ȝmol/l, proteinuria 10.3 ± 
4.7 g/day and serum albumin 18 ± 7 g/l. Twenty-three patients received immunosuppressive 
therapy (9 prednisone and 14 prednisone and cyclophosphamide). After a median follow-up 
of 58.3 (4.9–127.6) months, 17 patients were in remission (10 complete, 7 partial), 6 patients 
still had a nephrotic syndrome, renal failure developed in 6 patients, and 3 patients had died. 
Remission rate was similar in patients with FE IgG less or greater than 0.14%. More patients 
with FE IgG  0.14% had received immunosuppressive therapy. Additional analysis revealed 
that the predictive value of FE of albumin, transferrin and ȕ2m was low. In untreated 
patients, FE ȕ2m < 1 predicted a better renal survival.  
Conclusions: Our data indicate that a FE IgG   0.14% is not invariably associated with a 
poor outcome in patients with primary FSGS. Therefore, high FE IgG should not lead to 
therapeutic nihilism. Low FE ȕ2m predicted a good prognosis without immunosuppressive 
therapy. 
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Introduction 
Primary, idiopathic focal segmental glomerulosclerosis (FSGS) is an important cause of the 
nephrotic syndrome in adults, accounting for 15–35% of cases.1;2 Since the first description 
of FSGS by Rich, many authors have emphasized the poor outcome in adult patients with 
FSGS, characterized by unresponsiveness to therapy and progression to end-stage renal 
disease (ESRD).3 However, it is now clear that up to 60% of patients can achieve a remission 
of proteinuria with aggressive corticosteroid therapy.4-6 Patients who attain a partial or 
complete remission have a favorable prognosis, with, respectively, less than 15 and 2% 
progressing to ESRD.7 Treatment of patients with FSGS could be optimized if we could 
predict the likelihood of attaining a remission in an individual patient.  
In patients with membranous nephropathy, we and others have studied the predictive value 
of different urinary proteins. Specifically these studies have evaluated markers of glomerular 
size selectivity (IgG and protein selectivity index) and markers of tubulointerstitial injury 
(the low-molecular weight proteins ȕ2-microglobulin and Į1-microglobulin). Both urinary 
IgG excretion and urinary excretion of low-molecular weight proteins accurately predicted 
disease progression.8-12 Recently, Bazzi et al. reported that in patients with primary FSGS, 
fractional excretion (FE) of IgG predicted remission rate, progression to ESRD and response 
to therapy.13 A cut-off value of 0.14% proved most discriminative with a sensitivity of 87.5% 
and a specificity of 100%. Specifically, remission rate was 0% in patients with a FE IgG 
0.14% despite treatment with steroids and cyclophosphamide. If confirmed, use of this 
parameter could help in guiding the decision to refrain from cytotoxic medication in these 
patients.  
In the present study, we analyzed the predictive value of a threshold of 0.14% for FE IgG for 
remission, response to therapy and renal survival in patients with idiopathic FSGS. In 
addition, we assessed the predictive value of other urinary proteins. 
Subjects and methods 
In our centre, patients with proteinuria are evaluated using a standard protocol. In all these 
patients, standardized urine and blood measurements are performed as summarized below. 
For the present study, we included adult patients (> 18 years at biopsy) with a nephrotic 
syndrome due to idiopathic FSGS, evaluated from 1995 onward. The diagnosis of idiopathic 
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FSGS was established by the presence of a nephrotic syndrome with out evidence for another 
primary glomerular disease in the renal biopsy or a disease associated with secondary 
FSGS.14
The renal biopsy specimens were reviewed by a renal pathologist without knowledge of the 
clinical outcome and categorized according to the criteria described by D’Agati et al.15 Only 
patients with definite pathologic findings of FSGS on light microscopy and either negative 
immunofluorescence or only segmental IgM and/or C3 were considered for the study.  
Standardized measurement of urinary proteins 
Patients came to the ward after an overnight fast. On the evening before the patients had 
taken 4,000 mg of sodium bicarbonate to ensure a urinary pH above 6.0, which is mandatory 
for the measurement of urinary ȕ2-microglobulin. Upon arrival, up to 500 ml tap water is 
given to enforce diuresis. The patients remain supine during 2 hours except for voiding. 
Timed urine samples are collected, and in the middle of the collection period, a blood sample 
is drawn. In addition, two 24-hour samples are collected for assessment of daily excretion of 
total protein and creatinine. 
Laboratory measurement 
Creatinine, cholesterol, albumin, transferrin, IgG, ȕ2-microglobulin (ȕ2m) were measured in 
blood samples. In the timed urine samples we measured creatinine, albumin, transferrin, IgG 
and ȕ2m. Measurement of creatinine was done with the modified Jaffe technique on a 
Hitachi 747 autoanalyzer (Roche, Almere, The Netherlands). The concentration of albumin, 
transferrin and IgG in serum and urine were measured by immunonephelometry on a BNII 
nephelometer (Behring, Marburg, Germany) using antibodies whose specificity was checked 
by Ouchterlony double immunodiffusion and immunoelectrophoresis (Dako, Glastrop, 
Denmark). Urinary and serum ȕ2m were measured by ELISA.15
Calculations 
The amounts of albumin, transferrin, IgG and ȕ2m in the timed urine samples are expressed 
as fractional excretion, using the following formula: (urinary protein/serum protein) × (serum 
creatinine/urinary creatinine) × 100. The selectivity index (SI) was calculated as the 
clearance of IgG divided by the clearance of transferrin. 
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Definitions 
Renal failure was defined as a sustained increase of the serum creatinine of > 50% from 
baseline measurement or progression to end-stage renal disease (ESRD). ESRD was defined 
as a serum creatinine of more than 450 ȝmol/l or the need for renal replacement therapy or 
kidney transplantation. Nephrotic syndrome was defined as proteinuria of  3 g/day in 
association with serum albumin of  30 g/l. A complete remission was defined as proteinuria 
< 0.3 g/day with a stable serum creatinine (< 50% increase from baseline) and a partial 
remission was defined as proteinuria between 0.3 g/day and 2.0 g/day with a stable serum 
creatinine. A relapse was defined as a proteinuria > 3 g/day after prior reduction of the 
proteinuria to less than 2.0 g/day. 
Statistics 
Values are given as means ± SD or median (range) when appropriate. For comparison 
between 2 groups Mann-Whitney U-test was used for continuous data and Fisher’s exact test 
was used for categorical data. Differences in continuous data between more than 2 groups 
were analyzed with use of the Kruskal-Wallis test, with multiple comparison procedures 
(Dunn’s method) for comparison between groups. A p-value < 0.05 was considered as the 
level of statistical significance. Receiver operating characteristics (ROC) curves were used to 
determine the most discriminative threshold for FE albumin, FE transferrin, FE IgG, FE 
ȕ2m, proteinuria and SI in predicting renal failure or persistence of nephrotic syndrome. The 
difference in renal survival and remission rate for the selected thresholds was analyzed with 
Kaplan-Meier statistics. Log-rank test was used for comparison of the Kaplan-Meier curves. 
To adjust for multiple comparisons, a p-value <0.008 was considered as the level of 
statistical significance. 
45
Chapter 3 
Results
Between 1995 and 2002, a total of 32 patients with idiopathic FSGS who fulfilled the 
inclusion criteria, were evaluated. Baseline characteristics are given in table 1. The baseline 
measurement was performed within 16 months from biopsy in 90% of the patients. Nine 
patients had already received a course of immunosuppressive therapy be fore baseline 
measurement. Seven patients were non responsive (prednisone n=2, prednisone and 
cyclophosphamide n=3, prednisone and cyclosporine n=2) and 2 patients, both treated with 
prednisone, had relapsed after a partial remission. Baseline measurement was performed 
without use of immunosuppressive medication. Review of the renal biopsy showed the tip 
lesion in 22 patients (69%) and FSGS NOS in 10 patients (31%). Thirty patients were treated 
with an ACE inhibitor. Twenty-three patients received immunosuppressive therapy, 3.2 
(range 0.03–91) months after the baseline measurement. Nine patients were treated with 
prednisone monotherapy for a median of 6.5 (range 3.9–18.3) months. Fourteen patients 
were treated with prednisone for a median of 6.2 (range 1.3–21.4) months in combination 
with cyclophosphamide for a median of 3 (range 1.3–3.9) months. Prednisone was given as a 
single dose of 1 mg/kg/day and subsequently tapered. Cyclophosphamide was administered 
orally at a daily dose of 1.5–2 mg/kg. The nephrotic syndrome was more severe in patients 
treated with prednisone or prednisone and cyclophosphamide compared to untreated patients. 
In addition, patients treated with prednisone and cyclophosphamide had a significantly 
higher serum creatinine and FE of proteins compared to untreated patients (table 1). Six out 
of 9 patients (67%) treated with prednisone and 6 out of 14 patients (43%) treated with 
prednisone and cyclophosphamide attained a remission of proteinuria. In addition, 6 out of 9 
untreated patients (67%) developed a spontaneous remission. Two patients, initially 
responsive to prednisone, experienced a relapse and were successfully treated with 
prednisone. and cyclophosphamide. Two patients responsive to prednisone and 
cyclophosphamide had 1 or more relapses, all relapses responded to retreatment with 
prednisone and cyclophosphamide.  
At the end of follow-up, 17 patients (53%) were in remission (10 complete and 7 partial), 6 
patients still had a nephrotic syndrome (1 patient with a serum creatinine > 135 ȝmol/l) and 6 
patients had developed renal failure. Three patients died during follow-up; Two patients died 
while nephrotic, due to a myocardial infarction and myocarditis with arrhythmia, 1 patient 
with a partial remission died due to a myocardial infarction. 
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Predictive value of FE IgG less or greater than 0.14% 
We analyzed the predictive value of FE IgG less or greater than 0.14%. Baseline 
characteristics are given in table 2. Patients with FE IgG  0.14% had worse baseline 
characteristics. Serum creatinine was significantly higher in patients with FE IgG  0.14%. 
In addition, the nephrotic syndrome was more severe in patients with FE IgG  0.14% as 
reflected by a significantly lower serum albumin and a significantly higher proteinuria and 
serum cholesterol. Significantly more patients with FE IgG  0.14% received immuno-
suppressive therapy, 100 versus 40% (table 2, p<0.001). 
Table 2. Characteristics of patients with FE IgG less or greater than 0.14% 
   FE IgG < 0.14% FE IgG  0.14% p-value
   (n=15) (n=17) 
Sex (M/F)   9/6 14/3 0.24
Age (years)   40 ± 17 45 ± 17 0.09 
Serum albumin (g/L)   24 ± 6 18 ± 7.2 <0.001
Serum creatinine (Pmol/L)   94 ± 27 128 ± 58 0.001 
 Serum creatinine > 135 Pmol/l (n)  1 (7%) 10 (59%) <0.01
Serum cholesterol (mmol/L)      7.8 ± 2.0 9.4 ± 3.1 <0.01
Proteinuria (g/day)   7.8 ± 3.6 10.3 ± 4.8 <0.01
Follow-up (months)   38 (15-123) 58 (5-128) 0.98 
Remission of proteinuria (n)   8 (53%) 10 (59%) 0.75
Renal failure (n)   4 (27%) 2 (12%) 0.38
Immunosuppressive medication (n)   6 (40%) 17 (100%) <0.001 
Prednisone 4 (26%) 5 (29%)
 Prednisone and cyclophosphamide 2 (13%) 12 (71%) 
Remission
Although patients with FE IgG  0.14% had worse baseline characteristics, remission rate 
was not significantly different compared to patients with FE IgG < 0.14%, respectively 59% 
and 53%, (p=NS, table 2). Survival analysis also showed that FE IgG less or greater than 
0.14% did not predict a remission of proteinuria (figure 1, p=0.37). 
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Figure 1. Remission rate in patients with a FE IgG less or greater than 0.14%
Renal failure 
Twenty-seven percent of patients with FE IgG < 0.14% and 12% of patients with FE IgG 
0.14% developed renal failure (p=NS, table 2). Survival analysis showed no significant 
difference in progression to renal failure between patients with FE IgG less or greater than 
0.14% (figure 2, p=0.44). 
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 Figure 2. Renal survival in patients with a FE IgG less or greater than 0.14%
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Predictive value of FE of proteins, selectivity index and proteinuria 
We separately analyzed the predictive value of all measured urinary proteins. Threshold 
values for FE of proteins (albumin, transferrin, IgG and ȕ2m), SI and 24-hour proteinuria 
predicting persistent nephrotic syndrome or renal failure were selected using ROC curves 
(table 3). Values selected showed the best combination of sensitivity and specificity. As 
reflected by the low area under the curve, the discriminative ability of the threshold values 
was relatively poor. Survival analysis showed that the selected threshold values for FE of 
proteins, SI and 24-hour proteinuria did not predict a remission of proteinuria or progression 
to renal failure with statistical significance. Similarly, the response to prednisone or 
prednisone and cyclophosphamide could not be predicted by FE of proteins, SI or 24-hour 
proteinuria. In contrast, in untreated patients, a FE ȕ2m <1 was associated with a significant 
better renal survival (100% versus 0%, p=0.005). Remission rate was also higher in untreated 
patients with FE ȕ2m <1, however, this difference did not reach the level of statistical 
significance (86% versus 0%, p log-rank=0.08). Treatment with immunosuppressive 
medication resulted in similar remission rates and renal survival for patients with FE ȕ2m 
less or greater than 1. 
We also analyzed all data with out the 9 patients who had al ready received a course of 
immunosuppressive therapy before baseline measurement. Exclusion of these patients did 
not change the results (data not shown).  
Table 3. Sensitivity and specificity of the most discriminative threshold levels of fractional excretion of 
proteins, selectivity index and proteinuria in the prediction of renal failure or persistent nephrotic 
syndrome.  
Threshold
value AUC Sensitivity Specificity 
Proteinuria (g/day) 
Selectivity Index 
FE ȕ2m (%) 
FE IgG (%) 
FE transferrin (%) 
FE albumin (%) 
10.5
0.2
1.0
0.05
0.2
0.2
0.631
0.627
0.571
0.480
0.431
0.421
71
79
79
86
93
93
72
50
59
33
22
22
AUC=area under the curve; FE=fractional excretion
50
Fractional excretion of high and low molecular weight proteins in primary FSGS 
FE of proteins, SI and 24-hourproteinuria in the different histologic variants 
FE of proteins, SI and 24-hour proteinuria were not significantly different between patients 
with the tip variant and patients with FSGS NOS. Patients with the tip variant had a median 
FE IgG and FE ȕ2m of 0.19 (range 0.01–1.9) and 1.5 (range 0.06–24.2), compared to 0.08 
(range 0.01–0.75) and 0.88 (range 0.1–16.7) for patients with FSGS NOS (p=0.56 and 
p=0.57 for the differences between the tip variant and FSGS NOS). Selectivity index was 
0.26 ± 0.1 in patients with the tip variant and 0.25 ± 0.11 in patients with FSGS NOS 
(p=0.6). 
Discussion
Predicting prognosis in patients with primary FSGS remains difficult. Several clinical and 
histological parameters such as the degree of proteinuria, serum creatinine and 
tubulointerstitial damage have been described that are associated with outcome in primary 
FSGS.6;17-19 However, these parameters lack sensitivity and specificity and do not allow to 
guide treatment. Thus far, the best prognostic indicator in patients with primary FSGS is 
attainment of a remission.19 Therefore, patients with primary FSGS are usually treated with 
immunosuppressive therapy in an attempt to induce a remission. However, it would be ideal 
if outcome and response to treatment could be predicted before initiation of 
immunosuppressive therapy. A recent study by Bazzi et al. in 29 patients with a normal renal 
function reported that FE IgG less or greater than 0.14% not only predicted remission and 
progression to ESRD but also responsiveness to immunosuppressive therapy.13 In fact, a FE 
IgG above 0.14% was associated with complete unresponsiveness to steroids alone or in 
combination with cyclophosphamide. In contrast, our study shows that FE IgG  0.14% is 
not associated with a worse outcome. Although baseline characteristics were less favorable, 
remission rate and renal survival were not different from patients with FE IgG less than 
0.14%. Of note, patients with FE IgG  0.14% only attained a remission after 
immunosuppressive therapy. We, therefore, agree that patients with a FE IgG  0.14% have 
more severe disease and are more often in need of immunosuppressive therapy. However, 
with treatment, prognosis is favorable. We have further analyzed our data and evaluated 
other threshold values for FE IgG as well as other proteins. As indicated by the rather low 
AUC of the ROC curves, neither FE IgG, albumin, transferrin and ȕ2m nor 24-hour 
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proteinuria and SI predicted remission or progression to renal failure with high 
sensitivity/specificity.  
Admittedly, our study was retrospective and, thus, has limitations. Still, the data are 
sufficient to question the conclusions of Bazzi et al.13 We feel that it is not justified to 
withhold immunosuppressive therapy to patients with FSGS based on FE IgG.  
An explanation for the different results in study by Bazzi et al. is not immediately evident.13
However, it is likely that the relatively small number of patients with FE IgG  0.14% (n=7) 
included in the study by Bazzi et al. contributed to the different findings. As our study 
shows, still 41% of patients with FE IgG  0.14% do not attain a remission with 
immunosuppressive therapy. Therefore, if only a few patients with Fe IgG  0.14% are 
included, a response to immunosuppressive medication may be missed. The difference might 
also be explained by an inadequate course of immunosuppressive medication in some 
patients in the study by Bazzi et al.13 To attain a remission in primary FSGS, 
immunosuppressive therapy has to be sufficiently long, up to 6–8 months.4;5;20 Although at 
first sight the duration of immunosuppressive therapy in the Italian study appears adequate 
and not significantly different from our study, at closer look, several patients included in the 
study were treated between 1974 and 1991. During that period, immunosuppressive courses 
were often limited to 8 weeks.20;21 Especially in patients with a high FE IgG, this period may 
be too short to induce a remission. This notion is supported by the study of Bazzi et al.,
showing that to achieve a remission, immunosuppressive therapy has to be continued for a 
longer period of time as FE IgG becomes higher.13
Alternatively, based on the rapid progress to ESRD it was suggested that patients with a FE 
IgG  0.14 included in the Italian study were unresponsive to immunosuppressive 
medication due to a sporadic podocytic mutation.13;22 Although a possible relationship may 
exist between immunosuppressive-resistant FSGS due to a podocytic mutation and a high FE 
IgG, our study shows that this should not lead to the conclusion that all patients with a high 
FE IgG are therapy resistant.  
It is important to emphasize that the favorable prognosis in patients with a higher FE IgG in 
our study, does not exclude the possibility that FE of proteins can be used to guide treatment 
as reported by Bazzi et al.13 In the present study, the decision regarding the type of 
immunosuppressive therapy was made by the patient’s physician. Therefore, 14 patients 
received a combination of prednisone and cyclophosphamide after characterization of 
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proteinuria. We cannot exclude that the use of an escalating treatment regimen (i.e. first 
prednisone in case of no response followed by prednisone and cyclophosphamide) would 
have shown that the response to prednisone or prednisone and cyclophosphamide can be 
predicted by FE of proteins. FE of proteins may even al low to identify patients who can 
attain a remission without immunosuppressive therapy. In the present study, we observed a 
significant better renal survival in untreated patients with a FE ȕ2m <1. These findings are in 
agreement with a previous study that showed a good renal survival in patients with primary 
FSGS and a selective proteinuria.23 Therefore, FE ȕ2m may be a useful marker in selecting 
the best treatment for patients with primary FSGS. However, the small number of untreated 
patients in the present study does not allow to draw definitive conclusions, and prospective 
studies using a stepwise treatment regimen are necessary to establish whether FE of proteins 
can be used to decide whether or not immunosuppressive treatment should be started and if 
so which regimen is most effective.  
We did not detect a significant difference in FE of proteins between patients with the tip 
variant and FSGS NOS. However, the number of patients with FSGS NOS was relatively 
low. Definitive conclusions about differences in FE of proteins between patients with the tip 
variant and FSGS NOS can only be reached after studies including more patients with 
different histologic types, preferably also collapsing FSGS and perihilar FSGS.  
In conclusion, our study shows that in patients with primary FSGS, a FE IgG  0.14% is not 
inevitably associated with a poor renal prognosis or unresponsiveness to treatment and 
should not lead to therapeutic resignation. Treatment with immunosuppressive therapy 
results in a high remission rate in patients with FE IgG  0.14%. Patients with a FE ȕ2m < 1 
have a good renal prognosis even without immunosuppressive therapy. Further studies are 
necessary to determine if FE of proteins can guide treatment.
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Abstract
Background: A working group has defined five subtypes of focal segmental 
glomerulosclerosis (FSGS) based on light microscopic assessment (Columbia classification). 
Limited information is available on the prognostic and therapeutic implications of this 
classification in an European population. We conducted a retrospective analysis in 93 adult 
patients with biopsy-proven FSGS to determine the clinical features and outcome of FSGS 
variants.  
Methods: Renal biopsy specimens of adult patients (>16 year) diagnosed with FSGS 
between 1980 and 2003 were reviewed according to the Columbia classification without the 
knowledge of clinical outcome. The medical records were reviewed for clinical data. Primary 
outcomes were remission rate and renal survival. 
Results: The frequencies of the FSGS variants was: 32% NOS (FSGS not otherwise 
specified), 37% tip, 26% perihilar and 5% collapsing. Cellular FSGS was not found in the 
biopsies. The nephrotic syndrome was less frequent in FSGS NOS (57%) and perihilar FSGS 
(25%) compared to the tip variant (97%). Renal function was significantly better 30 in 
patients with the tip variant compared to FSGS NOS (p<0.05). Glomerular sclerosis and 
hyalinosis was most severe in patients with perihilar FSGS, intermediate in FSGS NOS and 
the least severe in patients with the tip variant. Patients with perihilar FSGS were less likely 
to receive immunosuppressive medication. Renal survival at 5 years was significantly better 
for patients with the tip variant (78% for tip vs 63 and 55% for FSGS NOS and perihilar 
FSGS;p=0.02). Type of FSGS and serum creatinine concentration were independent 
predictors of renal survival. Remission rate was higher in patients with the tip variant 
(p=0.1). 
Conclusion: The collapsing variant was rare in our population. Renal survival and remission 
rates were higher in patients with the tip variant. Use of the classification scheme for FSGS 
may be clinically useful. 
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Introduction
Focal segmental glomerulosclerosis (FSGS) is primarily a histological diagnosis, 
characterized by the presence of segmental sclerotic lesions involving some but not all 
glomeruli. Since the first descriptions by Fahr and Rich, several different histological 
variants of FSGS have been described.1-5 A group of renal pathologists redefined these 
histological variants and proposed a standardized pathological classification system for 
FSGS based entirely on light microscopic examination.6 This classification presumes 
previous exclusion of other primary glomerular diseases associated with FSGS, such as IgA 
nephropathy, diabetic glomerulosclerosis, membranous nephropathy and Alport’s syndrome. 
Five histological variants were described: FSGS not otherwise specified (NOS), perihilar 
variant, cellular variant, tip variant and collapsing variant. The prognostic significance of this 
classification is still not clear. A study by Chun et al. was unable to detect a significant 
difference in remission rate among patients with collapsing FSGS, FSGS NOS and the tip 
variant.7 In contrast, two other studies reported a lower remission rate and worse renal 
survival among patients with the collapsing variant compared to the tip variant and FSGS 
NOS.8;9  Patients with the cellular variant had intermediate remission rates.8 In the reported 
studies, 32–67% of the patients were Afro-Americans. It is questionable if the conclusions of 
these studies are applicable to an European population.  
In the present study, we analysed the characteristics and renal outcome of FSGS variants in 
adult Dutch patients and evaluated their predictive value compared to other known risk 
factors for renal failure. 
Patients and methods  
From the pathology registry we identified all adult patients (age >16 years at biopsy) 
diagnosed with FSGS between 1980 and 2003 at the Radboud University Nijmegen Medical 
Center and affiliated hospitals. The renal biopsy specimens 10 were reviewed by the renal 
pathologist (E.J.S) without knowledge of the clinical outcome. A minimum of five glomeruli 
in the light microscopy section was required for inclusion in the study. This number was 
chosen for a better comparison with previous studies by Chun et al. and Thomas et al.7;9
Light microscopic assessment of glomeruli for FSGS lesions was performed in accordance 
with the Columbia classification system described by D’Agati et al.6 This classification  
59
Chapter 4
defines five light microscopic patterns of FSGS: FSGS NOS, perihilar  variant, cellular 
variant, tip variant and collapsing variant. Adult patients with one of the above light 
microscopic variants of FSGS and either negative immunofluorescence or only segmental 
IgM and/or C3 were considered for the study. Patients with FSGS due to other primary 
glomerular diseases, such as IgA nephropathy, membranous nephropathy, pauci-immune 
glomerulonephritis, lupus nephritis or hereditary nephritis were excluded.  
Renal biopsies 
For light microscopy, pieces of kidneys were fixed in Bouin’s solution overnight at room 
temperature, dehydrated and embedded in Paraplast. Two micrometer-thick sections were 
stained with periodic acid Schiff and methenamine silver. For immunofluorescence, kidney 
fragments were snap frozen in liquid nitrogen, and 2 mm cryostat sections were incubated 
with fluorescein-labelled antisera directed to human IgG, IgM, IgA, C1q, C3, ț, Ȝ, and 
fibrinogen. Electron microscopic examination was performed on small pieces of kidneys 
fixed in glutaraldehyde. Glomerular cross sections were arbitrarily assessed for the extent of 
sclerosis and hyalinosis, and called normal, mild, moderate or severe. 
Clinical data 
Medical records were reviewed for clinical data at presentation, at biopsy and at 3 months 
intervals thereafter. Data collected were: age, sex, weight, blood pressure, level of protein 
excretion, serum creatinine concentration, serum albumin concentration, serum cholesterol 
concentration, use of immunosuppressive therapy and antihypertensive medication, initiation 
of dialysis and death. In addition, the medical records were reviewed for diseases associated 
with secondary FSGS: morbid obesity, renal dysplasia, solitary kidney, reflux nephropathy, 
infections (HIV, parvovirus B19), medication (pamidronate, lithium, interferon-a) or 
intravenous drug abuse, family history of renal disease and sickle cell anaemia. 
Definitions 
Presentation was defined as the time when proteinuria was first detected. Renal failure was 
defined as a sustained increase of the serum creatinine concentration of >50% from baseline 
(renal biopsy), or  development of end-stage renal disease (ESRD). ESRD was defined as a 
serum creatinine concentration of >450 ȝmol/l or the need for renal replacement therapy or 
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kidney transplantation. Nephrotic syndrome was defined as proteinuria of  3 g/day in 
association with serum albumin concentration of 30 g/l. Patients treated with 
antihypertensive drugs or with a systolic blood pressure >140mmHg or a diastolic blood 
pressure >90mmHg were considered hypertensive. A complete remission (CR) was defined 
as proteinuria <0.3 g/24 h with a stable serum creatinine concentration (<50% increase from 
baseline) and a partial remission (PR) was defined as proteinuria between 0.3 g/24 h and 2.0 
g/24 h with at least 50% reduction in proteinuria from baseline and a stable serum creatinine 
concentration. A relapse was defined as a proteinuria >3 g/24 h after prior reduction of the 
proteinuria to less than 2.0 g/24 h. 
Statistical analysis 
Values are given as means ± SD or median (range) when appropriate. Differences in 
continuous data were analysed with use of the Kruskal–Wallis test, followed by Dunn’s post 
hoc rank test in case of more groups. Fisher’s exact test was used for differences in 
categorical data. Renal survival and remission rates for the different FSGS variants were 
estimated with Kaplan–Meier statistics. The log-rank test was used for comparison of the 
Kaplan–Meier curves. The univariable Cox proportional-hazards model was used to select 
variables associated with renal survival or attainment of a remission. The following variables 
were tested: serum creatinine concentration, serum albumin concentration, serum cholesterol 
concentration, proteinuria and mean arterial blood pressure all measured at biopsy, sex, age 
and type of FSGS. As for strongly skewed variables the high values may have a 
disproportionate influence on the outcome of the analysis, the log transformation was used to 
reduce their impact. In order to identify independent predictive parameters, the multivariable 
proportional hazards model was used in a forward stepwise fashion, with p<0.05 for 
inclusion of variables. Due to the low number of patients, data for the collapsing variant are 
presented but not included in the statistical comparison among variants.  
Throughout, a two-sided p-value <0.05 was considered as the level of statistical significance. 
The analysis was performed using SPSS 14.0 for windows (SPSS Inc., Cambridge, MA, 
USA). Multiple comparison procedures (Dunn’s method) was performed using GraphPad 
InStat version 3.00 for Windows 95, GraphPad Software, San Diego, CA, USA.  
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Results
A search of the pathology registry identified 116 patients with a diagnosis of FSGS. Twenty-
three patients were not included in the study due to missing slides or less than five glomeruli 
in the renal biopsy. Baseline characteristics of the remaining 93 patients are shown in table 1.
The majority of the patients were native Dutch. There were no Afro-American patients. One 
patient was Indonesian, two patients were Indian and one patient was Turkish. In this cohort, 
the frequency of the FSGS variants was: 32% NOS, 37% tip, 26% perihilar and 5% 
collapsing. Notably, the cellular variant was not observed. Renal function was significantly 
better in patients with the tip variant compared to FSGS NOS (p<0.05). Significantly, more 
patients with the tip variant presented with a nephrotic syndrome compared with patients 
with FSGS NOS and perihilar FSGS (p<0.01). The nephrotic syndrome was also more 
common in patients with FSGS NOS compared to perihilar FSGS (p<0.05). A secondary 
cause was identified in eight patients. Four patients with FSGS NOS and two patients with 
perihilar FSGS had a solitary kidney. Reflux nephropathy was present in one patient with 
perihilar FSGS and one patient with the tip variant was diagnosed with a thymoma. There 
were no cases of HIV. 
Pathology 
The median number of glomeruli for evaluation by light microscopy was 12 (range 5–62). 
The number of glomeruli was significantly higher in patients with the tip variant (16, range 
5–62) compared with patients with perihilar FSGS (11, range 5–35; p=0.01). The median 
number of glomeruli in patients with FSGS NOS was 12 (range 5–60) and 20 (5–28) for 
patients with collapsing FSGS. Glomerular sclerosis and hyalinosis was most severe in 
patients with perihilar FSGS, intermediate in FSGS NOS and the least severe in patients with 
the tip variant (p<0.001, perihilar vs the tip variant and FSGS NOS and p<0.01, tip variant vs 
FSGS NOS). Electron microscopic examination was available for 51 patients. These patients 
were equally distributed among the four groups. Significantly more patients with the tip 
variant (90%) showed diffuse foot process fusion compared with patients with FSGS NOS 
(50%; p=0.01) and perihilar FSGS (27%; p<0.001). Diffuse foot process fusion was present 
in 67% of the patients with collapsing FSGS.  
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Treatment
Seventy-five patients (81%) were treated with an ACE inhibitor or an angiotensin receptor 
blocker. A total of 40 patients (43%) received immunosuppressive therapy (table 2). There 
was a significantly greater use of immunosuppressive medication in patients with the tip 
variant and FSGS NOS compared with patients with perihilar FSGS (p<0.001 and p=0.018,
respectively). Patients treated with immunosuppressive medication had significantly more 
proteinuria, a lower serum albumin concentration and a higher serum cholesterol 
concentration (table 3). The initial course of immunosuppressive therapy consisted of 
prednisone alone (n=24) or prednisone and cyclophosphamide (n=15). One patient was 
treated with prednisone and azathioprine due to severe side-effects shortly after initiation of 
treatment with cyclophosphamide. Patients received high dose prednisone (1 mg/kg/day) for 
a median of 2.3 months (range 0.4–8.6). The total duration of prednisone treatment was 5.6 
months (range 1.3–55.3). Cyclophosphamide was administered orally in a dose of 1.5–2 
mg/kg/day for a median of 3 months (range 2–12). The duration of immunosuppressive 
therapy was not significantly different among the groups. 
Table 3. Baseline characteristics of patients treated and not treated with immunosuppressive 
 medication. 
Treated patients 
(n=40)
Untreated patients 
(n=53)
p-value
Sex (M/F) 
Age at biopsy (years) 
Serum creatinine concentration (ȝmol/l) 
Serum creatinine concentration > 135 μmol/l 
Serum albumin concentration (g/L)  
Proteinuria (g/24 hours) 
Serum cholesterol (mmol/l) 
Nephrotic syndrome (%) 
Mean arterial blood pressure (mmHg) 
Hypertension (%) 
FSGS variant 
NOS
 Tip  
 Perihilar
Collapsing
27/13
48 ± 17 
146 ± 88 
48%
21 ± 9 
10.4 ± 5.8 
9.9 ± 3.3 
83%
107 ± 14 
68%
13
21
3
3
36/17
49 ± 15 
148 ± 109 
32%
32 ± 9 
5.8 ± 3.7 
8.1 ± 2.9 
49%
112 ± 14 
70%
17
13
21
2
0.99
0.99
0.62
0.14
<0.001
<0.001
0.01
0.001
0.13
0.83
0.01
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Remission and renal survival 
Remission rate at 5 years was 44% (table 2). Patients with the tip variant had the highest 
remission rate compared with patients with FSGS NOS and perihilar FSGS (p=0.2 and 
p=0.04, respectively); however, the overall difference between the three variants did not 
reach the level of statistical significance (p=0.1; table 2). A spontaneous remission occurred 
more often in patients with the tip variant compared with patients with FSGS NOS or 
perihilar FSGS (p<0.01; table 2). Two patients with collapsing FSGS also had a spontaneous 
remission. At the end of follow-up a remission was attained by 12 patients (6 CR/6 PR) with 
FSGS NOS, 18 patients (15 CR/3 PR) with the tip variant, 5 patients (3 CR/2 PR) with 
perihilar FSGS and 2 (2 CR) patients with collapsing FSGS. The overall renal survival was 
66 and 54% at 5 and 10 years, respectively. Patients with the tip variant had a significantly 
better renal survival compared with FSGS NOS and perihilar FSGS (p=0.02; table 2 and
figure 1). Renal survival at 5 and 10 years of patients attaining a remission was 100% for all 
variants. 
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Figure 1. Renal survival of patients with FSGS by variant subtype. 
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Predictors of remission and renal survival 
On univariable analysis, a remission was predicted by a lower serum creatinine 
concentration, a lower serum albumin concentration and a higher serum cholesterol 
concentration (table 4). Type of FSGS, proteinuria at renal biopsy and immunosuppressive 
therapy did not predict a remission. On multivariable analysis, only serum albumin 
concentration (p=0.03) predicted a remission (table 4).
On univariable analysis, renal survival was predicted by a lower serum creatinine 
concentration, a lower serum albumin concentration, a higher serum cholesterol 
concentration and type of FSGS (tip variant; table 5). Proteinuria at renal biopsy and 
immunosuppressive therapy did not predict renal survival. On multivariable analysis both 
serum creatinine concentration (p=0.02) and type of FSGS (tip variant; p=0.03) predicted 
renal survival (table 5). 
Table 4. Cox proportional hazard analysis of factors influencing remission rate.
Univariable analysis 
 HRR (95% CI) p-value
Multivariable analysis 
 HRR (95% CI) p-value
FSGS 
 Tip 
 NOS 
 Perihilar** 
 2.72 (1.01-7.33) 
 1.69 (0.59-4.79 
-
0.11
0.05
0.33
-
Age (years)  0.99 (0.97-1.01) 0.20
Sex 
 Male 
 Female** 
 1.90 (0.86-4.19) 
-
0.11
0.11
-
Serum creatinine 
concentration (ȝmol/l)* 
 0.15 (0.03-0.77) 0.02
Serum albumin 
concentration (g/L) 
 0.96 (0.93-0.99) 0.02 0.96 (0.93-0.99) 0.03
Serum cholesterol 
concentration (mmol/l) 
 1.12 (1.01-1.23) 0.03
Proteinuria (g/24 hours)  1.04 (0.98-1.11) 0.16
Mean arterial blood 
pressure (mmHg) 
 0.99 (0.97-1.02) 0.67
Immunosuppressive 
therapy 
 1.03 (0.53-2.01) 0.94
* Log-transformed values; ** Reference; HRR: Hazard rate ratio
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Table 5. Cox proportional hazard analysis of factors influencing renal survival.
Univariable analysis 
 HRR (95% CI) p-value
Multivariable analysis 
 HRR (95% CI) p-value
FSGS 
 Tip 
 NOS 
 Perihilar** 
0.28 (0.11-0.70) 
0.64 (0.29-1.4) 
-
0.02
0.006
0.26
-
0.29 (0.11-0.74) 
0.43 (0.18-1.04) 
-
0.03
0.01
0.06
-
Age (years) 1.02 (0.99-1.04 0.16
Sex 
 Male 
 Female** 
0.76 (0.38-1.52) 0.43
Serum creatinine 
concentration (ȝmol/l)* 
5.99 (1.60-22.4) 0.008 6.30 (1.30-30.2) 0.02
Serum albumin 
concentration (g/L) 
1.04 (1.00-1.07) 0.03
Serum cholesterol 
concentration (mmol/l) 
0.88 (0.78-0.99) 0.03
Proteinuria (g/24 hours) 0.95 (0.88-1.03) 0.19
Mean arterial blood 
pressure (mmHg) 
1.01 (0.99-1.03) 0.35
Immunosuppressive 
therapy 
0.98 (0.48-2.00) 0.95
* Log-transformed values; ** Reference; HRR: Hazard rate ratio
Discussion
In the present study, we examined the characteristics and outcome of FSGS variants in an 
adult West-European population. In our population collapsing FSGS was rare. This is in 
agreement with other studies showing that 54–91% of patients with collapsing FSGS were 
Afro-Americans.5;7;9 In a more detailed study of 42 patients with non-HIV collapsing FSGS 
only five patients were of European descent and three were hepatitis C positive after 
intravenous drug abuse.10 Thus, collapsing FSGS is rare in our population, and the small 
number of patients precludes firm conclusions on prognosis and outcome. We also did not 
observe the cellular variant. There is some dispute if the cellular variant is a separate entity. 
Some authors do not discriminate between the cellular and collapsing variant.7 Furthermore, 
careful analysis of biopsies with the cellular lesion often results in reclassification into the tip  
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and the collapsing lesion.8 In two studies by Thomas et al. and Stokes et al., the prevalence 
of the cellular variant was only 3–4.5%.8;9 In view of these low percentages it is not 
unexpected that we did not observe the cellular lesion in our study population.  
The tip variant was the most frequent variant in our study. This finding is somewhat in 
contrast to literature data reporting a lower prevalence of the tip variant compared to FSGS 
NOS.8;9 Most likely, this reflects the difference in composition of the study populations. In 
contrast to previous reports, there were no Afro-American patients in our study. 
Alternatively, this series, like most others, relies on the diagnosis of FSGS given 
contemporaneously with biopsies, almost always by different pathologists. Therefore, it is 
likely that not all biopsies were classified as FSGS and may be missed, especially in case of 
the tip variant, which may have been diagnosed as minimal change disease (MCD). This may 
also be part of the explanation of differences in outcome between reported series. Patients 
with the tip variant more often presented with a nephrotic syndrome, had a better renal 
function and less histological damage compared with patients with FSGS NOS and perihilar 
FSGS. These findings are in agreement with literature data.8;9;11
The perihilar variant is often associated with secondary forms of FSGS, especially due to 
maladaptive responses that follow loss of functioning nephrons, hyperfiltration or increased 
glomerular pressure.12 Typically, these patients present with nephrotic range proteinuria 
without a full nephrotic syndrome. Serum albumin concentration usually remains normal 
even though proteinuria exceeds 3 g/day.13 Most patients with perihilar FSGS in our study 
also presented without a nephrotic syndrome. Nevertheless, an identifiable secondary cause 
was rare in our patients with perihilar FSGS. Admittedly, this conclusion is not unexpected 
since in patients with a readily identifiable cause of secondary FSGS, a renal biopsy is not 
done. Nearly all patients included in the study underwent examination by ultrasound or 
intravenous pyelogram, which makes it unlikely that secondary causes due to a reduced renal 
mass, e.g. renal agenesis or dysplasia, were missed. Alternatively, long-standing 
hypertension, a known cause of secondary FSGS, may have been present in our patients with 
the perihilar variant. Most patients with perihilar FSGS indeed had a history of hypertension 
before presentation to our centre or one of the affiliated hospitals. However, due to the 
retrospective nature of the study, it was not possible to establish the duration and severity of 
hypertension in these patients. Most patients with perihilar FSGS did not receive 
immunosuppressive therapy. This is likely due to the low number of patients with a nephrotic  
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syndrome. Although data on the use of  immunosuppressive therapy in nonnephrotic patients 
are lacking, currently most authors would advise against immunosuppressive therapy in these 
patients.14 In addition, Praga et al. showed that patients with secondary FSGS due to 
maladaptive responses are usually characterized by a normal serum albumin concentration 
even though proteinuria is in the nephrotic range.13 Therefore, most treating physicians did 
not use immunosuppressive medication in patients with perihilar FSGS. Prognosis of patients 
with perihilar FSGS is comparable to FSGS NOS. After 10 years renal function remains 
stable in ~50% of the patients.  
The tip variant was associated with the highest remission rate (57%). The remission rate 
compares very well to previous studies reporting remission rates varying between 53% and 
59%.7;9;11 Notably, a large proportion of patients with the tip variant in the present study 
attained a spontaneous remission. Stokes et al. demonstrated that the presenting features and 
outcome of the tip variant more closely resembled MCD.11  Although patients with MCD 
usually receive immunosuppressive therapy, up to 50% of the patients with MCD can attain a 
spontaneous remission after a prolonged period.15;16 We have published our experience in 
patients with primary FSGS. Spontaneous remissions occurred relatively frequent in a 
subgroup of patients that more closely resembled MCD, i.e. a more selective proteinuria and 
few sclerotic lesions.17 Howie et al. reported  similar results in a group of patients presenting 
with only tip lesions.18 Some patients behaved as though they had MCD. Half the patients 
did not progress even though some may not have been treated or had received similar 
treatment as those who progressed. Our results and those of Howie suggest that some 
patients with the tip lesion may not need immunosuppressive therapy to attain a remission. 
Admittedly, in multivariable analysis the tip variant did not predict attainment of a remission. 
This is probably related to a relatively low number of patients. A low serum albumin 
concentration was an independent predictor of a remission. However, inclusion of serum 
albumin as a variable may not be justified since clinical decisions may have depended on the 
actual serum albumin concentration. Although the differences in remission rate can be 
disputed, our study clearly showed a renal survival advantage for patients with the tip variant 
compared with patients with FSGS NOS and perihilar FSGS. The better renal survival of the 
tip variant only became apparent after 5 years of follow-up. This explains why Thomas et al.
were unable to show a renal survival benefit in patients with the tip variant, in spite of a 
higher remission rate.9 In their study follow-up ended after four years. The tip variant was an  
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independent predictor of renal survival. Only serum creatinine concentration at biopsy 
predicted renal survival better. In agreement with a previous study by Chun et al, the overall 
renal survival in our patients attaining a remission was good irrespective of the type of 
FSGS.7 Therefore, the difference in renal survival, especially between the tip variant and 
FSGS NOS, is most likely explained by a better prognosis in patients with the tip variant 
who did not attain a remission. Half of these patients did not progress to renal failure 
compared with only 22% of patients with FSGS NOS. Our results support the concept of 
Howie, who suggested that the tip variant may be a manifestation of two diseases, i.e. MCD 
and FSGS.18 In some patients with MCD, tip lesions may occur, however, these patients do 
not progress to sclerosis or renal failure.3 On the other hand, tip lesions may occur early in 
the course of classical nephrotic FSGS, and these patients can progress to renal failure.19 The 
existence of two forms of FSGS may also explain the different results reported in studies by 
Stokes and Chun.7;11 In the study by Stokes et al., of eight patients with the tip variant who 
did not attain a remission, only one progressed to ESRD.11 In contrast, Chun et al. reported a 
poor prognosis in patients with the tip variant not attaining a remission.7
Patients with the tip variant of FSGS present more often with a nephrotic syndrome, a better 
renal function and less histological damage. Patients with the tip variant have a better 
prognosis, and can attain a remission without treatment. Our data demonstrate the clinical 
usefulness of the FSGS classification. 
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Abstract
Background: The course of idiopathic membranous nephropathy (iMN) is variable in 
untreated patients. 
Accurate prediction of renal outcome would allow optimal treatment decisions. We 
demonstrated that urinary ȕ2-microglobulin (ȕ2m) predicted prognosis in iMN with high 
sensitivity and specificity. It has been suggested that focal segmental glomerulosclerosis 
(FSGS) is a discriminative parameter with independent prognostic value. 
Methods: We selected patients with iMN biopsied between 1988 and 2002. Biopsies were 
analysed for the presence of FSGS, interstitial fibrosis and vascular lesions. Serum 
creatinine, creatinine clearance, proteinuria and blood pressure were recorded at baseline. 
Outcome variables included remission of proteinuria, renal death (RD) defined as serum 
creatinine >135 mmol/l or increase of serum creatinine of >50%, or end-stage renal disease 
(ESRD). In a subgroup of patients, urinary ȕ2-microglobulin (ȕ2m) was measured.  
Results: We included 53 patients (33M, 20F). Mean age was 51 years, serum creatinine 99 
ȝmol/l, and proteinuria 7.0 g/10 mmol creatinine. FSGS was present in 22 patients. These 
patients were characterized by a higher serum creatinine at time of biopsy (p=0.035), more 
severe interstitial fibrosis (p=0.001) and higher stage of membranous nephropathy (p=0.001). 
During follow-up 24 patients developed RD, almost equally distributed between patients 
with and without FSGS. Renal survival was numerically, but not significantly, lower in 
patients with FSGS. In Cox proportional hazard analysis, only serum creatinine at the time of 
biopsy was an independent predictor of RD or ESRD (p<0.001). In patients with known 
urinary ȕ2m, there was no significant correlation with FSGS score (p=0.174).
Conclusion: FSGS is not an accurate prognostic marker in iMN. Histological scoring of 
FSGS is inferior to measurement of urinary proteins in predicting renal outcome in iMN. 
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Introduction 
Idiopathic membranous nephropathy (iMN) is one of the most common causes of the 
nephrotic syndrome in adults.1 The course of iMN in untreated patients is variable, as 
approximately 34–62% develop renal insufficiency and 14–56% will have a spontaneous 
remission.2 The identification of parameters that predict prognosis with sufficient accuracy 
would allow individualized treatment and avoid unnecessary immunosuppressive therapy. 
Well-known risk factors for deterioration of renal function such as proteinuria, age and sex 
lack sensitivity or specificity.3-5 In previous studies, we have found that urinary ȕ2-
microglobulin (ȕ2m) accurately predicts prognosis in patients with iMN.6-8 Recent studies 
have provided evidence that morphological parameters—specifically focal segmental 
glomerulosclerosis (FSGS)—may be used as prognostic parameter.9-12
In the present study, we have evaluated FSGS as prognostic parameter in patients with iMN. 
In addition, we performed a meta-analysis of studies analysing the prognostic significance of 
FSGS in iMN. 
Subjects and methods 
Patient selection 
We included patients with a diagnosis of membranous nephropathy, biopsied between 1988 
and 2002 in any of five nephrology units in the Nijmegen region. Only patients with iMN 
were considered in this study. 
Clinical data 
From selected patients, their age, sex, serum creatinine, serum cholesterol, serum albumin, 
proteinuria (expressed per 10 mmol creatinine), creatinine clearance (ECC) calculated 
according to the Cockcroft Gault formula13, systolic and diastolic blood pressure and 
medication had been recorded at the time of biopsy (table 1), and were frequently measured 
during follow-up. The mean arterial pressure was calculated as the diastolic blood pressure 
plus a third of the pulse pressure.  
In patients who were seen at the University Hospital, additional standardized measurements 
were done as described to determine urinary excretion of ȕ2-microglobulin.8 Renal death was 
defined as a serum creatinine concentration of >135 ȝmol/l or an increase of serum creatinine 
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of more than 50% over time. Patients who met these criteria were advised to start with 
immunosuppressive therapy. As described before, start of immunosuppressive therapy, 
because of severe nephrotic syndrome, was also considered as renal death (RD).8
End-stage renal disease (ESRD) was defined as an ECC <10 ml/min. A complete remission 
was defined as proteinuria below 0.2 g/10 mmol creatinine and a partial remission as 
proteinuria between 0.2 and 2.0 g/10 mmol creatinine, without deterioration of renal 
function. Follow-up started at the time of biopsy and continued until December 2003 or 
ended at the time of death or development of ESRD.  
Pathology 
All biopsy specimens were processed for light microscopy using standardized techniques. 
For the  evaluation and quantitation of FSGS lesions we have used the biopsy slides stained 
with methenamine silver in which FSGS is best recognized. Biopsies with less than five 
glomeruli were excluded from the analysis.  
The presence of FSGS was evaluated by a qualitative and a quantitative analysis. In the 
qualitative analysis, all available slides were screened for the presence of FSGS and tubulo-
interstitial fibrosis. The risk of overlooking FSGS was thereby considered negligible. In the 
quantitative analysis, glomerular slides were selected at random and evaluated in detail for 
the extent of FSGS.  
Focal glomerulosclerosis was defined as a focal lesion with mesangial matrix expansion 
leading to collapse of the glomerular capillary loops. The extent of sclerosis was scored by 
counting the number of glomerular quadrants with sclerosis. FSGS was expressed as a 
percentage by dividing the total score of sclerosis by four times the number of evaluated 
glomeruli. Globally sclerosed glomeruli were excluded in this analysis, but were included in 
the calculation of total sclerosis. Total sclerosis was defined as the sum of focal sclerosed 
glomerular quadrants and globally sclerosed glomeruli x 4 divided by the total number of 
glomeruli x 4.  
The interstitium was evaluated for the presence and extent of tubulo-interstitial fibrosis, 
intimal fibrosis and foam cells. Tubulo-interstitial fibrosis was scored semiquantitatively on 
a scale of 0–3.  
The glomerular deposits were evaluated by electronmicroscopy (EM) and the stage of 
membranous nephropathy was taken from the corresponding pathology report. 
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Meta-analysis 
We performed a thorough search of the MEDLINE, EMBASE and Cochrane Controlled 
Trial Register databases. The following keywords were used: ‘membranous nephropathy’, 
‘membranous glomerulopathy’, ‘FSGS’, ‘outcome’, ‘remission’. The search was limited to 
studies published in English. The following types of studies were included: randomized 
controlled trials, non-randomized prospective trials and retrospective studies. Case reports 
were not included. Only studies analysing the outcome in patients with iMN according to the 
presence or absence of FSGS were considered. The primary outcome was remission of 
proteinuria.  
Statistical analysis 
Statistical analysis was performed using the SPSS version 11.0 for Windows. For differences 
between groups, Chi-square test, t-test and the Mann–Whitney U test were applied, if 
appropriate. Correlations were calculated using Spearman’s correlation test.  
The Kaplan–Meier univariate analysis was used to select variables associated with 
progression to RD. Significance was determined by the log–rank test. In order to identify 
independent predictive parameters, Cox proportional hazard was performed in forward 
stepwise fashion on variables selected by univariate analysis. For this purpose, 
nonparametric variables were transformed using log 10 or square root transformation. For all 
analyses, p<0.05 was considered significant. All statistical calculations for the meta-analysis 
were performed using the computer software Review Manager (RevMan) version 4.2.9 
provided by the Cochrane Collaboration. A pooled estimate of the odds ratios with 95% 
confidence intervals was calculated using the  random effects model using the DerSimonian–
Laird method. A p-value <0.05 was considered significant. Heterogeneity was evaluated by 
using the Ȥ2 test. Given the low power of this test, a p-value <0.1 was considered significant. 
Results
Clinical and pathological findings 
We identified 61 eligible patients. In eight patients, the biopsy contained an insufficient 
number of  glomeruli. Thus, we have studied 53 patients (33 M, 20 F) with a mean (SD) age 
of 51 ± 15 years. Mean follow-up was 62 ± 43 months. Mean creatinine was 99 ȝmol/l and 
mean proteinuria 7 g/10 mmol. Baseline characteristics of all patients are given in table 1.
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FSGS was present in 22 patients (41.5%). The clinical and pathological findings at baseline 
of patients without FSGS lesions (n=31, group I) and patients with FSGS lesions (n=22, 
group II) are listed in table 2. Patients with FSGS had a significantly higher serum creatinine 
and were numerically older. FSGS was significantly associated with a higher MN stage and 
more severe tubulo-interstitial lesions (table 2). Vascular changes were also more marked in 
patients with FSGS, however, the differences were not statistically significant.  
For the quantitative analysis of FSGS, we evaluated an average of 336 glomerular profiles 
per biopsy in group I (min 62, max 830) and 342 glomerular profiles per biopsy in group II 
(min 63, max 811). A mean of 2.3% of glomerular quadrants was sclerosed in group II (min 
0.11, max 13.3%). There were significantly more obsolescent glomeruli in group II (8.1%) 
than in group I (4.9%), p=0.034. Serum creatinine at time of biopsy, ECC and serum 
cholesterol were significantly correlated with the percentage of FSGS (serum creatinine 
r=0.339; p=0.013; ECC r=-0.333;p=0.031; serum cholesterol r=-0.308; p=0.039).
Table 1. Clinical data at baseline
Sex (M/F) 
Age (years) 
Serum creatinine (ȝmol/L) 
Serum albumin (g/L) 
Serum cholesterol (mmol/L) 
ECC (ml/min) 
Proteinuria (g/10mmol creatinine)  
MAP (mmHg) 
Follow-up (months)
33 / 20 
50.9 ± 15.1 
98.8 ± 41.5 
24.0 ± 6.1 
10.4 ± 3.3 
84.5 ± 31.8 
7.0 ± 3.2 
105.0 ± 11.9 
62 ± 43 
Values are given as means ± SD; S= serum: ECC= creatinine clearance;  
MAP= mean arterial pressure 
Renal outcome 
At the time of biopsy, serum creatinine was >135 ȝmol/l in four patients. Another 20 patients 
reached the defined end point RD during follow-up. The reason for RD was a serum 
creatinine >135 ȝmol/l in 22 patients, a rise of >50% of serum creatinine in one patient and 
the start of immunosuppressive therapy with normal serum creatinine in one patient. The 
outcome was not different between the groups, with development of RD in 41.9% of patients 
without and 50% of patients with FSGS (table 3).
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Table 2. Clinical and pathological data at baseline 
FSGS – 
(n=31)
FSGS + 
(n=22) p-value
Sex (M/F) 
Age (years) 
Serum creatinine (ȝmol/L) 
Serum albumin (g/L) 
Serum cholesterol (mmol/L) 
ECC (ml/min) 
Proteinuria (g/10mmol creatinine) 
MAP (mmHg)
% FSGS 
MN-stage (%) 
I
II
III
IV
Interstitial fibrosis (%) 
0
1
2
3
20/11
48.3 (15.3) 
95.4 (41.1)  
23.2 (5.1) 
11.2 (3.2) 
90.8 (29.6) 
6.8 (3.1) 
104.0 (11.7) 
-
32.3
48.4
12.9
0
9.7
51.6
43.3
6.5
13/9
54.4 (14.3) 
103.5 (34.4) 
25.0 (7.2) 
9.4 (3.2) 
73.1 (33.4) 
7.4 (3.3) 
106.5 (12.2) 
2.3
13.6
31.8
50
4.5
0
18.2
31.8
50.0
NS
NS
0.035
NS
NS
NS
NS
NS
0.001
0.001
0.001
Values are given as means ± SD. S= serum; ECC= creatinine clearance; MAP= mean arterial pressure;    
MN= membranous nephropathy; NS= not significant 
Table 3. Clinical outcome
FSGS – 
(n=31)
FSGS + 
(n=22) p-value
Renal death 
ESRD 
Death
Immunosuppressive therapy 
Remission during FU 
Remission end FU 
13 (41.9%) 
3 (9.7%) 
1 (3.2%) 
13 (41.9%) 
21 (67.7%) 
21 (67.7%) 
11 (50.0%) 
3 (13.6%) 
2 (9.1%) 
7 (31.8%) 
11 (50.0%) 
10 (45.5%) 
NS
NS
NS
NS
NS
NS
ESRD is end-stage renal disease; FU= follow-up; NS= not significant
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 Figure 1. FSGS does not predict renal outcome in patients with iMN.  
 See methods for definition of renal death. Renal survival is depicted for  patients with  
 FSGS (FSGS+; interrupted line; n=22) and without FSGS (FSGS-; straight line; n=31).
Renal survival is depicted in figure 1. Only three patients died, two with FSGS lesions (ns). 
During follow-up, slightly more patients without FSGS had a complete or partial remission 
of proteinuria (67.7% vs 50% in group II). Also at the end of follow-up a higher proportion 
of 20 patients without FSGS (67.7% vs 45.5%) had a complete or partial remission. These 
differences were not statistically significant. A complete remission at the end of follow-up 
was attained in 11/31 patients without FSGS and in 4/22 patients with FSGS (ns).  
Twenty patients received immunosuppressive treatment during follow-up; 13 patients 
without FSGS, 7 patients with FSGS (ns).  
Risk factors for RD 
To determine which variables were associated with the development of RD, univariate 
analysis was performed for all of the clinical variables (table 4). The most discriminate 
variable was serum creatinine at time of biopsy (p<0.001, log-rank test). Other variables 
associated with progression to RD were ECC (p<0.001), diastolic blood pressure ( p<0.001), 
mean arterial pressure (p=0.012), proteinuria (p=0.004) and serum albumin (p=0.035). 
Notably FSGS was not associated with progression to RD (p=0.46). 
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Table 4. Risk factors associated with renal death in the study population 
Univariate (p-value) Multivariate (p-value) 
Serum creatinine  
Serum albumin 
ECC
Proteinuria
Diastolic blood pressure  
MAP
FSGS
0.001
0.035
0.001
0.004
0.001
0.012
NS
0.001
NS
NS
NS
0.05
NS
NS
S=serum; ECC=creatinine clearance: MAP=mean arterial pressure; NS=not significant 
Cox proportional hazard analysis was performed using variables selected by univariate 
analysis. Serum creatinine, at time of biopsy, was the strongest independent predictive factor 
for progression to RD (p <0.001). Diastolic blood pressure also had independent significant 
prognostic value for progression to RD (p=0.050).  
Our analysis could have been biased because at the time of biopsy several patients already 
had decreased renal function. A subgroup analysis was, therefore, performed limited to 
patients with a serum creatinine at the time of biopsy of <106 mmol/l. This subgroup 
consisted of 39 patients, 25 without and 14 with FSGS. During follow-up, 11 patients 
developed RD, 7/25 without FSGS and 4/14 with FSGS (p=ns). In univariate analysis, serum 
albumin (p=0.0061), diastolic blood pressure (p=0.007) and mean arterial pressure (p=0.023) 
were significantly related to RD. Also in this subgroup, FSGS was not related to RD. 
Multivariate analysis revealed that serum albumin (p=0.005) and diastolic blood pressure 
(p=0.008) both had significant prognostic value for progression to RD. In 21 patients, urinary 
ȕ2-microglobulin excretion was determined. FSGS was present in eight of 21patients. 
Although urinary ȕ2-microglobulin (uȕ2m) was higher in patients with FSGS (uȕ2m: 3865.3 
vs 1041 ng/min), the difference was not statistically significant. In a previous study, we have 
demonstrated that urinary ȕ2-microglobulin >500 ng/min predicted outcome with high 
sensitivity and specificity. In the present dataset, we observed development of RD in five out 
of seven patients with uß2m >500 ng/min and in one of 14 patients with uß2m <500 ng/min 
(p<0.01). In figure 2, urinary ȕ2-microglobulin excretion is plotted against the percentage of 
FSGS. There was no strong correlation between these variables (p=0.17).
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 Figure 2. Urinary ȕ2m excretion plotted against percentage FSGS. 
 Urinary ȕ2m is a validated prognostic parameter with a reported  
threshold value of 500 ng/min. There is no significant correlation.
Meta-analysis of studies analysing the prognostic significance of FSGS in iMN  
A total of seven studies, including the present study, fulfilled the inclusion criteria.9-12;14;15
All studies were retrospective by design. Detailed data of one study were unavailable.14 An 
overview of all seven studies is given in table 5. The study by Troyanov et al. did not report  
the absolute number of patients attaining a remission.15 Only the remission rate of treated and 
untreated patients with and without FSGS were reported. However, given that FSGS was 
present in 25% of patients and the percentage of treated and untreated patients with and 
without FSGS was not reported to be different, we were able to extrapolate the number of 
patients with and without FSGS attaining a remission.  
The six papers included in the review contained a total of 695 patients with membranous 
nephropathy (235 with FSGS and 460 without FSGS). The results show a significantly 
higher remission rate for  patients with iMN alone (odds ratio, 2.5; 95% CI, 1.3–4.8) 
compared to patients with iMN and FSGS lesions (figure 3). However these results must be 
read with caution as there was considerable heterogeneity between studies. Serum creatinine, 
proteinuria and blood pressure were higher in patients with FSGS, especially in studies 
showing a higher remission rate in patients with iMN alone. Of note, the results of the meta-
analysis were not altered, if we assumed that a higher percentage of patients with FSGS in 
the study by Troyanov had been treated. 
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Discussion
Patients with iMN would greatly benefit if their prognosis could be predicted with high 
accuracy.  Several studies have defined risk factors for deterioration of renal function such as 
proteinuria, age and sex3;4;16-18 These factors, however, do not have sufficient predictive 
value for renal outcome to  allow firm decisions about start of immunosuppressive therapy. 
The level and duration of proteinuria in a model introduced by the Toronto 
Glomerulonephritis Registry proved a better predictor.5;19 We recently have validated urinary 
excretion of ȕ2-microglobulin and IgG as prognostic markers of  iMN.6;8 Sensitivity and 
specificity exceeded 85%, and when ȕ2-microglobulin excretion and serum albumin were 
combined, specificity of these parameters was 100%.  
Several studies suggested that the presence of FSGS in the renal biopsy predicted a worse 
outcome in patients with iMN.9-12 In the study of Dumoulin et al., FSGS proved an 
independent predictor of outcome, apparently outweighing clinical parameters such as 
creatinine and proteinuria. The latter study prompted the current study. 
Evidently, FSGS did not predict outcome in our patients with iMN. Our patient cohort 
consisted of patients with a nephrotic range proteinuria. During follow-up, 45% of patients 
progressed, which is in agreement with the natural history in nephrotic patients with iMN. 
Obviously, there were some differences in patient characteristics related to the presence of 
FSGS. Patients with FSGS were somewhat older and had a significantly higher baseline 
serum creatinine and more proteinuria. Univariate analysis failed in identifying FSGS as a 
predictor of RD. Clinical and laboratory parameters proved better predictors and multivariate 
analysis revealed serum creatinine and diastolic blood pressure at time of biopsy as 
independent predictive variables.  
The conclusions of our analysis could be biased by the fact that some patients already had 
renal insufficiency at the time of biopsy. Therefore, we separately analysed data of a 
subgroup of patients with normal renal function at time of biopsy. Again, we failed to 
identify FSGS as prognostic parameter.  
Another bias could have been the inclusion of patients with biopsies containing 5–9 
glomeruli. Patients with FSGS may not have been identified correctly. In our study, biopsies 
of 16 patients contained 5–9 glomeruli. In 11 patients, FSGS was not observed. Five of these 
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developed RD. Even if we would assume that all these patients had FSGS, the analysis 
would not reveal FSGS as an independent prognostic marker. 
Unfortunately, we lacked information on urinary ȕ2-microglobulin excretion in many 
patients. Urinary ȕ2-microglobulin is an accurate predictor of outcome in patients with iMN. 
In a validation study, using predefined threshold values, sensitivity and specificity exceeded 
85%. Still, the available data show a weak correlation between percentage of FSGS and 
urinary ȕ2-microglobulin excretion (figure 2). This underlines the weakness of FSGS as a 
prognostic marker.  
Several studies have evaluated FSGS as a predictor of outcome. Our meta-analysis of studies 
with available data shows that outcome is worse in patients with iMN and FSGS lesions. The 
meta-analysis does indicate that the presence of FSGS identifies high-risk patients. However, 
our data suggest that FSGS is not an independent risk factor, in agreement with all other 
studies but one. In most studies, patients with FSGS had higher serum creatinine, more 
proteinuria and more hypertension. A multivariate analysis was done in one of the older 
studies and in two recent studies, which both concluded that the presence of FSGS was not 
an independent predictor of outcome.9;14;15 FSGS emerged as an independent prognostic 
factor by multivariate analysis only in the study of Dumoulin.9 These authors studied 72 
patients with iMN, FSGS being present in 42%. The patients in this study were younger and 
had somewhat better renal function. The outcome in these patients was rather grim, with only 
24% developing persistent remission and 53% progressing to ESRD after ten years. These 
differences in patient characteristics may explain the different results.  
Especially, the timing of renal biopsy in relation to the natural outcome of the disease may be 
relevant. We propose the following sequence of events in progressive iMN: proteinuria ĺ
tubular injury reflected by increased urinary ȕ2-microglobulin ĺ focal sclerosis ĺ renal 
failure. The data of Dumoulin suggest that this model may be valid: some patients without 
FSGS at initial biopsy progressed to renal failure. These patients were rebiopsied and in all 
of them the new biopsy revealed typical FSGS lesions. Thus, the presence of FSGS may be a 
better predictor of outcome in studies where biopsies are taken in a later phase of the disease. 
It will be difficult to attain high specificity and sensitivity with histological parameters. Most 
studies use only qualitative measures. Furthermore, in routine practice renal biopsies often 
contain inadequate amounts of tissue. In our study, eight out of 61 biopsies (13%) contained 
less than five glomeruli. Thus, overall accuracy would never reach 90%, even if specificity 
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was 100%. The abovementioned studies, in fact, noted a specificity of 56–59%, clearly too 
low to be used as a guide for treatment  decisions. 
In conclusion, FSGS is not an accurate predictor of renal outcome in patients with iMN. 
Renal biopsy results cannot be used to guide decisions on immunosuppressive therapy. 
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Abstract
Background: Podocyte foot process effacement is characteristic of proteinuric renal 
diseases. In minimal change nephrotic syndrome (MCNS) foot processes are diffusely 
effaced whereas the extent of effacement varies in focal segmental glomerulosclerosis 
(FSGS). Little is known about the pathogenesis of foot process effacement. In the present 
study we studied the determinants of foot process effacement in FSGS in comparison to 
MCNS and normal kidneys.
Methods: This is a retrospective study of patients with a histological diagnosis of FSGS. 
Electron microscopic specimens of 27 patients with FSGS, 15 patients with minimal change 
nephrotic syndrome (MCNS), and 12 control patients were available for examination. 
Predefined criteria were used to make a clinical diagnosis of idiopathic or secondary FSGS. 
Foot process width (FPW) was determined by morphometric methods.  
Results: We have studied 27 patients with FSGS. A clinical diagnosis of idiopathic FSGS 
and FSGS secondary to maladaptive responses was made in 13 and 12 patients, respectively. 
Two patients with FSGS could not be classified based on clinical criteria. Median FPW was 
2551 nm in patients with idiopathic FSGS,  1083 nm in secondary FSGS, and 1725 nm in 
patients with MCNS  as compared to 562 nm in controls. Multivariate analysis revealed that 
FPW did not correlate with proteinuria or serum albumin levels but was significantly 
associated as an independent factor with the type of disease (idiopathic FSGS, secondary 
FSGS, or MCNS). An FPW > 1500 nm differentiated idiopathic from secondary FSGS with 
a high sensitivity and specificity.   
Conclusion: Idiopathic FSGS, MCNS and FSGS secondary to maladaptive responses differ 
in foot process width, independent of proteinuria. Our results show that quantitative analysis 
of foot processes may offer a potential tool to distinguish idiopathic FSGS from FSGS 
secondary to maladaptive responses.
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Introduction
Podocyte foot process effacement is an invariable feature of proteinuric glomerular diseases 
such as focal segmental glomerulosclerosis (FSGS), minimal change disease, IgA 
nephropathy and diabetic nephropathy.1-3 Few studies have assessed foot process effacement 
in a quantitative way. It was suggested that the degree of foot process effacement might 
depend on the underlying disease. In patients with minimal change nephrotic syndrome 
(MCNS), foot process effacement estimated by foot process width, was more extensive than 
in patients with proteinuric IgA nephropathy.2 The degree of foot process effacement 
appeared to be independent of the level of proteinuria, suggesting that the extent of foot 
process effacement is determined by the nature of podocyte injury.2 Podocyte damage in 
idiopathic MCNS and idiopathic (primary) FSGS has been linked to a putative glomerular 
permeability factor, which would suggest that the extent of podocyte damage is similar in the 
two disorders.4-6 Alternatively, the group of Kerjaschki demonstrated that the expression of 
dystroglycan, an adhesion molecule between the podocyte and the glomerular basement 
membrane, is significantly lower in minimal change disease compared to FSGS, suggesting 
that the mechanism of foot process fusion may differ in MCNS and FSGS.7
To our knowledge the degree of foot process fusion in FSGS has never been compared to 
that in MCNS. We are aware of a limited number of semiquantitative studies on podocyte 
alterations in patients with idiopathic and secondary forms of FSGS.8;9 These studies showed 
that the mean percentage of the glomerular surface area affected by foot process fusion was 
less in patients with FSGS secondary to maladaptive structural-functional responses, such as 
obesity, reflux nephropathy compared to idiopathic FSGS. However, there was a 
considerable degree of overlap. The semiquantitative method used in these studies in FSGS 
precludes a direct comparison with the quantitative method used to assess the degree of foot 
process effacement in patients with MCNS.2
In the present study, we have performed a morphometric analysis of podocyte foot processes 
in patients diagnosed with idiopathic and secondary forms of FSGS. The degree of foot 
process effacement in patients with FSGS was compared to the degree of foot process 
effacement in MCNS and normal kidneys.
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Subjects and Methods 
Patients and controls 
Twenty-seven patients with biopsy proven FSGS were included in the study. Light 
microscopic assessment of glomeruli for FSGS lesions was performed in accordance with the 
Columbia classification system described by D’Agati et al.10 This classification defines five 
light microscopic patterns of FSGS: FSGS not otherwise specified (NOS), perihilar variant, 
cellular variant, tip variant and collapsing variant. Adult patients with one of the above light 
microscopic variants of FSGS and either negative immunofluorescence or only segmental 
IgM and/or C3 were considered for the study.  
For comparison we have used renal biopsy material of patients with MCNS and control 
patients. Data on foot process width of 12 patients with MCNS and six patients after renal 
transplantation (used as control) were available from a previous study.2 We have added three 
additional patients with MCNS and six control renal tissue, consisting of the apparently 
unaffected part of kidneys removed because of a malignancy. 
Light microscopy and electron microscopy 
For light microscopy pieces of kidneys were fixed in Bouin’s solution overnight at room 
temperature, dehydrated and embedded in paraplast (Amstelstad Amsterdam The 
Netherlands). Two ȝm-thick sections were stained with periodic acid Schiff and 
methenamine silver.  
For electron microscopy small pieces of kidneys were fixed in 2.5% glutaraldehyde 
dissolved in 0.1M sodium cacodylate buffer, pH 7.4 overnight at 4q C and washed in the 
same buffer. The tissue fragments were postfixed in cacodylate-buffered 1% OsO4 for 2 h, 
dehydrated, and embedded in Epon 812 (Merck, Darmstadt, Germany). Ultrathin sections 
were cut on an ultratome (Leica, Reichert Ultracuts, Wien, Austria), and contrasted with 4% 
uranyl acetate for 45 min and subsequently with lead citrate for 4 min at room temperature. 
Sections were examined in a Jeol 1200 EX2 electron microscope (JEOL, Tokyo, Japan). 
Measurements of foot processes and glomerular basement membrane 
Negatives of electron micrographs (magnification x6000) were scanned at 600 d.p.i. 
resolution using a scanner (Epson Perfection 1200 Photo, Epson Europe, Amsterdam), 
resulting in a specimen-level pixel size of ~ 7 x 7 nm2. Measurement of the resulting images  
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was performed using Zeiss KS400 (Carl Zeiss Imaging Systems, Germany). The system was 
calibrated using the marker bar on the electron micrographs. The magnification data were 
verified via a grating replica with parallel lines (2160 lines/mm; EMS, Washington, USA).
The glomerular basement membrane (GBM) was indicated interactively using a graphic 
tablet. The image analysis software was used to measure the length of the GBM for each 
loop. Also, for each loop the number of podocyte foot processes overlying the capillary 
basement membrane was manually counted. A foot process was defined as any connected 
epithelial segment butting on the basement membrane, between two neighbouring filtration 
pores or slits. For each patient, the average foot process width was calculated by dividing the 
total number of foot processes by the total length of the GBM. A correction factor of S/4 was 
used to correct for presumed random variation in the angle of the section relative to the long 
axis of the podocyte.11;12 The measurements were performed without knowledge of the 
clinical data. As indicated above, we have used data of 18 patients that were previously 
reported.2 To evaluate the influence of inter-observer variation and differences in equipment, 
we have randomly measured 32 negatives of electron micrographs from these patients. There 
was a high correlation between the results obtained in both centers (r=0.97;p<0.001), 
although there was a systematic bias, measurements in our center (RUNMC) being 11% 
(confidence interval 6-16%) lower. FPW measured by our method was 1584 ± 740 nm fitting 
very well with the results from the previous study, which measured An FPW of 1432 ±805 
nm (p=ns). The difference in FPW was 11% with a 95% confidence interval of 6 to 16%. 
FPW measured by our method showed a high correlation with the data from the previous 
study (r=0.97;p<0.001).  
Clinical data 
Medical records were reviewed for clinical and laboratory data at renal biopsy. Data 
collected were: age, gender, race, weight, blood pressure, level of protein excretion, serum 
creatinine, serum albumin, serum cholesterol, use of immunosuppressive therapy and 
antihypertensive medication, initiation of dialysis and death. In addition, the medical records 
were reviewed for diseases associated with secondary FSGS: obesity (BMI > 30 kg/m2), 
renal atrophy, unilateral renal agenesis, reflux nephropathy, infections (HIV, parvovirus 
B19), medication (pamidronate, lithium, interferon-Į) or intravenous drug abuse, family 
history of renal disease, sickle cell anemia or maligancies.10;13
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Definitions 
Presentation was defined as the time when proteinuria was first detected. Nephrotic 
syndrome was defined as proteinuria of  3 g/day in association with serum albumin 
concentration of  30 g/l. Patients treated with antihypertensive drugs or with a systolic 
blood pressure > 140 mmHg or a diastolic blood pressure > 90 mmHg were considered 
hypertensive. A complete remission (CR) was defined as proteinuria < 0.3 g/24 hours with a 
stable serum creatinine concentration (< 50% increase from baseline) and a partial remission 
(PR) was defined as proteinuria between 0.3 g/24 hours and 2.0 g/24 hours with at least 50% 
reduction in proteinuria from baseline and a stable serum creatinine concentration.  
Idiopathic FSGS was defined as a serum albumin  30 g/L in two measurements in the 3 
month period before and after renal biopsy, with a normal renal size and anatomy (observed 
by intravenous urogram or renal ultrasound), a body mass index < 35 kg/m2 and no other 
discernible cause of FSGS.1 A clinical diagnosis of secondary FSGS was made in patients 
with either an identifiable cause of FSGS or nephrotic range proteinuria (> 3g/day) with a 
serum albumin > 35 g/L in two measurements in the 3 month period before and after renal 
biopsy.14
Statistical analysis 
Values are given as means ± SD or median (range) when appropriate. Differences in 
continuous data were analyzed with use of the Wilcoxon summed rank test or Kruskal–
Wallis test in case of more than two groups. If the result of the Kruskal–Wallis test was 
significant (p<0.05), then pairwise comparisons were performed with the Wilcoxon rank-sum 
test. Fisher's exact test was used for categorical data. Spearman’s rank correlation 
coefficients were calculated to assess the relation of foot process width to proteinuria, serum 
albumin and disease type (MCNS, idiopathic or secondary FSGS). Multiple regression 
analysis was performed in a forward stepwise fashion to determine the relationship between 
foot process width and variables that were significant in univariate analysis, with p<0.05 for 
inclusion of variables. As for strongly skewed variables the high values may have a  
disproportionate influence on the outcome of the analysis, the natural log transformation was 
used to reduce their impact.  
Receiver operating characteristics (ROC) curves were used to determine the most 
discriminative threshold for foot process width in predicting idiopathic FSGS, MCNS or  
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FSGS secondary to maladaptive responses. A two-sided p-value < 0.05 was considered as the 
level of statistical significance. The level of significance was adjusted for multiple 
comparisons (two-sided test, p<0.01). The analysis was performed using SPSS 14.0 for 
windows (SPSS Inc., Cambridge, MA, USA). 
Results
Baseline characteristics of the 27 patients with FSGS are shown in table 1. By clinical 
criteria, idiopathic FSGS was diagnosed in thirteen patients and FSGS secondary to 
maladaptive responses was diagnosed in 12 patients. A secondary cause was identified in 7 
out of these 12 patients: reflux nephropathy (n=2), atrophic kidney (n=2), unilateral agenesis 
of the kidney (n=1), nephrectomy after hydronephrosis (n=1) and obesity (n=1; BMI of 33.2 
kg/m2).
   
Table 1. Characteristics of patients with FSGS at biopsy. 
All patients 
(n=27)
Idiopathic FSGS 
(n=13)
FSGS secondary 
to maladaptive 
responses (n=12) 
p-value
Sex (M/F) 
Age at biopsy (years) 
Serum creatinine (ȝmol/l)  
Serum creatinine > 135 μmol/l 
Serum albumin (g/L) 
Proteinuria (g/day) 
Serum cholesterol 
Mean arterial blood pressure 
(mmHg)
Hypertension (%) 
Presentation to biopsy  
(months)
FSGS variant 
NOS
 Tip  
Perihilar 
Collapsing
18/9
47 ± 15 
174 ± 130 
48%
30 ± 10 
6.8 ± 3.6 
9.0 ± 3.1 
113 ± 14 
74%
7.3 (0.3-477) 
6
9
11
1
9/4
46 ± 15 
123 ± 97 
23%
21 ± 5 
9.3 ± 3.5 
11.3 ± 2.0 
112 ± 11 
69%
2.1 (0.5-10.6) 
2
9
1
1
7/5
50 ± 14 
221 ± 154 
67%
39 ± 4 
4.8 ± 1.5 
6.4 ± 1.4 
113 ± 18 
83%
93 (0.3-477) 
2
0
10
0
0.67
0.47
0.01
<0.05
<0.001
<0.001
<0.001
0.83
0.65
<0.001
<0.001
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Five patients had nephrotic range proteinuria with a normal serum albumin, compatible with 
a diagnosis of FSGS secondary to maladaptive responses.14 The baseline characteristics of 
these 5 patients were not different from patients with an identifiable secondary cause (table 
2). Two patients without an apparent secondary cause had a normal serum albumin and non-
nephrotic proteinuria at biopsy. These patients could not be classified based on clinical 
criteria. Perihilar FSGS was more common in patients diagnosed with secondary FSGS, 
whereas the tip lesion was seen more often in idiopathic FSGS (table 1). As expected 
proteinuria and serum cholesterol were lower in patients with secondary FSGS. These 
patients also had a higher serum creatinine concentration compared to idiopathic FSGS.  
Table 2. Baseline characteristics of patients with secondary FSGS due to maladaptive responses with 
  and without an identifiable secondary cause. 
FSGS secondary to maladaptive responses 
(n=12)
With identifiable  Without identifiable 
secondary cause (n=7)   secondary cause n=5) 
p-value
Sex (M/F) 
Age at biopsy (years) 
Serum creatinine (ȝmol/l) 
Serum creatinine > 135 μmol/l 
Serum albumin (g/L) 
Proteinuria (g/day) 
Serum cholesterol 
Mean arterial blood pressure 
(mmHg)
Hypertension (%) 
Presentation to biopsy (months) 
FSGS variant 
NOS
 Tip  
Perihilar 
 Collapsing
 4/3 
 54 ± 14 
 262 ± 182 
 71% 
 37 ± 5 
 5.0 ± 1.8 
 6.8 ± 1.4 
 120 ± 17 
 86% 
 63.7 (0.3-135) 
 2 
 0 
 5 
 0 
 3/2 
 45 ± 15 
 162 ± 88 
 60% 
 41 ± 3 
 4.5 ± 0.9 
 5.8 ± 1.3 
 104 ± 17 
 80% 
 120 (60.1-477) 
 0 
 0 
 5 
 0 
0.92
0.34
0.34
0.68
0.27
0.53
0.28
0.20
0.79
0.27
0.47
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This is probably related to the more indolent course in of FSGS secondary to maladaptive 
responses. As a consequence a renal biopsy is often not performed until renal function 
deteriorates. Six patients (46%) with idiopathic FSGS and two patients (14%) with FSGS 
secondary to maladaptive reponses received immunosuppressive therapy with prednisone 
(n=2) or prednisone and cyclophosphamide/cyclosporine (n=6) after renal biopsy . 
Remission rate at 5 years was significantly higher in patients with idiopathic FSGS (71%) 
compared to patients with FSGS secondary to maladaptive responses (9%;p<0.01).Patients 
with MCNS presented with a mean proteinuria of 9.2 ± 4.1 g/day and a mean serum albumin 
of 21 ± 5 g/L. A renal biopsy was performed within one month after presentation in 63% of 
patients with MCNS. The controls had no proteinuria with a mean serum albumin of 39 ± 7 
g/L. 
Morphometric analysis and determinants of FPW  
Median FPW was 1606 nm (range 626-6486 nm) in patients with FSGS irrespective of the 
underlying cause (idiopathic or secondary) and 1725 nm (range 1216-2685 nm) in MCNS 
(figure 1;p=ns). The foot process width in normal kidneys was significantly lower compared 
to FSGS and MCNS with a median foot process width of 562 nm (range 508-827 nm; 
p<0.001). 
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 Figure 1. Median foot process width with 95% confidence interval 
in patients with FSGS, minimal change nephrotic syndrome and controls 
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In patients with FSGS, foot process width correlated with proteinuria (r=0.58;p=0.002;figure 
2) and with serum albumin (r=-0.68;p<0.001). Foot process width also correlated with type 
of disease (idiopathic or secondary FSGS) (r=0.82;p<0.001). Exclusion of the 5 patients 
without an identifiable secondary cause did not change the association between type of FSGS 
and foot process width. On multivariate analysis, including all patient groups, type of disease 
(MCNS, idiopathic or secondary FSGS) remained the most important determinant of foot 
process width (p=0.001). 
Figure 2. Proteinuria versus foot process width in the individual patients 
with idiopathic FSGS (   ),  minimal change nephrotic syndrome (   ), FSGS 
secondary to maladaptive responses (   ) and undetermined type of FSGS (   ).  
We further analyzed the differences in foot process width between idiopathic and secondary 
FSGS in comparison with MCNS (figure 3). Foot process effacement was most severe in 
idiopathic FSGS and intermediate in MCNS, as reflected by a foot process width of 2551 nm 
(range 1581-6486 nm) and 1725 nm (range 1216-2685 nm) respectively (p=0.001 for 
idiopathic FSGS vs MCNS). Foot processes were relatively preserved in FSGS secondary to 
maladaptive responses, with a foot process width of 1083 nm (range 626-1800 nm). 
Statistical significance was p<0.001 for idiopathic vs secondary FSGS and p=0.001 for 
MCNS vs secondary FSGS. 
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Figure 3. Foot process width of patients with idiopathic FSGS, minimal 
change nephrotic syndrome (MCNS) or FSGS secondary to maladaptive 
  responses. Median foot process width is indicated by horizontal line. 
The degree of overlap in foot process width between idiopathic and secondary FSGS was 
low. Patients with idiopathic FSGS were characterized by a foot process width above 1500 
nm (table 3). ROC curve analysis showed that this cutoff value differentiated patients with 
idiopathic FSGS from secondary FSGS with a high sensitivity (100%) and specificity (83%). 
The degree of overlap between MCNS and idiopathic or secondary FSGS was high, and foot 
process width could not accurately differentiate between these diseases. 
Table 3. Predicting disease type by foot process width or disease type   
Primary FSGS 
(n=13)
FSGS secondary to 
maladaptive responses  
(n=12)
MCNS
(n=15) P-value
Foot process width 
> 1500 nm 
< 1500 nm 
13
0
2
10
10
5
<0.001
p<0.001 for difference between idiopathic FSGS and FSGS secondary to maladaptive responses   
p=0.02 for difference between MCNS and FSGS secondary to maladaptive responses 
p=0.04 for difference between idiopathic FSGS and MCNS 
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Discussion
Podocyte foot process effacement is present in most proteinuric diseases, such as MCNS, 
FSGS, membranous nephropathy, and IgA nephropathy. It is considered to be a stereotypical 
reaction of podocytes to injury or damage. Although insight in the podocytes is still 
increasing, the exact mechanism resulting in foot process effacement remains unkown.15;16
Our study confirms previous findings suggesting that the degree of foot process effacement 
is primarily dependent on the nature of the underlying disease and not a consequence of 
proteinuria.2 In multivariate analysis, type of disease was the most important determinant of 
foot process width. Admittedly, in univariate analysis, proteinuria also correlated with foot 
process effacement in patients with FSGS. However, this finding probably reflects the fact 
that foot process effacement and proteinuria are consequences of podocyte injury and not 
necessarily causally related. It also correlates with more recent insights into podocyte 
biology, indicating that both proteinuria and morphological alterations in podocytes or slit 
pores are consequences of podocyte injury.15;17;18 In an experimental model of acutely 
induced proteinuria, we observed widespread effacement of foot processes before the onset 
of proteinuria.18  Also from human studies,  there is evidence that proteinuria and podocyte 
alterations are not causally related.19 We have previously described a familial nephropathy, 
characterized by marked longstanding proteinuria but with normal podocytic foot 
processes.20  These observations strengthen our conclusion that it is the type of disease (i.e. 
MCNS, idiopathic or secondary FSGS ), rather than the amount of proteinuria, that 
determine foot process effacement. 
Over the last years several causes of podocyte injury have been identified that can lead to 
foot process effacement.17 Important causes are interference with structural components of 
the slit diaphragm complex and its lipid rafts, direct interference with the actin-cytoskeleton 
and interference with podocyte-GBM interaction.21 In addition, at least in some patients with 
idiopathic FSGS and MCNS there is evidence that podocyte injury is the direct result of a 
circulating factor.4-6 Thus far identification of this factor has been unsuccessful. The 
difference in foot process effacement in idiopathic FSGS and MCNS in our study suggests 
that the underlying cause of podocyte injury differs between the two disorders. This is in 
agreement with the notion that different plasmafactors appear to be involved in idiopathic 
FSGS and MCNS.22 Inclusion of patients with genetic mutations in basement membrane of 
podocyte proteins (dystroglycans, nephrin, podocin or actinine) may be another explanation 
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for the difference in foot process effacement.7;15;17;23 However, it is unlikely that mutations in 
any of these proteins contributed to the difference in foot process effacement. Familial forms 
were excluded after examination of the patient charts. Sporadic genetic mutations are also 
unlikely, since these mutations are rare in adult patients and if present they are characterized 
by therapy resistance.24-26 Alternatively, the difference may not be associated with the 
underlying cause, but merely represent a difference in time to biopsy. Patients with MCNS 
were biopsied earlier after onset of the proteinuria, and foot process effacement may not have 
reached the maximum extent of foot process effacement. Several animal models also suggest 
that proteinuria can precede foot process effacement. In mice deficient of laminin ȕ2, a 
component of the GBM, proteinuria develops before widespread foot process effacement.27
However, since the primary defect in this mouse model resides in the GBM, it may not fully 
reflect the situation in patients with MCNS.  A Japanese group developed an animal model 
that is similar to MCNS. Injection of mAb 5-1-6, an antigen directed at the extracellular 
domain of the rat homolog of nephrin, causes massive proteinuria without histologic 
abnormalities on light microscopy.28 Even after repeated doses for 25 weeks light 
microscopy showed minimal glomerular lesions.29 Eight days after injection of Mab 5-1-6 
partial retraction of foot processes was seen on electron microscopic examination.28 These 
models show that proteinuria can precede the effacement of foot processes. Thus, if a biopsy 
is performed shortly after the onset of proteinuria foot process effacement may be less 
severe. 
Foot processes in patients with FSGS secondary to maladaptive responses were more 
conserved than in idiopathic FSGS and MCNS. In fact, the difference in foot process 
effacement with idiopathic FSGS was large enough to define a cut-off value for foot process 
width that can predict idiopathic or secondary FSGS with a high sensitivity and specificity. 
Our results are in agreement with studies in a specific group of patients with secondary 
FSGS due to obesity.8;13 These latter studies demonstrated that obesity-related FSGS was 
characterized by relatively mild foot process fusion, indicating that idiopathic and FSGS 
secondary to maladaptive responses can be distinguished by different morphologic features. 
Admittedly measurement of foot process width is time consuming and cannot be routinely 
performed. Clinical parameters such as serum albumin are often sufficient to distinguish 
between idiopathic FSGS and FSGS secondary to maladaptive responses. In a study of 37 
patients with nephrotic range proteinuria due to biopsy proven FSGS, Praga et al. showed 
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that serum albumin was significantly lower in patients with presumed idiopathic FSGS 
(serum albumin < 30 g/L) compared to FSGS secondary to maladaptive responses (serum 
albumin > 35 g/L).14;30 However, in patients with a serum albumin between 30 and 35 g/L 
without an apparent secondary cause the distinction between idiopathic and secondary forms 
of FSGS often poses a challenge to the nephrologist caring for patients with FSGS.31 In these 
patients foot process measurement could be helpful in guiding diagnosis and prevent 
inappropriate treatment with steroids and cytotoxic agents that are not effective in secondary 
forms of FSGS.32 Our study did not include patients with a serum albumin between 30 and 
35 g/L without a secondary cause, therefore future studies in this patient group are needed to 
determine whether morphometric analysis of podocytic foot processes can guide diagnosis 
and treatment of FSGS. 
There are some potential limitations to the study. First, clinical criteria were used to make a 
diagnosis of idiopathic or secondary FSGS. By using a combination of predefined clinical 
criteria, we have tried to avoid misdiagnosis. Second, in five patients secondary FSGS was 
diagnosed without an apparent secondary cause. Nevertheless, we do feel that classification 
of these cases as FSGS secondary to maladaptive responses is justifiable. Baseline clinical 
characteristics and prognosis of these five patients were indistinguishable from patients with 
a secondary cause. Renal biopsies of all five patients showed the perihilar variant, which is 
known to be associated with FSGS secondary to maladaptive responses.1 Even more 
important, the results were not altered after exclusion of these patients from the analysis.   
In conclusion, our study demonstrates that foot process width correlates very well with 
idiopathic FSGS, MCNS and FSGS secondary to maladaptive responses, independent of the 
degree of proteinuria. Foot processes are more effaced in idiopathic FSGS than in MCNS 
suggesting different mechanism of podocyte injury. In selected cases measurement of foot 
process width can be useful to distinguish between idiopathic FSGS and FSGS secondary to 
maladaptive responses.  
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Abstract
Recurrence of primary focal glomerulosclerosis (FSGS) after renal transplantation is 
associated with poor graft survival. Plasma exchange (PE) can reduce proteinuria and even 
induce complete remission 
of proteinuria. It is, however, unknown whether the use of PE therapy improves long-term 
graft survival. In our center, PE has been used to treat recurrent FSGS after renal 
transplantation since 1994. 
Thus far, 13 patients have been treated with PE for recurrent FSGS and followed for up to 77 
months after the onset of the recurrence. We reviewed the transplantation data in these 
patients, and, for comparison, ten patients who underwent transplantation  between 1973 and 
1991 and were not treated with PE served as historical controls. Recurrence of FSGS 
occurred within 4 weeks of transplantation in 74% of the patients. PE was started within 14 
days of the onset of proteinuria in 85% of the patients. Two patients lost their graft within the 
first month of transplantation due to untreatable rejection; the remaining 11 patients (85%) 
achieved complete (n=7) or partial (n=4) remission. Seven patients remained in remission 
after a short period of treatment with PE (  18 sessions in 2 months), whereas four patients 
needed prolonged treatment (median of 58 sessions). 
The need for prolonged PE was associated with a late (>30 days after transplantation) 
recurrence of FSGS (p=0.02). A comparison with the historical control group revealed not 
only a significant reduction in proteinuria, but also significantly better long-term graft 
survival in the treated group, 85% and 30%, respectively, at 5 years (p=0.02). In conclusion, 
PE is an effective form of treatment for recurrent FSGS, especially if initiated early. Failure 
to maintain stable remission after the initial period of PE does not necessarily imply a poor 
outcome, and sustained remissions can be achieved after prolonged treatment. 
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Introduction 
The reported recurrence rate of focal glomerulosclerosis (FSGS) after renal transplantation 
averages 30%.1,2,3 The risk of recurrence is even higher (50%) in patients younger than 20 
years of age, in patients with a rapid clinical course of their original disease and also in 
patients with evidence of mesangial proliferation in their native kidney biopsy.3,4,5 Recurrent 
FSGS typically becomes manifest within 3 months of transplantation.6,7 Alterations in 
baseline immunosuppressive regimens have not influenced recurrence rate.8,9,10,11 Prognosis 
is poor in patients with a recurrence, and approximately half the patients will loose their graft 
within 5 years.4
Recent studies have suggested that recurrent FSGS is mediated by a circulating protein factor 
that alters the permeability of glomeruli.3,12 This finding has led to the use of plasma 
exchange for the treatment of recurrent FSGS. We and others have reported that plasma 
exchange treatment effectively reduces proteinuria, especially when plasma exchange is 
started shortly after onset of proteinuria.2,3,13,14,15,16,17 Long-term results of plasma exchange 
are less well known.  
Earlier, we published the short-term effect of plasma exchange treatment in seven patients 
with recurrent FSGS.13 In this paper we describe the extended follow-up of these patients, 
who have now been followed for up to 77 months after the onset of the recurrence. In 
addition, the results of plasma exchange in six more patients are reported. For comparison, 
we have used a group of historical controls, consisting of patients with recurrent FSGS not 
treated with plasma exchange. 
Patients and methods 
In the period between 1973 and 2002 a diagnosis of recurrent FSGS was made in 23 adult 
patients (17 years) who received a renal graft at our center. In 19 patients the original 
disease was biopsy proven FSGS, but in four patients a biopsy was not available pre-
transplantation. In these patients recurrent FSGS was considered the most likely diagnosis 
because heavy proteinuria developed almost immediately after transplantation and the 
transplant biopsies did not disclose evidence of other  glomerular diseases. A clinical 
diagnosis of recurrent FSGS was made in the case of a rapid onset or firm increase in 
proteinuria of > 3 g/day. The renal transplant biopsy of patients with recurrent proteinuria  
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either disclosed glomeruli with evidence of focal and segmental glomerulosclerosis on light 
microscopy (LM) or normal glomeruli on LM, but evidence of effacement of the epithelial 
foot processes on electron microscopy.13 In three patients with recurrent proteinuria no renal 
biopsy was done; however, the clinical course was compatible with a recurrence of FSGS, 
and there was a rapid improvement of proteinuria after the start of plasma exchange. 
During the study period we used different regimens of immunosuppressive therapy. From 
1973 to 1983, basic immunosuppressive therapy consisted of prednisone (25 mg/day for 1 
month tapered to 10 mg/day after 4 months) and azathioprine (3 mg/kg per day). From 1983 
to 1985, patients were treated in a randomized study with either cyclosporine A (CyA; 
starting with 17.5 mg/kg per day and tapering to 5 mg/kg per day at 3 months) and 
prednisone for the first 3 months, followed by conversion to azathioprine and prednisone 
thereafter, or azathioprine and prednisone for the whole period.18 From 1985 to 1989, all 
patients received CyA and prednisone during the first 3 months and azathioprine and 
prednisone thereafter. In the period from 1989 to 1992, patients were treated with CyA 
(starting with  12 mg/kg per day and tapering to 4 mg/kg per day at 3 months) and 
prednisone for the first 3 months and thereafter randomized for continued treatment with 
either azathioprine and prednisone or CyA monotherapy.19 From 1992 to 1997, patients were 
treated with a combination of CyA and prednisone, and since 1997, patients have been 
treated in a randomized study with mycophenolate mofetil (MMF; 1000 mg b.i.d.), 
prednisone and high-dose (10 mg/kg per day) or low-dose (6 mg/kg per day) CyA.20 Since
2000, patients have been treated with tacrolimus and MMF in combination with either 
prednisone or daclizumab. Patients who received an HLA-identical living, related-donor  
kidney were treated with different immunosuppressive regimens. Until 1985 these patients 
received azathioprine and prednisone. Thereafter, they were treated with CyA (starting with 
12 mg/kg per day and tapering to 4 mg/kg per day at 3 months) and prednisone for the first 3 
months, followed by conversion to azathioprine and prednisone. 
During their hospital stay, patients’ serum creatinine level and urine protein levels were 
measured daily. After discharge, all patients were followed weekly for the first 4 months, 
every 2 4 weeks thereafter, and at least every 3 months from 1 year on. At each visit, serum 
creatinine level and urinary  protein concentration were recorded. For the purpose of this 
study the medical records of the 23 patients with recurrent FSGS were analyzed. The 
following data were documented for each patient: gender, age at diagnosis of the original 
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disease, biopsy result, time from diagnosis to end-stage renal failure, time on dialysis, age at 
transplantation, donor source, immunosuppressive therapy post- transplantation, time from 
transplantation to recurrence, proteinuria, serum creatinine, and time from recurrence to the 
start of plasma exchange therapy. Before 1998, the time of onset of recurrent FSGS was 
defined as proteinuria exceeding 3.5 g/day. At that time we became aware that plasma 
exchange should be started as quickly as possible after onset of proteinuria. Therefore, since 
then, even lower  values of proteinuria were considered compatible with recurrent FSGS.  
Since 1994, all patients with recurrent FSGS have been treated with plasma exchange. 
Plasma exchange was performed with the CS-3000 Plus Cell Separator (Baxter, Deerfield, 
Ill., USA). A total of 1.5  plasma volumes were replaced per session with either fresh frozen 
plasma or 5% albumin. The treatment protocol consisted of daily plasma exchanges for up to 
3 days. Thereafter, intensity of plasma exchange treatment was decreased, depending on the 
clinical response. The initial cycle of plasma  exchange treatment consisted of a maximum of 
ten treatment sessions. In cases of relapse, plasma exchange was re-instituted and the 
frequency of treatment sessions was slowly reduced, based on the effect on protein excretion.  
Two patients, recipients of a kidney from a living donor, received pre-emptive treatment with 
plasma exchange. The pre-emptive treatment regimen consisted of one plasma exchange 
session on the day before transplantation. 
Complete remission was defined as proteinuria of less than 0.2 g/day and stable serum 
creatinine; a partial remission was defined as a decrease in  proteinuria of more than 50% to 
less than 2 g/day. 
Statistical analysis 
The values are given as means ± SD or median (range) when appropriate. Survival 
probabilities were calculated with the Kaplan-Meier method. Log-rank test was used for 
comparison of survival curves. For comparison between groups, an unpaired t-test or Mann-
Whitney U-test were used. Categorical variables were assessed with use of the X2-test or 
Fisher’s exact test, as appropriate. A p-value of 0.05 was considered as the level of statistical 
significance. 
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Results
A diagnosis of recurrent FSGS was made in 23 patients. Ten patients, who received 
transplants before February 1991, were not treated with plasma exchange and served as 
historical controls. In table 1 the demographic characteristics of the 13 patients with 
recurrent FSGS who were treated with plasma exchange are compared with those of the 
controls. It should be noted that recurrence could not be prevented by any of the 
immunosuppressive protocols that were used. Four patients in the plasma-exchange group 
received a graft from a living donor, and three patients had already lost one or more previous 
renal grafts due to recurrent FSGS. 
Table 1. Characteristics of  patients with recurrent FSGS treated or not treated with plasma exchange 
(PE). Values are given as mean ± SD or as median (range) or non-parametric data. 
Treated with PE 
(n=13)
Not treated with PE 
(n=10
Gender (M/F) 
Age at diagnosis (years) 
Time to ESRD (years) 
Age at transplantation (years) 
1st/2nd/3rd/4th transplantation 
Donor source 
 Cadaver 
 Living related 
 Living unrelated 
Immunosuppressive medication 
 Pred/Aza 
 Pred/CyA 
 Pred/CyA/Aza 
 Pred/MMF/Tacro 
 Pred/MMF/CyA 
Acute rejection (number of patients)
Onset recurrence (days)
Proteinuria at onset (g/day) 
Interval recurrence-biopsy (days) 
Follow-up (years) 
Allograft loss (n) 
 Due to recurrence 
8/5
27 ± 13 
8.4 ± 8.8 
40 ± 16 
10/1/1/1
 9 
 2 
 2  
 1 
 4 
 1 
 4 
 3 
 7
 4 (0-2100)
 5.7 ± 3.9 
 7 (2-93) 
 3.4 ± 2.4 
 2
 0 
6/4
24 ± 12 
7.1 ± 4.9 
33 ± 13 
10/0/0/0
 10 
 0 
 0 
 3 
 7 
 0 
 0 
 0 
 5
  9 (0-137)
 5.8 ± 4.8 
 28 (0-217) 
 3.6 ± 2.6 
 10*
 0 
ESRD = end-stage renal disease; CyA=cyclosporine; Pred = prednisone; Aza = azathioprine; Tacro = tacrolimus. *
p<0.001 
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In the control group, renal biopsy showed characteristic changes of FSGS on LM in eight 
patients. In addition, there was evidence of acute interstitial rejection in two, and of a chronic 
vascular rejection in one of these patients. In two patients, LM showed no evidence of FSGS, 
only changes compatible with  acute interstitial rejection or cyclosporine toxicity. In both 
patients there was evidence of foot process effacement on electron microscopy. No patient in 
the control group achieved remission of proteinuria. Heavy proteinuria persisted, both in 
patients treated with azathioprine and in those treated with CyA. The median time between 
the diagnosis of recurrence and graft failure was 44 months (range 0.3-97 months). Graft 
failure occurred in all ten control patients. 
Recurrent FSGS was the sole cause of graft failure in five patients. Graft failure was due to 
recurrent FSGS in combination with acute interstitial rejection in four patients and recurrent 
FSGS in combination with chronic vascular rejection in one patient. Graft survival at 3 and 5 
years was 70% and 30%, respectively (figure 1). Graft survival of the cohort of patients 
without FSGS, aged 15-55 years, who  received a first cadaveric renal graft in the same 
period (1973-February 1991; n=672) was 65% and 59% at 3 and 5 years, respectively (figure 
1). Thus, in the period that plasma exchange was not regularly used, graft survival was 
significantly lower in the patients with recurrent FSGS (p< 0.01).  
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 Figure 1.  Kaplan Meier probability of graft survival in patients with recurrence of FSGS who either 
 underwent transplantation after 1991 and were treated with plasma exchange (solid line) or underwent 
 transplantation  before 1991 (broken line). For comparison, graft survival curves are depicted in grey  
 for the contemporary patient cohort, transplanted before (broken line) and after (solid line) 1991.
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Individual data for the patients treated with plasma exchange are given in tables 2 and 3.
FSGS recurred early (within 30 days of transplantation) in ten patients and late (more than 30 
days after  transplantation) in three patients. A renal-graft biopsy was performed in ten 
patients. No glomerular abnormalities were found by LM in eight patients (nos. 1, 3, 5, 7, 9-
12); however, by electron microscopy, effacement of the epithelial foot processes was seen 
in all of them. There was also evidence of acute interstitial rejection in two of these patients 
(nos. 1 and 5) and acute vascular rejection in another patient (no. 10). In patient no. 2, whose 
biopsy showed signs of acute tubular necrosis and rejection, an adhesion was found in one 
glomerulus, suggestive of FSGS. Patient no. 6, who was biopsied 14 days after onset of the 
proteinuria, had evidence of focal segmental sclerosis on LM. A renal biopsy was not 
performed in two patients (nos. 8 and 13) because renal function and proteinuria improved 
within several days of initiation of plasma exchange. 
Finally, in one patient the diagnosis of recurrence was made late after transplantation (no. 4). 
This patient was treated with cyclosporine monotherapy. She developed mild proteinuria and 
a decrease in renal function. A renal biopsy revealed vascular changes compatible with 
cyclosporine toxicity and/or chronic vascular rejection. In the glomeruli there was mesangial 
matrix and cell proliferation with mild influx of mononuclear leukocytes. There was mild 
swelling of the epithelial cells. Electron  microscopy (EM) showed a focal fusion of the foot 
processes. Cyclosporine was replaced by  azathioprine and prednisone. Shortly thereafter, a 
tremendous increase in proteinuria occurred, without evidence of renal function 
deterioration. A clinical diagnosis of recurrent FSGS was made, but a renal biopsy was not 
done in view of the known abnormalities in the previous biopsy. 
Patients with evidence of rejection in the biopsy received anti-rejection treatment consisting 
of oral prednisone (no. 4), intravenous (i.v.) methylprednisolone (no. 5), i.v. methyl-
prednisolone followed by anti-thymocyte immunoglobulin (no.1), i.v. methylprednisolone 
followed by oral prednisone (no. 2) or i.v. methylprednisolone followed by monoclonal anti 
T-cell antibody therapy (no. 10).  
Plasma exchange was initiated within 14 days of recurrence of FSGS in 85% of patients 
(n=11) and in the two other patients at 19 and 50 days after the onset of a recurrence. Two 
patients (nos. 2 and 5) lost their graft after 0.7 and 1.0 month because of concomitant biopsy 
proven untreatable rejection.  
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Table 2. Characteristics of patients treated with plasma exchange for recurrent FSGS after 
transplantation.  
Patient
No. 
Age at Tx 
(years) 
Gender Time to 
ESRD 
(years) 
Time on 
dialysis 
(months)
Donor
source
Immuno-
suppressive
medication
ATN Number
of Tx 
1
2
3
4
5
6
7
8
9
10
11
12
13
46
54
59
27
37
17
32
50
68
43
20
49
20
male  
male 
male 
female
male 
male 
female
female
male 
male 
male 
female
female
6.6
0
19.3
5.7
2.7
5.2
6.0
18.4
30.2
1.4
7.0
4.7
2.4
11
48
28
57
61
28
57
23
49
242
29
29
90
CAD
CAD
CAD
CAD
LRD
CAD
CAD
LURD
CAD
LURD
LRD
CAD
CAD
P-CyA 
P-Aza 
P-Aza 
CyA 
P-CyA-Aza 
P-CyA 
P-CyA 
P-Tac-MMF 
P-Tac-MMF 
P-Tac-MMF 
P-CyA-MMF 
P-CyA-MMF 
P-Tac-MMF 
No
Yes
No
No
No
No
No
No
Yes
No
No
No
Yes
1st
1st
1st
1st
3rd
1st
1st
1st
1st
4th
1st
1st
2nd
ATN = acute tubular necrosis; Tx=transplantation; ESRD=end-stage renal disease; CAD=cadaveric; LRD=living 
related donor; LURD=living unrelated donor; MMF=mycophenolate mofetil; P=prednisone; Tac=tacrolimus. 
In all the remaining patients treatment with plasma exchange resulted in a decrease in 
proteinuria. Seven patients achieved sustained remission of proteinuria, either complete 
(n=5) or partial (n=2). Four patients suffered a relapse and needed prolonged treatment. 
However, after a median of 58 sessions (range 43-63 sessions) these four patients also 
achieved complete (n=2) or partial (n=2) remission. 
Subgroup analysis of the 11 patients without graft failure showed that those with a late 
recurrence (> 30 days after transplantation) were more likely to need prolonged therapy 
(p=0.02). These patients  also tended to be younger (p=0.08). During follow-up, serum 
creatinine has remained stable in all 11 patients. For patients treated with plasma exchange, 
graft survival after recurrence of FSGS was as high as 85% at 5 years (Fig. 1). Graft survival 
was significantly better for patients who underwent plasma exchange than for historical 
controls (p=0.02). Graft survival of the cohort of patients without FSGS, aged 116-69 years, 
who received either a renal graft from a living donor or a cadaveric renal graft in the same 
period (after May 1991; n=1,032) was not significantly different, with 72% at 5 years.
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Discussion
Our study clearly demonstrates that patients with recurrent FSGS after transplantation benefit 
from treatment with plasma exchange. We have extended our previous observations that 
plasma exchange therapy rapidly decreases proteinuria in the majority of patients.13 Most 
importantly, the beneficial effects of plasma exchange are well maintained during longer 
follow-up, thus improving graft survival rates in our cohort of treated patients when 
compared with untreated, historical controls. Admittedly, the use of historical controls 
introduces a bias, since, in recent years, supportive therapy and immunosuppressive 
treatment have changed. However, most authors would agree that outcome is poor in patients 
with recurrent FSGS who are not treated with plasma exchange. Reported rates of graft 
failure in untreated patients vary from 58% to 68% in adults and from 50% to 80% in 
children, values comparable to the 70% graft failure rate at 5 years in our historical 
controls.2,4,9,21,22 Moreover, we have compared graft survival rates of our patients with 
recurrent FSGS with graft survival rates of patients who received transplants in the same 
periods. It is evident that graft survival of patients with recurrent FSGS was significantly less 
in the period before 1991. This survival disadvantage was completely lost with the 
introduction of plasma exchange after 1991. This indicates that plasma exchange, and not a 
different immunosuppressive regimen, caused the difference in graft survival between 
patients treated with plasma exchange and the historical controls. 
Could our results have been biased otherwise? We have included three patients in whom a 
diagnosis of recurrent FSGS was made on clinical grounds, i.e., the rapid occurrence and 
incremental rise of proteinuria after transplantation. Some authors have required histological 
evidence of FSGS in the allograft before starting plasma exchange.17,23 However, in early 
biopsies, glomerular lesions are mostly absent under LM.13, 24
Moreover, we feel that the clinical course in patients with recurrent FSGS is quite specific. 
Recently, Kaplan- Pavlovcic et al.25 have also provided evidence that the development of 
nephrotic range proteinuria early after transplantation is sufficient to allow a diagnosis of 
recurrent FSGS. 
We have included two patients who were pre-emptively treated with plasma exchange 
therapy. One might argue that the inclusion of these patients may have favored the outcome 
data. This is unlikely, however, since these patients still developed massive proteinuria after 
transplantation, which necessitated further plasma exchange therapy. Also, exclusion of these  
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patients did not alter the results. From the patients' characteristics, one might even have 
suspected a worse prognosis in our treated patients, since we have  included patients who 
received a second, third and fourth transplant after having lost a previous graft due to 
recurrent FSGS. Also, we have allowed living-donor transplantation. This demonstrates the  
change in our recent policy, being less restrictive in accepting patients with FSGS for 
transplantation, in view of the potential benefits of plasma exchange therapy. 
Overall, 11 patients (85%) achieved sustained remission of proteinuria (54% complete, 3 1 % 
partial). Admittedly, in four of these patients repeated courses of plasma exchange therapy 
were needed. Young age and development of a recurrence somewhat later after renal 
transplantation characterized these patients. Still, it is evident that prolonged treatment is 
justified in view of the good ultimate outcome. The overall rate of sustained remissions in 
our study is quite high when compared with the reported remission rates in adult patients, 
which range from 15% to 67%. A likely explanation for the difference in remission rates is 
the early initiation of plasma exchange therapy in our patient group, with treatment being 
started within 14 days in 85% of patients. Larger series also suggest an association between 
rapid initiation of plasma exchange and remission rates, since all remissions in these studies 
occurred in patients who were started on plasma exchange early after the onset of  recurrent 
disease.3,14,17,26 In addition, although the onset of a recurrence cannot be prevented by any of 
the immunosuppressive regimens used, relapse after plasma exchange might be prevented by 
an immunosuppressive maintenance regimen containing prednisone. We have recently 
described a patient (no. 12) who was initially managed on steroid-free immunosuppression.27
Proteinuria recurred whenever plasma exchange therapy was reduced. Only after re-
introduction of prednisone was sustained remission achieved. A review of the literature data 
on recurrent FSGS supports the notion that prednisone must be part of the 
immunosuppressive therapy to achieve a sustained remission of proteinuria after plasma 
exchange treatment (table 4). In addition to our study, sustained responses in adult patients 
have also been reported by Artero et al.2  In contrast, in the studies of Dantal et al. most 
patients suffered a relapse of proteinuria after discontinuation of plasma exchange.3,28
Differences in baseline characteristics and timing of initiation of plasmapheresis treatment 
cannot explain these differences. However, the maintenance immunosuppressive regimen 
was clearly different, prednisone being stopped within 60 days of transplantation by Dantal. 
Matalon et al. also reported a low rate of sustained remissions. In this study, however, 
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plasmapheresis was initiated more than 30 days after recurrence in over half the patients.17
This probably contributed to the lower rate  of remission. Furthermore, the latter authors do 
not report the duration or dose of prednisone therapy. Plasmapheresis treatment has been 
more effective in children, with over 60% achieving sustained, plasmapheresis-independent, 
remission of proteinuria (table 4).14,15,16,29
Table 4. Results of plasmapheresis for recurrent FSGS after renal transplantation in adults and 
children.
Author Number of 
patients (n)
Interval recurrence 
to plasmapheresis 
(days) 
Sustained
remission (%) 
Prednisone part 
of maintenance 
immunosuppressive
therapy? 
Adults
 Artero et al.26 9 19 (9-91) 67 Yes
 Dantal et al.3 9 28 (21-120) 0 No
 Dantal et al. 28 8 63 (11-292) 13 No
 Matalon et al.17 13 60 (0-1520) 8 NA
 Present study 13 6 (-1-50) 85 Yes
Children
 Cheong et al.31 6 NA 33a Yes
 Cochat et al.29 3 10 (7-18) 10 Yes
 Dall’ Amico et al.15 13 NA 62 Yes
 Greenstein et al.14 6 2 (1-441) 83 Yes
 Laufer et al.16 2 124 (86-180) 100 Yes
a Two children also had an acute rejection and plasmapheresis treatment was delayed for 2 months in another child. 
NA = not available. 
Notably, in children, plasmapheresis treatment has been accompanied by more intensive 
immunosuppression, either pulse  solumedrol, cyclophosphamide or high-dose CyA. 
Furthermore, in all studies in children, prednisone has been part of maintenance 
immunosuppression.   
In children, there is also limited evidence that recurrent FSGS can be successfully treated 
with high-dose intravenous CyA, without the need for plasma exchange. A recently 
published uncontrolled study by Salomon et al. demonstrated that high-dose intravenous 
CyA could induce persistent remission of proteinuria in 65% of children with recurrent 
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FSGS.30 The role of highdose intravenous CyA in adults is unknown. Of note, we observed 
recurrences of FSGS in 15 patients who were treated with i.v. CyA for 3 days, followed by 
high-dose oral CyA therapy. 
In conclusion, plasma exchange therapy improves outcome in patients with recurrent FSGS. 
For a high success rate to be obtained, plasma exchange therapy must be instituted shortly 
after onset of the recurrence. If a relapse of proteinuria occurs after the first course of plasma 
exchange, prolonged treatment is warranted. In view of the improved outcome with plasma 
exchange, we have adopted a less-restricted policy for transplantation in patients with 
primary FSGS. 
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Patients with focal glomerulosclerosis (FSGS) are at high risk for developing recurrent 
disease after renal transplantation.1 Recent studies indicate that plasmapheresis effectively 
reduces proteinuria in most patients with recurrent FSGS.2-5 However, in many patients 
proteinuria recurs after cessation of plasmapheresis treatment.3 Thus far, the role of 
immunosuppressive therapy in preventing or treating recurrent FSGS is unclear. We describe 
a patient with recurrent FSGS in whom maintenance therapy with prednisone proved 
essential to achieve a persistent remission of proteinuria.  
In 1992, a 42-year-old woman presented with biopsy proven FSGS. She developed end-stage 
renal disease in 1996 and received a cadaveric renal graft in 1999. There was immediate 
graft function. Six weeks after transplantation, overt proteinuria was noted. At that time, 
immunosuppressive medication consisted of prednisone (15 mg daily), cyclosporine A 
(target trough level 200–400 ng/mL), and mycophenolate mofetil (1 g twice daily). A renal 
biopsy specimen was normal except for complete effacement of the epithelial foot processes 
on electron microscopy. A diagnosis of recurrent FSGS was made, and treatment with 
plasmapheresis was started, resulting in a complete disappearance of proteinuria (figure).
However, the subsequent course was characterized by recurrences of proteinuria, which 
responded to intensified plasmapheresis treatment (figure). Plasmapheresis at weekly 
intervals was needed to maintain a stable remission. 
In the meantime, the immunosuppressive regimen had been changed. Prednisone treatment 
was tapered from 3 months after transplantation and ultimately stopped at 11 months because 
of severe osteoporosis. Furthermore, immunosuppressive maintenance therapy with 
mycophenolate mofetil (750 mg twice daily) was not tolerated because of severe 
gastrointestinal side effects. Cyclosporine A caused renal dysfunction and sirolimus 
persistent ulceration of the mouth. 
Therefore, 15 months after transplantation, prednisone (10 mg twice daily) was started again 
in combination with tacrolimus. One month later, plasmapheresis treatment had to be 
stopped because of an acute thrombosis of the arteriovenous-fistula; an attempt to create a 
new one failed. Much to our surprise, proteinuria did not recur. To minimize side effects, 
prednisone was slowly tapered from 18 months after transplantation and finally stopped and 
replaced by azathioprine at 26 months. Within 1 month, proteinuria returned.  
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Reintroduction of prednisone (10 mg twice daily) resulted in an almost immediate decrease 
of proteinuria (figure). Currently the patient is treated with tacrolimus, azathioprine, and 
prednisone (5 mg twice daily), with no proteinuria and a stable creatinine of 1.2 mg/dL. 
It is evident that prednisone treatment cannot prevent the development of recurrent FSGS. In 
fact, even the introduction of the newer immunosuppressive agents has not influenced 
the incidence of recurrent FSGS. Although not proven in controlled studies, plasmapheresis 
therapy effectively induces remission of proteinuria. The literature is somewhat conflicting 
about the potential to achieve a persistent remission after cessation of plasmapheresis. We 
believe that the course in our patient strongly suggests that the use of prednisone may be 
essential in maintaining a sustained remission of proteinuria in patients with plasmapheresis-
dependent recurrent FSGS after renal transplantation. Admittedly, prednisone may not be the 
only beneficiary agent. The potential role of the immunosuppressive regimen in the treatment 
of recurrent FSGS is further illustrated by the fact that sustained remissions are more often 
observed in children than in adults: in the former group, plasmapheresis therapy is most often 
combined with the addition of cyclophosphamide or a large increase in cyclosporine dose.5
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Abstract
We describe a 24-year old female patient with recurrent focal segmental glomerulosclerosis 
(FSGS) after renal transplantation. At the age of 10 years, the patient presented with a 
nephrotic syndrome due to biopsy proven FSGS. Three years after presentation she 
progressed to end-stage renal disease. A first renal transplant failed due to recurrent FSGS. 
Seven years later the patient received a second renal transplant. One week after 
transplantation, recurrent FSGS was diagnosed. Treatment with plasma exchange (PE) 
resulted in a complete remission. However, three months later proteinuria recurred, which 
responded to another course of PE. A third relapse was diagnosed two years later. A renal 
biopsy confirmed recurrent FSGS. A new remission was attained with PE, however the 
following 15 months attempts to reduce PE frequency failed and the patient remained 
dependent on PE. Therefore, it was decided to treat the patient with 4 weekly doses of 
rituximab i.v. (375 mg/m2). Over the next months PE treatment could be reduced and was 
ultimately stopped. A relapse was successfully treated with a new infusion of rituximab. At 
present the patient has attained a partial remission of proteinuria with a stable serum 
creatinine. In conclusion, B-cell depletion with rituximab may benefit patients with PE 
dependent recurrent FSGS.    
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Introduction 
Focal segmental glomerulosclerosis (FSGS) can recur after renal transplantation and is 
associated with a reduced graft survival. In case of recurrent FSGS, treatment with plasma 
exchange (PE) results in a remission of proteinuria in up to 85% of patients, especially if 
started shortly after the onset of recurrence.1;2 However, many patients require repeated 
courses of PE because of frequent relapses.1;3 Recently, a 7-year old boy with recurrent 
FSGS after renal transplantation responded to rituximab, a monoclonal anti-CD20 antibody, 
which was administered for a transplantation-related lymphoma.4 We describe the results of 
treatment with rituximab in a 24-year-old female patient with recurrent FSGS after renal 
transplantation.  
Case
At the age of 10 years, the patient presented with a nephrotic syndrome due to biopsy proven 
FSGS. Treatment with prednisone, cyclophosphamide, and cyclosporine was unsuccessful 
and end-stage renal disease (ESRD) developed within 3 years after presentation. At the age 
of 13 years the patient received a renal graft, which failed after one year due to recurrent 
FSGS. Seven years later, she received a second renal graft. Baseline immunosuppressive 
therapy consisted of prednisone (10 mg), tacrolimus (target through level 15-20 mg/l) and 
mycophenolate mofetil (MMF 750 mg bid). There was almost immediate graft function. One 
week after transplantation the patient developed nephrotic range proteinuria. A presumptive 
diagnosis of recurrent FSGS was made. Treatment with PE was started immediately and 
resulted in a complete remission. Three months after cessation of PE proteinuria recurred. At 
that moment the immunosuppressive regimen consisted of prednisone (15 mg) and 
tacrolimus (target through level 5-10 mg/l). A second course of PE (8 sessions) again 
resulted in a complete remission. A third relapse occurred 2 years later. To exclude other 
causes of proteinuria a biopsy of the renal graft was performed, which demonstrated diffuse 
foot process effacement, without significant lesions on light microscopy and IF, favoring a 
diagnosis of recurrent FSGS. Although treatment with PE induced a remission of proteinuria, 
repeated trials of cessation of PE failed (figure). A remission of proteinuria could only be 
maintained with continuous PE (one session every 7-10 days), even though the patient was  
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treated with a more intensive immunosuppressive regimen consisting of prednisone (10 mg), 
tacrolimus (target through level 5-10 mg/l), and MMF (500 mg bid), which was replaced by 
azathioprine (2 mg/kg/day) because of gastrointestinal side effects. Because of PE 
dependency, the decision was made to start treatment with rituximab. She tolerated the entire 
course of 4 weekly infusions (375 mg/m2) without significant side effects, although we 
observed a temporary neutropenia. B-cell markers were measured 4 months after completion 
of rituximab therapy. Both CD19+ and CD20+ B-cells were undetectable. In the first 4 
months after treatment with rituximab three PE sessions were necessary because of 
increasing proteinuria. Thereafter, proteinuria gradually decreased without further 
interventions. Seven months after treatment with rituximab a partial remission was attained. 
Nine months later she experienced a relapse of proteinuria (figure). At that time CD19+ and 
CD20+ B-cells were still undetectable. The patient was retreated with a single infusion of 
rituximab 1000 mg. Proteinuria gradually decreased, and a partial remission  was reached 
two months after treatment.  
Discussion
Our case report indicates that rituximab may be effective in patients with recurrent FSGS 
after renal transplantation. Admittedly, we cannot exclude that PE contributed to the 
response after initial therapy. However, the efficacy of rituximab was virtually proven by the 
response to rituximab monotherapy after relapse.  
Rituximab was used with apparent success in children with recurrent FSGS (table).4;5 These 
children were treated with rituximab for EBV-related posttransplant lymphoproliferative 
disease (PTLD). Coincident with the remission of the PTLD proteinuria also disappeared. In 
contrast, two children without PTLD failed to respond to treatment with rituximab for 
recurrent FSGS after renal transplantation.6 Data in adults are also conflicting. Recently, 
Hristea and Kamar reported three adult patients with recurrent FSGS after transplantation 
(table).7;8 One patient did not respond to rituximab, the other two patients attained a 
remission of proteinuria. However, since both patients were simultaneously treated with PE, 
it cannot be excluded that PE alone induced the remission. In contrast, Gossmann reported a 
patient who was resistant to treatment with PE but responded to rituximab.9 Recurrent FSGS 
has been attributed to a thus far unidentified circulating permeability factor and T-cells have 
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 Rituximab in recurrent FSGS after renal transplantation
been implicated as a source of the permeability factor.2;10;11 The efficacy of rituximab might 
suggest that recurrent FSGS is dependent on a B-cell derived antibody or cytokine. However, 
B-cells are important for T-cell activation, thus rituximab may exert its effect by indirectly 
affecting T-cell function.12;13 In our patient, the first remission was attained more than 5 
months after treatment with rituximab. The time to remission is clearly longer compared to 
previous case reports in recurrent FSGS and minimal change disease, but similar to studies 
performed in patients with refractory SLE or ANCA associated vasculitis (AAV).4;5;7 In these 
patients, especially those with SLE, attainment of a remission can take up to 8 months after 
treatment with rituximab.14;15 The slower response has been attributed to different kinetics of 
tissue and peripheral blood B-cells.16 Studies involving a murine model for human CD20 
expression demonstrated that depletion is slower for tissue B-cells than for peripheral blood 
B-cells.17 In humans with rheumatoid arthritis, treatment with rituximab also resulted in a 
variable degree of depletion of B-cells in bone marrow.18 Slow depletion of tissue B-cells 
may thus explain the slower response in our patient. 
Alternatively, the difference in response to rituximab may be associated with different types 
of plasma cells. It is known that some plasma cells have short life spans, whereas other 
plasma cells are able to live for extended periods of time continuously secreting 
antibodies.19;20 Rituximab only results in depletion of immature and mature B–cells, but not 
plasma cells. Thus, depending on the type of plasma cells that are involved (short- or long-
lived), time to remission may differ.  
Our patient relapsed before the return of circulating B-cells. This has also been described in a 
few patients with SLE and AAV.14 This finding also underscores the possible role of tissue 
B-cells. Stimulation of T-cells by tissue B-cells that return before peripheral blood B-cells 
are measurable could explain the development of a relapse in the presence of undetectable 
CD19 positive B-cells.14
In conclusion, rituximab appears to offer a new treatment option for patients with recurrent 
FSGS after renal transplantation. Further studies are necessary to confirm our findings and to 
elucidate the pathogenetic role of B-cells. 
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Abstract
Focal segmental glomerulosclerosis (FSGS) is one the most important causes of the 
nephrotic syndrome in adult patients. FSGS is not a disease entity. The identification of 
underlying causes of FSGS (secondary FSGS) has increased our insight in the pathogenesis 
of FSGS. Moreover, differentiating between primary (idiopathic) and secondary forms of 
FSGS is important to allow appropriate treatment. Recently a new pathological classification 
of FSGS was proposed, expanding FSGS to include non-sclerotic lesions. In this review we 
discuss the current diagnostic and therapeutic options in patients with FSGS. 
Introduction 
In 1957, Rich provided the first detailed pathologic description of focal segmental 
glomerulosclerosis (FSGS).1 It was not until the 1970’s that FSGS emerged as a separate 
clinico-pathologic entity.2 Currently, FSGS is one of the most common patterns of 
glomerular injury encountered in human renal biopsies.3 A recently proposed pathology 
classification has pointed to the existence of new, non-sclerotic forms of FSGS.4
FSGS is usually divided in idiopathic (primary) FSGS or secondary FSGS (table 1). This 
distinction is important because treatment differs depending on the underlying cause.5 For a 
long period of time idiopathic FSGS in adults has been considered to be prednisone 
resistant.6 The initial results of treatment with corticosteroids were extremely disappointing 
with complete remission rates below 15% in almost all studies performed before 1980.7-14
However over the last 25 years the results of treatment have improved, with complete 
remission rates exceeding 30-40%.15-27 As put forward by Korbet, the improvement in 
response appears to be associated with longer duration of treatment with corticosteroids.28
Based on the experience in children, the earlier studies in adults limited the use of 
corticosteroids to eight weeks. However, the response of adults to corticosteroids appears to 
be much slower than in children.15;23;29 In this review, we provide an update on the diagnosis 
and treatment of FSGS. 
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Table 1. Etiologic classification of FSGS  
Idiopathic (primary) FSGS 
Secondary FSGS 
 1. Familial 
A. Mutations in Į-actinin 4 
B. Mutations in nephrin 
C. Mutations in podocin 
D. Mutations in WT-1 
E. Mutations in CD2-associated protein 
F. Mutations in TRPC 6 
G. Mitochondrial cytopathies 
 2. Virus associated 
A. HIV-associated nephropathy  
B. Parvovirus B19 
 3. Medication 
A. Heroin-nephropathy 
B. Interferon-Į
C. Lithium 
D. Pamidronate / Alendronate 
 4. Adaptive structural-functional responses likely mediated by glomerular hypertrophy or hyperfiltration 
  4.1 Reduced renal mass 
   A. Oligomeganephronia 
   B. Unilateral renal agenesis 
   C. renal dysplasia 
   D. Cortical necrosis 
   E. Reflux nephropathy 
   F. Surgical renal ablation 
G. Chronic allograft nephropathy 
H. Any advanced renal disease with reduction in functioning nephrons 
 . 4.2 Initially normal renal mass  
   A. Diabetes mellitus 
   B. Hypertension 
   C. Obesity 
   D. Cyanotic congenital heart disease 
   E. Sickle cell anemia 
 5. Malignancy (lymphoma) 
Nonspecific pattern of FSGS caused by renal scarring in glomerular disease 
A. Focal proliferative glomerulonephritis (IgA nephropathy, lupus nephritis, pauci-immune focal 
necrotizing and crescentic glomerulonephritis) 
B. Hereditary nephritis (Alport syndrome) 
C. Membranous glomerulopathy 
D. Thrombotic microangiopathy 
Adapted from D’Agati et al.4
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Diagnosis of idiopathic and secondary FSGS 
Distinguishing among idiopathic and secondary forms is not merely semantic, but has 
important therapeutic implications as discussed below. Generally, the distinction can be 
made from the history (with special attention to secondary causes) and some additional 
laboratory (serum albumin) and radiologic studies (chest X-ray and kidney ultrasound).  
In patients with nephrotic range proteinuria ( 3 g/day), serum albumin is an important 
clinical parameter to distinguish between FSGS secondary to hyperfiltration and other forms 
of FSGS.  In a study of 37 patients with nephrotic range proteinuria due to biopsy proven 
FSGS, Praga et al. showed that serum albumin was significantly lower in patients with 
presumed idiopathic FSGS (serum albumin <30 g/L) compared to FSGS secondary to 
massive obesity, vesicoureteral reflux, or renal mass reduction (serum albumin > 35 g/L).30
In contrast to hyperfiltration-associated FSGS other forms of secondary FSGSG such as 
viral-associated FSGS, drug-induced FSGS and familial FSGS may also present with a low 
serum albumin. Especially, the latter form cannot be differentiated from idiopathic FSGS on 
clinical grounds. 
Although clinical data and serum albumin levels thus often allow to differentiate between 
idiopathic FSGS and FSGS secondary to hyperfiltration, sometimes discussion remains, 
especially in patients with a serum albumin between 30 g/L and 35 g/L. It has been suggested 
that these forms could be differentiated by evaluation of foot process effacement in electron 
microscopy, with mild effacement occurring in secondary FSGS and complete effacement in 
idiopathic FSGS.31;32 In a recent study of podocyte alterations we noted that the mean foot 
process width was significantly higher in patients with idiopathic FSGS compared to 
secondary FSGS mediated by adaptive structural-functional responses.33 The association 
between foot process width and type of FSGS was independent of proteinuria. Furthermore, 
the degree of overlap in foot process width between idiopathic and secondary FSGS was low, 
suggesting that quantitative assessment of foot processes may provide a means for 
distinguishing between idiopathic and secondary FSGS. Electron microscopy can also help 
in determining other underlying causes of FSGS. Special attention should be paid to the 
presence of tubulo-reticular inclusions in endothelial cells (HIV), viral particles, or the 
presence of abnormal mitochondria in the podocyte (mitochondrial DNA mutation).  
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A positive family history identifies patients with FSGS based on mutations in podocytic 
proteins.34-36 Obviously, it is important to consider if patients with FSGS need genetic testing 
to evaluate spontaneous mutations. In contrast to children, spontaneous mutations in adults 
with FSGS are rare, with a reported prevalence of 1.5-5%.37-39 He et al. screened 78 adult 
patients with non-familial FSGS (15 steroid-sensitive and 63 steroid-resistant) for known 
mutations in the podocin gene. Compound heterozygous mutations were detected in only one 
patient with steroid-sensitive FSGS, no homozygous mutations were found. These results are 
consistent with the findings of Caridi et al, who found only 3 heterozygous mutations in a 
cohort of 64 patients with steroid-resistant nephrotic syndrome.38 The study by He et al. also 
identified 8 patients with heterozygous R229Q, a podocin polymorphism. The allele 
frequency of this variant did not differ from normal controls. The significance of the R229Q 
variant as a disease causing mutation in FSGS is currently unknown.40 Similarly, mutations 
in the gene encoding Į-actinin-4 are also rare. Aucella et al. found no Į-actinin-4 gene 
mutations in 33 adults with non-familial FSGS.39 In view of the low incidence of 
spontaneous mutations, we do not recommend mutation screening in adult patients with non-
familial FSGS.   
Prognosis
Important clinical features predicting the clinical course of FSGS are the amount of 
proteinuria and the level of plasma creatinine. Half of the patients presenting with a 
proteinuria >3 g/day or a serum creatinine over 115 ȝmol/l progress to end-stage renal 
disease within 5-10 years.16;21;41 Renal survival is even worse if proteinuria exceeds 10 g/day, 
with ESRD occurring in majority of patients within 5 years after presentation. In contrast, 
non-nephrotic proteinuria portends a much better prognosis, with a renal survival of >80% 
after 10 years.30;42 Still, the single best predictor of a favorable outcome is attainment of a 
complete or partial remission of proteinuria. Less than 15% of patients attaining a remission 
progress to ESRD.15;27;43 Most reported remissions were induced by steroid therapy and it is 
generally suggested that spontaneous remissions occur infrequently in patients with FSGS. 
However, we have recently shown a high spontaneous remission rate of 60% in patients with 
idiopathic FSGS who present with a normal renal function. These patients were characterized 
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by a selective proteinuria (selectivity index <0.2) at presentation and by a serum albumin > 
20 g/l and a proteinuria < 8 g/day at three months after renal biopsy.44
Other authors have attempted to determine if prognosis in patients with FSGS can be 
predicted. Bazzi et al. showed that a fractional excretion (FE) of IgG <0.14%, was associated 
with a high remission rate after immunosuppressive therapy.45 In contrast, patients with a FE 
of IgG > 0.14% had a dismal prognosis even with immunosuppressive therapy. Recently, we 
have also reported on the predictive value of FE IgG in 32 patients with idiopathic FSGS.46
Our data do not support the conclusion of Bazzi that FE IgG predicts resistance to 
immunosuppressive medication. Although a FE IgG >0.14% was associated with worse 
baseline characteristics, remission rate was high (59%) and not different from patients with 
FE IgG < 0.14%. Therefore, until more data become available, FE IgG should not be used to 
guide treatment in patients with FSGS. 
Approximately 50% of patients who develop a remission after prednisone therapy will 
develop recurrent proteinuria during tapering of the prednisone (steroid dependent) or after 
stopping treatment (relapse). Patients who do not develop a remission after a minimum of 8-
16 weeks of prednisone therapy are called steroid resistant. The latter definition is subject to 
debate (see below) 
proteinuria (selectivity index <0.2). In addition these patients were characterized by a serum 
albumin > 20 g/l and a proteinuria < 8 g/day at three months after renal biopsy.44   
Treatment
Obviously, in patients with secondary FSGS therapy should be directed at the underlying 
disorder or removal of the inciting drug. In patients with severe obesity, weight loss (>10% 
of BMI) induces a significant decrease of proteinuria, which is almost similar to the effect of 
ACEi .47 However, maintaining the weight loss is often difficult and many patients relapse.48
Small cohort studies suggest that antiretroviral therapy improves renal survival in patients 
with HIV-associated FSGS.49;50 Case reports also provide support for the use of antiretroviral 
therapy, with recovery of dialysis-dependent renal failure after initiation of antiretroviral 
therapy.51 FSGS associated with hematological conditions such as multiple myeloma and 
(non) Hodgkin lymphoma’s often responds with a resolution of the proteinuria after 
successful treatment of the underlying hematological condition.52;53 Familial forms of FSGS 
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are known to be steroid-resistant.35;54-56 A possible exception are patients with a non-familial 
(sporadic) heterozygous podocin mutation.57
It is well known that blood pressure control and reduction of proteinuria significantly slows 
the progression of renal insufficiency in patients with proteinuric nondiabetic renal disease.58-
62 Proteinuria should be reduced to <0.5 g/day. Target blood pressure are 130/80 mmHg in 
patients with proteinuria 1 g/day and 125/75 mmHg in patients with proteinuria >1 
g/day.60;63 ACE inhibitors (ACEi) or in case of side effects angiotensin receptor blockers 
(ARB), are preferred because they are more effective than other antihypertensive agents in 
slowing the progression of most nondiabetic kidney diseases.58;63;64 Despite the recognized 
beneficial effect of ACEi in patients with chronic kidney disease, little is known about the 
efficacy of ACEi in patients with idiopathic FSGS. Although ACEi reduce proteinuria in 
idiopathic FSGS, the few available studies suggest that ACEi rarely induce a complete 
remission and development of end-stage renal disease is not prevented.65;66 However, there is 
some evidence that ACEi slow the progression to ESRD.67 Furthermore, treatment with 
ACEi also improves the hypoalbuminemia and hyperlipidemia that is associated with 
idiopathic FSGS.68 Therefore treatment with ACEi is recommended for all patients with 
FSGS. The antiproteinuric effect of ACEi is most prominent in patients who are on a low 
sodium diet (50-100 mmol/day) or who are treated with diuretics, since relative volume 
depletion results in greater angiotensin II-dependence of the glomerular microcirculation. 
Other antihypertensive drugs should be added if the goals for blood pressure and proteinuria 
are not reached with ACEi, a low sodium diet and diuretics.  
An abnormal lipid metabolism usually accompanies a nephrotic syndrome. Most prominent 
are an increased LDL-cholesterol, hypertriglyceridemia and an increased lipoprotein A 
(LP(a)).69;70 This combination is highly atherogenic.71;72 HMG CoA reductase inhibitors 
(statins) are very effective in lowering total and LDL cholesterol and to a lesser degree 
triglycerides and LP(a), also in patients with a nephrotic syndrome.73-77 Although a 
cardioprotective effect of statins has never been proven in patients with a nephrotic 
syndrome, prevention studies in the general population with similar lipid disorders have 
shown a marked reduction of cardiovascular diseases.78;79 Notably, recent studies have also 
suggested that the use of statins in patients with proteinuria attenuates the deterioration of 
renal function.80;81
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Immunosuppressive therapy should be considered in patients with idiopathic FSGS and a 
proteinuria 3 g/day. Current recommendations for the initial treatment of idiopathic FSGS 
are almost entirely based on retrospective studies.15 Data from these studies show that 
corticosteroids remain the mainstay of treatment in idiopathic FSGS. Remission rates do not 
improve if cytotoxic agents are added to the initial treatment of FSGS with corticosteroids.23
To attain a remission both the duration and dose of corticosteroid therapy are important 
factors. The median time until a remission is attained is 3-4 months, with the majority of 
patients entering a remission within 6 months.16;18-23;26 In addition, studies reporting higher 
remission rates are also characterized by a longer duration (2-4 months) of high dose 
treatment.21 FSGS is often considered to be steroid-resistant if no remission has occurred 
after 2-4 months of treatment with high dose prednisone.82 However, a significant number of 
patients do attain a remission four to six months after initiation of treatment with high dose 
prednisone. It is our experience that patients who eventually will develop a remission show 
some reduction in proteinuria within the first months of treatment. Therefore, one could 
argue that patients who respond to treatment with a significant reduction of proteinuria 
(>50%), should be treated for a total of six months before considering them resistant to 
corticosteroids.83;84
Few studies have addressed the best therapeutic approach for relapsing or corticosteroid-
dependent FSGS. The most important goal is to achieve a stable remission without the need 
for long-term prednisone. Both cyclophosphamide and cyclosporine appear to be beneficial, 
inducing a new remission in respectively 78% and 73% of patients.15 However, despite 
similar remission rates, a new relapse is more common after cessation of cyclosporine. In 
contrast, cyclophosphamide induces more stable remissions.85 Cyclophosphamide is usually 
given in a dose of 2 mg/kg/day for 2-3 months.  
Several studies have evaluated the effect of cytotoxic agents and cyclosporine in patients 
with corticosteroid resistant FSGS. The definition of steroid-resistance was quite variable in 
these studies, ranging from 4-16 weeks of treatment with prednisone. Alkylating agents do 
not seem to benefit patients with steroid-resistant FSGS. Retrospective studies in adults 
report low remission rates for alkylating agents compared to cyclosporine (11% vs 
40%).8;13;14;18;22;26;86-92 Two prospective trials been conducted in adults, comparing 6-12 
months of treatment with cyclosporine to placebo.87;88 Remission rate was significantly 
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higher in patients treated with cyclosporine (60-69%) compared to placebo (4-33%). 
However, within one year after discontinuation of cyclosporine, 60-80% of the patients had 
relapsed.  
The high relapse rate may decrease with prolonged use of cyclosporine. A study by Meyrier 
et al. suggests that continuing treatment with cyclosporine for one year in case of a remission 
followed by a slow tapering of the dose results in a more durable remission.82 However, this 
study included a low number of patients with FSGS with relatively mild FSGS lesions on the 
first renal biopsy. Therefore, the results should be interpreted with caution.  
A major concern is the nephrotoxicity of cyclosporine. Continuous use for more than 12 
months is associated with a significant increase in tubulointerstitial fibrosis. In most cases 
serum creatinine does not significantly change despite the aggravation of fibrosis.82 In 
addition, cyclosporine may accelerate the progression of FSGS. The number of glomeruli 
with sclerotic lesions increases significantly during treatment with cyclosporine, even in 
patients with a partial or complete remission. Cyclosporine nephrotoxicity is associated with 
higher doses of cyclosporine (> 5.5 mg/kg/day), a higher percentage of glomeruli with FSGS 
lesions and renal insufficiency prior to treatment. Therefore, cyclosporine dose should not 
exceed 5.5 mg/kg/day and treatment with cyclosporine should be limited to patients with a 
creatinine clearance > 60 ml/min/1.73 m2).82
Uncontrolled studies have demonstrated an improvement in both renal function and 
proteinuria for patients with HIV associated FSGS treated with corticosteroids.93-95 The data 
from these studies are conflicting regarding increased risk for serious infections and 
hospitalization. Nevertheless, a recent guideline for the management of chronic kidney 
disease in HIV infected patients advised to consider prednisone therapy at 1 mg/kg/day 
(maximum dose 80 mg/day) for 2 months, followed by 2-4 months taper in patients with 
HIV associated FSGS whose kidney function deteriorates despite use of antiretroviral 
therapy.96 Before considering corticosteroids active infection and active illicit intravenous 
drug use should be excluded. In patients with obesity, treatment with corticosteroids can 
even be detrimental, because of a further increase in body weight.  
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A new pathological classification of FSGS 
Recently D’Agati et al. proposed a consensus classification of FSGS based entirely on light 
microscopic examination of the renal biopsy.4 This schema presumes previous exclusion of 
FSGS conditions caused by glomerular scarring in the course of other primary glomerular 
diseases. Five light microscopic variants are defined, including FSGS not otherwise specified 
(NOS), perihilar variant, cellular variant, tip variant, and collapsing variant (table 2). 
Clinical presentation and sociodemographic findings differ between the FSGS variants (table
3).46;97;98 Collapsing FSGS has a predilection for Afro-Americans and typically presents with 
a severe nephrotic syndrome and substantial renal insufficiency. The tip variant has a low 
proportion of Afro-Americans. The majority of these patients also presents with a severe 
nephrotic syndrome (>90%). Renal function is usually preserved in patients with the tip 
variant. Perihilar FSGS has the lowest frequency of nephrotic syndrome. 
Table 2. Morphological variants of FSGS 
Subtype Characteristics Exclusion criteria
NOS variant At least one glomerulus with segmental increase in matrix 
 obliterating the capillary lumen. 
There may be segmental glomerular basement membrane 
 collapse without overlying podocyte hyperplasia 
Exclude perihilar, 
cellular, tip and 
collapsing variant  
Perihilar
variant 
At least one glomerulus with perihilar hyalinosis, with or 
 or without sclerosis  
> 50% of glomeruli with segmental lesions must have 
 perihilar sclerosis and/or hyalinosis 
Exclude cellular, tip 
and collapsing variant 
Cellular 
variant 
At least one glomerulus with segmental endocapillary 
 hypercellularity occluding lumina, with or without 
 foam cells and karyorrhexis 
Exclude tip and 
collapsing variant 
Tip variant At least one segmental lesion involving the tip domain 
 (outer 25% of tuft next to origin of proximal tubule) 
The tubular pole must be identified in the defining lesion 
The lesion must have either an adhesion or confluence of 
 podocytes with parietal or tubular cells at the tubular  
 lumen or neck  
The tip lesion may be cellular or sclerosing 
Exclude collapsing 
variant 
Collapsing 
variant 
At least one glomerulus with segmental or global collapse 
 and overlying podocyte hyperplasia  
None
Adapted from D’Agati et al.4
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Patients with FSGS NOS tend to have clinical parameters intermediate between the tip 
variant and perihilar FSGS, whereas cellular FSGS had clinical parameters intermediate 
between the tip variant and collapsing FSGS. 
Several retrospective studies have reported on the prognostic utility of the Columbia 
classification. A recent study by Chun et al. was unable to detect a significant difference in 
remission rate among patients with collapsing FSGS, FSGS NOS and the tip variant.27
However, the statistical power of this study to detect a clinically significant difference was 
low due to the small number of patient with the tip variant. In contrast, two other studies 
reported a lower remission rate and worse renal survival among patients with the collapsing 
variant compared to the tip variant and FSGS NOS.97;98 Patients with the cellular variant had 
remission rates between those of patients with the tip variant and collapsing FSGS.97 A study 
by our group showed a significant better renal survival in patients with the tip variant 
compared to FSGS NOS and perihilar FSGS.99 These studies suggest that the tip variant has 
a higher remission rate and a better renal survival compared to other FSGS variants. At 
present classification of FSGS should not influence therapeutic decisions.  
Table 3. Clinical characteristics of FSGS variants as reported in two North American and one West-
European study.97-99
NOS
(n=200)
Tip
(n=128)
Perihilar
(n=76)
Collapsing
(n=83)
Cellular 
(n=28)
Male (%) 55% 57% 55% 47% 61%
Age at biopsy (years) 43 ± 5 48 ± 7 50 ± 6 35 ± 4 48 ± 7 
Afro-American 30% 11% 20% 60% 32%
Serum creatinine 
concentration (ȝmol/l) 
177 ± 91 129 ± 46 166 ± 113 317 ± 133 179 ± 53 
Renal insufficiency* 49% 35% 38% 75% 57%
Serum albumin 
concentration (g/L)
31 ± 5 22 ± 5 37 ± 6 22 ± 5 23 ± 4 
Proteinuria (g/24 hours ) 5.5 ± 2.9 8.9 ± 3.7 4.7 ± 3.1 9.2 ± 2.7 10.9 ± 4.2 
Serum cholesterol 7.3 ± 2.0 8.2 ± 2.1 6.7 ± 1.8 7.7 ± 1.6 6.3 ± 2 
Nephrotic syndrome (%) 60% 94% 46% 85% 84%
Mean arterial blood 
pressure (mmHg) 
108 ± 14 111 ± 14 107 ± 13 106 ± 14 110 ± 10 
Hypertension (%) 69% 62% 80% 68% 70%
* The definition of renal insufficiency varied between studies, either a serum creatinine >106 ȝmol/l or > 135ȝmol/l
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Guidelines for diagnosis and treatment of FSGS  
The Dutch Federation of Nephrology recently published guidelines for the diagnosis and 
treatment of patients with FSGS. An outline of the most important diagnostic steps is given 
in figure 1. Medical history and family history are important to rule out secondary causes of 
FSGS. We do not advocate routine use of mutational screening. In patients with nephrotic 
range proteinuria ( 3 g/day), serum albumin is an important clinical parameter to distinguish 
between idiopathic FSGS and FSGS secondary to maladaptive responses. If serum albumin 
is inconclusive, electron microscopy examination can also help to distinguish between 
idiopathic FSGS and FSGS secondary to maladaptive responses. Although for comparative 
studies the use of the Columbia classification is advised, this should not influence treatment 
decisions.
Immunosuppressive therapy should be limited to patients with idiopathic FSGS.  
Since spontaneous remissions occur frequently in patients with idiopathic FSGS, a normal 
renal function and a selective proteinuria, a wait and see approach should be considered in 
such patients (figure 1). Otherwise, patients with idiopathic FSGS and a nephrotic syndrome 
should initially be treated with high-dose prednisone for 4-6 months (table 4). To induce a 
remission, the initial immunosuppressive therapy should consist of high dose prednisone (1 
mg/kg/day, up to 80 mg/day) for 4 months. In the elderly (>65 years) an alternate day 
regimen (2 mg/kg/day) is also effective with less complications.20
In patients with steroid-dependent or frequently relapsing FSGS, cyclophosphamide 2 
mg/kg/day for 2-3 months in combination with prednisone results in more stable remissions. 
In steroid resistant FSGS, the most effective treatment consists of cyclosporine (target trough 
levels 125–225 ug/l) for six months. Treatment should be limited to patients with a relatively 
well-preserved renal function, to prevent nephrotoxicity. In case of a remission cyclosporine 
treatment should be continued for one year and then slowly tapered off to prevent a relapse. 
In the absence of a remission cyclosporine should be stopped after six months. 
146
Guidelines on diagnosis and treatment of FSGS 
Figure 1.  Flowchart of diagnosis and treatment of FSGS
FSGS with
proteinuria     3 g/day
No underlying cause
Idiopathic FSGS
High dose prednisone
 in combination with
symptomatic therapy
Differentiating between idiopathic
and secondary FSGS not possible
Consider measurement of foot
process width
Family history of FSGS, drugs or
infections known to be associated
with FSGS (table 1)
Secondary FSGS
 If possible treat underlying cause
 Start symptomatic therapy
YesNo*
Serum creatinine < 115 µmol/l
en
Selectivity index < 0.2
NoYes
Diseases associated with
glomerular hypertrophy or
hyperfiltration (table 1)
Serum albumin
30 g/l
Serum albumin
 > 30 g/l
Serum albumin
 < 35 g/l
Serum albumin
  35 g/l
Serum albumin
variabeld t
t
Symptomatic therapy
Increase in serum creatinine > 25%
or
after 3 months of symptomatic therapy serum albumine < 20 g/l
or
after 3 months of symptomatic therapy proteinuria > 8 g/day
* Patients fulfilling these criteria are eligible for immunosuppressive therapy, although the effect of 
symptomatic therapy can be awaited for a short period of time. 
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Table 4. Immunosuppressive therapy in adult patients with primary FSGS  
Drug Dosing scheme
Initial treatment 
prednisone* 1 mg/kg/day in patients < 65 yr (up to 80 mg/day) or alternate day  
 prednisone 2 mg/kg (up to 150 mg ) in the elderly (> 65 years) for 4  
 months; if a remission is not attained but proteinuria decreases > 50%,  
 continue  treatment for a maximum of 6 months  
in case of a complete remission taper prednisone:  reduce dose with 10 mg  per
 2 weeks up to 0.15 mg/kg/day, next taper dose every 2-4 weeks with 2.5 mg 
In steroid-resistant patients taper prednisone over 6 weeks   
Therapy for early relapsing or steroid dependent FSGS 
cyclophosphamide†‡ 2 mg/kg/day in patients < 65 years or 1.5 mg/kg/day in the elderly (> 65 years) 
 for 3 months (round off to 25 mg), in case of young patients who wish to  
 have children limit treatment  to 2 months because of fertility risks  
and
prednisone* 1 mg/kg/day in patients < 65 years (up to 80 mg/day) or alternate day  
 prednisone 2 mg/kg (up to 150 mg ) in the elderly (> 65 years) for 3 months; 
in case of a complete remission taper prednisone after 3 months: reduce dose 
 with 10 mg per 2 weeks up to 0.15 mg/kg/day, next taper dose every 2- 
 4 weeks with 2.5 mg 
In steroid-resistant patients taper prednisone over 6 weeks 
Therapy for late relapse of FSGS 
These patients should receive another course of high dose prednisone as described under initial treatment 
Therapy for steroid-resistant FSGS 
cyclosporine§** 3-5 mg/kg/day: in two divided doses  
in case of a remission continue treatment for 1 year then try to slowly taper 
cyclosporine:  reduce cyclosporine dose  with 25% every 2 months  
If no remission by 6 months, discontinue cyclosporine treatment 
and
prednisone* 0.15 mg/kg/day for 4-6 months then taper off over 4-8 weeks 
* prevention of peptic ulcers: histamine H2-receptor antagonist or proton pump inhibitor 
† consider pneumocystis jiroveci pneumonia prophylaxis with cotrimoxazole 1 dd 480 mg  
‡ dose adjustment for cyclophosphamide: Leucocytes < 4,0*109 /l or platelets < 100*109/l: dose should be halved; 
 Leucocytes < 3,0*109 /l or platelets < 75*109/l: discontinue cyclophosphamide. If leucocytes return to normal, 
 restart cyclophosphamide at a dose 50 mg lower than the previous dose  
§ dose adjustment cyclosporine: reduce dose by 25-50% if there is: >30% increase in serum creatinine, over the 
 basal values; an increase in serum potassium level to 6 mEq/liter or more; a doubling of the levels of serum 
 transaminases, alkaline phosphatase, bilirubin and/or ȖGt; an arterial hypertension (>145/90 mmHg) refractory to 
 treatment; if the reduction of the dose did not normalize the abnormal parameters within two weeks, further reduce 
 CsA by 25 to 50%, if abnormalities still persist after two weeks discontinue CsA.  
** treatment with cyclosporine should be limited to patients with a creatinine clearance > 60 ml/min 
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Focal segmental glomerulosclerosis (FSGS) is an important cause of the nephrotic syndrome 
in adults. FSGS can be idiopathic (primary) or secondary to a still increasing number of 
causes. New underlying causes of FSGS have been identified and improved our 
understanding of the pathogenesis of FSGS. Nevertheless, FSGS remains a puzzling disease, 
with significant differences in prognosis and response to therapy, even in patients who seem 
to have a similar form of the disease.   
Initially, most authors emphasized the poor outcome in patients with FSGS, characterized by 
unresponsiveness to therapy and progression to end-stage renal disease (ESRD). However, 
more recent studies show a better response to immunosuppressive therapy and nowadays 
most authors have become more optimistic about the efficacy of immunosuppressive 
medication in idiopathic FSGS. Whether all patients with idiopathic FSGS need 
immunosuppressive therapy is unclear. Most textbooks still report a low spontaneous 
remission rate of 5% or less. However, literature data must be interpreted with caution since 
many studies have included patients with normo-albuminemia, evidence of secondary 
hyperfiltration-associated FSGS. Furthermore, many studies have included patients with 
severe renal insufficiency at presentation. Thus, the spontaneous remission rate is probably 
underestimated.  
Therefore, in chapter 2 we have studied the remission rate in 20 initially untreated patients 
with recently diagnosed idiopathic FSGS and a relatively normal renal function (serum 
creatinine < 135 ȝmol/l). These patients were defined by strict criteria to ensure only 
inclusion of patients with idiopathic FSGS. In this patient group, we observed a high 
spontaneous remission rate of 60%. In addition, we tried to define prognostic parameters to 
predict renal outcome. Predictors of renal function deterioration were a nonselective 
proteinuria (selectivity index >0.2) at renal biopsy and decreased concentrations of serum 
albumin at three months after renal biopsy. A higher percentage of sclerosis, synechia or 
hyalinosis on renal biopsy also predicted a worse renal prognosis.  
In chapter 3, we assessed the value of urinary parameters in predicting remission rate, renal 
survival and response to treatment in idiopathic FSGS. In 32 adult patients the following 
urinary parameters were evaluated: 24-hour proteinuria, fractional excretion (FE) of albumin, 
IgG, transferrin and ȕ2-microglobulin. A previous study suggested that FE IgG predicts 
remission rate, progression to ESRD and response to therapy. A cut-off value of 0.14%  
156
Summary
proved most discriminative, in fact a FE IgG > 0.14% predicted complete unresponsiveness 
to immunosuppressive medication. Therefore, we specifically evaluated the usefulness of a 
cutoff value of 0.14% for FE IgG. In our study remission rate and renal survival of patients 
with a FE IgG > 0.14% were not different from patients with a FE IgG  0.14%. The 
predictive value of FE of albumin, transferrin and ȕ2-m was also low. In untreated patients a 
FE ȕ2-m < 1% predicted a better renal survival. However, the number of untreated patients 
was low, and these results should be confirmed in a larger study. Nevertheless, our data show 
that a FE IgG > 0.14% is not invariably associated with a poor outcome in patients with 
idiopathic FSGS. Therefore a high FE IgG should not lead to therapeutic nihilism.    
A working group of renal pathologists has recently proposed a standardized pathological 
classification system for FSGS based entirely on light microscopic examination. The 
prognostic significance of this classification is not clear. In chapter 4 we present the data of a 
retrospective analysis in 93 adult patients with biopsy-proven FSGS to determine the clinical 
features and outcome of FSGS variants. The majority of the patients were native Dutch. The 
frequency of FSGS variants was: 32% NOS, 37% tip, 26% perihilar and 5% collapsing. The 
cellular variant was not present in our population, this is not surprising given the low 
prevalence of this variant (3-4.5%). Patients with the tip variant presented more often with a 
nephrotic syndrome, a better renal function and less histological damage on the renal biopsy. 
Five-year renal survival was significantly better in patients with the tip variant compared to 
FSGS NOS and perihilar FSGS (respectively 78%, 63% and 55%). Type of FSGS was an 
independent predictor of renal survival. Remission rate was also higher in patients with the 
tip variant, however, the difference with FSGS NOS and perihilar FSGS did not reach the 
level of statistical significance.   
FSGS may also be used as a prognostic marker in other glomerular diseases. Several studies 
suggested that the presence of FSGS in the renal biopsy of patients with idiopathic 
membranous nephropathy predicts a worse renal outcome. In chapter 5 we compared renal 
outcome and remission rate in patients with idiopathic membranous nephropathy with 
(iMN+FSGS;n=22) and without FSGS lesions (iMN;n=31). There was no difference in renal 
function deterioration between patients with and without FSGS lesions. Only serum 
creatinine, but not FSGS was an independent predictor of renal function deterioration or  
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progression to ESRD. At the end of follow-up a higher proportion of patients with iMN had a 
complete or partial remission. The difference with patients with iMN+FSGS was not 
statistically significant. There was no correlation between the extent of FSGS lesions and 
urinary ȕ2-microglobulin excretion. A meta-analysis of 6 studies analyzing the prognostic 
significance of FSGS showed a significantly higher remission rate for patients with iMN 
alone compared to patients with iMN+FSGS. However, these results should be interpreted 
with some caution, because of the considerable heterogeneity between studies. In comparison 
to other prognostic factors, such as ȕ 2-microglobulin, histological scoring of FSGS is 
inferior.  
Podocyte foot process effacement is a characteristic feature of proteinuric renal diseases. 
However, the degree of foot process effacement differs depending on the underlying disease. 
In minimal change nephrotic syndrome (MCNS) foot processes are diffusely effaced, 
whereas the degree of foot process effacement appears to vary between idiopathic and FSGS 
and FSGS secondary to maladaptive responses. In contrast to MCNS, a quantitative 
assessment of foot processes has never been performed in patients with FSGS. We have 
assessed the degree of foot process effacement, estimated by foot process width (FPW), in 27 
patients with FSGS (chapter 6). The results were compared to foot process width in MCNS 
and normal kidneys. Based on predefined criteria, a clinical diagnosis of idiopathic FSGS 
and FSGS secondary to maladaptive responses was made in respectively 13 and 12 patients. 
Two patients could not be classified based on clinical criteria. Foot process effacement was 
most severe in idiopathic FSGS, intermediate in MCNS. Foot processes were relatively 
preserved in FSGS secondary to maladaptive responses. On multivariate analysis, type of 
disease was the most important determinant of FPW. Our result also showed that FPW could 
be used to distinguish between idiopathic FSGS and FSGS secondary to maladaptive 
responses.
FSGS can recur after renal transplantation. Depending on the underlying cause, recurrence 
rate can vary from 0% in patients with secondary FSGS to 60% in patients with idiopathic 
FSGS. Without treatment these patients will progress to ESRD. In a previous retrospective 
study, we published the short-term effect of plasma exchange (PE) treatment in patients with 
recurrent FSGS. However, long-term results of PE are less well known. In chapter 7 we
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describe the extended follow-up (3.4 years) after PE in 13 patients with recurrent FSGS after 
renal transplantation. Ten patients, not treated with plasma exchange, served as historical 
controls. Baseline characteristics were similar. Out of 13 patients treated with PE, 11 patients 
(85%) attained a remission. Two patients (15%) lost their graft within the first month after 
transplantation. Four patients needed prolonged treatment with PE, because of a relapse. 
After a median of 58 PE sessions these patients attained a sustained remission. These patients 
were characterized by a late recurrence (> 30 days) after transplantation. In the untreated 
patients, proteinuria persisted and eventually graft failure occurred in all ten patients. Graft 
survival at 5-years after transplantation was significantly better for treated patients (85% vs 
30%). 
Plasma exchange (PE) is an effective treatment for recurrent FSGS after renal 
transplantation. However, after cessation of PE proteinuria can recur. Often these patients 
need continuous treatment with PE to maintain a remission. The role of immunosuppressive 
therapy in preventing or treating recurrent FSGS is unclear. In chapter 8 we describe a 42-
year old female patient with PE dependent FSGS after renal transplantation. Proteinuria was 
first discovered 6 weeks after renal transplantation  Plasma exchange at weekly intervals was 
necessary to maintain a stable remission. Proteinuria recurred the moment PE frequency was 
reduced. Because of severe osteoporosis, prednisone was replaced by other 
immunosuppressive medication. However, severe side effects necessitated reintroduction of 
prednisone. After cessation of PE, proteinuria did not recur. A second attempt to discontinue 
prednisone, again resulted in a relapse. Proteinuria disappeared after treatment with 
prednisone. These observations suggest that prednisone therapy may be essential in 
maintaining a sustained remission of proteinuria in patients with PE dependent recurrent 
FSGS after renal transplantation.  
Recently, successful use of rituximab, a chimeric monoclonal anti-CD20 antibody, was 
reported in a child with recurrent FSGS after renal transplantation. This drug may be an 
alternative therapy for patients with recurrent FSGS, especially in case of plasma exchange 
(PE) dependency. In chapter 9 we describe successful treatment with rituximab in a 24-year-
old female patient with recurrent FSGS after a second renal transplantation. Although 
treatment with PE induced a remission of proteinuria, repeated trials of cessation failed.  
159
Chapter 11
Because the patient remained PE dependent for more than 15 months, she was treated with 4 
weekly infusions of rituximab. After rituximab treatment, PE could be discontinued. 
Currently the patient is in partial remission. 
In chapter 10, we propose a diagnostic and therapeutic strategy in patients with FSGS based 
on the studies in this thesis and a review of the literature.  
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Focale segmentale glomerulosclerose (FSGS) is een belangrijke oorzaak van het nefrotisch 
syndroom bij volwassenen. Op basis van een etiologische classificatie wordt FSGS 
onderverdeeld in een idiopatische (primaire) vorm en een groot aantal secundaire vormen. 
Onze kennis over de pathogenese van FSGS is sterk toegenomen door de identificatie van 
nieuwe secundaire vormen. Desondanks blijft FSGS een complex ziektebeeld, met grote 
verschillen in prognose en reactie op behandeling, zelfs bij patiënten die eenzelfde vorm van 
FSGS hebben. 
De eerste ervaringen met het gebruik van afweeronderdrukkende medicijnen bij patiënten 
met FSGS waren teleurstellend. Mede hierdoor werd lang aangenomen dat patiënten met 
FSGS een slechte prognose hebben met een grote kans op het ontwikkelen van terminaal 
nierfalen. Recentere studies laten echter veel betere resultaten zien van behandeling met 
afweeronderdrukkende medicijnen bij patiënten met idiopatische FSGS. Dit heeft ertoe 
geleid dat tegenwoordig de meeste patiënten met idiopatische FSGS behandeld worden met 
afweeronderdrukkende medicijnen. Het is echter de vraag of alle patiënten met idiopatische 
FSGS zo behandeld moeten worden. De meeste leerboeken geven aan dat slechts bij 5% van 
de patiënten met idiopatische FSGS, de aandoening spontaan verdwijnt (spontane remissie). 
De gegevens waarop deze aanname is gebaseerd moeten echter met enige voorzichtigheid 
worden geïnterpreteerd, aangezien veel studies patiënten includeerden met een normaal 
serum albumine, hetgeen kenmerkend is voor secundaire FSGS, een vorm die niet reageert 
op afweeronderdrukkende medicijnen. Daarnaast includeerden veel studies patiënten met een 
gestoorde nierfunctie. Hierdoor wordt de kans op een spontane remissie waarschijnlijk veel 
lager geschat dan dat deze daadwerkelijk is.  
In hoofdstuk 2 hebben wij derhalve het remissiepercentage geanalyseerd van 20 initieel 
onbehandelde patiënten met idiopatische FSGS en een relatief normale nierfunctie (serum 
kreatinine <135 ȝmol/l). Van deze patiënten ontwikkelde de meerderheid (60%) een 
spontane remissie. Aansluiten hebben wij gekeken naar voorspellende factoren voor 
progressief nierfalen. Verslechtering van de nierfunctie werd voorspeld door een niet-
selectieve proteïnurie (selectiviteitsindex > 0,2) ten tijde van de nierbiopsie, een serum 
albumine >20 g/l op 3 maanden na de nierbiopsie en een hoog percentage sclerose, 
synechieën of hyalinose in het biopt.  
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In hoofdstuk 3 hebben wij bij 32 patiënten met idiopatische FSGS onderzocht wat de waarde 
is van het meten van de uitscheiding van eiwitten in de urine voor het voorspellen van een 
remissie, behoud van nierfunctie en de respons op behandeling. Bij 32 volwassen patiënten 
zijn de volgende eiwitten gemeten in de urine: totale hoeveelheid eiwit per 24 uur, 
fractionele uitscheiding (FE) van albumine, IgG, transferrine en ȕ2-microglobuline (ȕ2m). In 
een eerdere studie werd gesuggereerd dat FE IgG kan worden gebruikt als voorspeller van 
remissie, progressief nierfalen en respons op behandeling. Een drempelwaarde van 0.14% 
leek de hoogste sensitiviteit en specificiteit te hebben. Derhalve hebben wij in onze studie 
specifiek de betrouwbaarheid van een drempelwaarde van 0.14% onderzocht. Wij vonden 
echter geen verschil in remissiepercentage en progressie naar nierfalen tussen patiënten met 
een FE IgG meer en minder dan 0.14%. De voorspellende waarde van FE albumine, 
transferrine en ȕ2m waren ook laag. Bij onbehandelde patiënten bleek een FE ȕ2m < 1% een 
betere renale overleving te voorspellen. Gezien het kleine aantal onbehandelde patiënten in 
onze studie, is het wel noodzakelijk om deze resultaten te bevestigen in een grotere studie. 
Desalniettemin toont onze studie aan dat een FE IgG > 0.14% bij patiënten met een 
idiopatische vorm van FSGS niet altijd gepaard gaat met een slechte prognose. 
Immunosuppressieve behandeling moet derhalve niet onthouden worden aan patiënten met 
idiopatische FSGS en een FE IgG > 0.14%. 
Recent is tijdens een internationale consensus bijeenkomst een nieuwe histologische 
classificatie van FSGS ontwikkeld, gebaseerd op lichtmicroscopisch onderzoek. De klinische 
relevantie van deze classificatie is nog onduidelijk. In hoofdstuk 4 presenteren wij de 
gegevens van een retrospectieve studie bij 93 volwassen patiënten met FSGS, gericht op de 
klinische kenmerken en de prognose van de verschillende histologische varianten. De 
meerderheid van de patiënten in onze studie was van Nederlandse afkomst. FSGS NOS werd 
bij 32% van de patiënten gediagnosticeerd, de tip variant bij 37%, perihilaire FSGS bij 26% 
en de collaberende variant bij 5% van de patiënten. The cellulaire variant werd niet 
aangetroffen in onze populatie. Dit is niet onverwacht, gezien de lage prevalentie van deze 
variant (3-4,5%). Patiënten met de tip variant presenteren zich vaker met een nefrotisch 
syndroom, een betere nierfunctie en minder histologische afwijkingen in het nierbiopt. De 5-
jaars overleving was significant beter bij patiënten met de tip variant in vergelijking met 
patiënten met FSGS NOS en perihilaire FSGS (respectievelijk 78%, 63% en 55%). Het type  
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FSGS was een onafhankelijk voorspellende factor voor de ontwikkeling van 
nierinsufficiëntie. Patiënten met de tip variant hadden ook een hoger remissie percentage, 
hoewel het verschil met patiënten met FSGS NOS en perihilaire FSGS niet statistisch 
significant was. 
De aanwezigheid van FSGS laesies is mogelijk ook van voorspellende waarde bij andere 
glomerulaire nierziekten. In een aantal studies bij patiënten met idiopatische membraneuze 
glomerulopathie (iMN) werd gesuggereerd dat de aanwezigheid van FSGS in het nierbiopt 
gepaard ging met een grotere kans op progressief nierfunctieverlies. In hoofdstuk 5
vergeleken wij patiënten met iMN en FSGS laesies in het nierbiopt (iMN+FSGS;n=22) met 
patiënten zonder FSGS laesies (iMN;n=31) in het nierbiopt. Hierbij is specifiek gekeken naar 
progressief nierfunctieverlies en remissiepercentage. Het aantal patiënten met progressief 
nierfalen verschilde niet tussen patiënten met en zonder FSGS laesies. Alleen de 
serumkreatinine concentratie, maar niet de aanwezigheid van FSGS laesies, was een 
onafhankelijk voorspellende factor voor het ontstaan van progressief nierfunctieverlies. Aan 
het eind van de follow-up hadden meer patiënten met iMN een remissie bereikt, het verschil 
met patiënten met iMN+FSGS was echter niet statistisch significant. Er kon geen verband 
worden aangetoond tussen de aanwezigheid van FSGS laesies en de uitscheiding van ȕ2-
microglobuline in de urine. Een meta-analyse van onze studie en 5 soortgelijke studies bij 
iMN toonde een significant hoger remissiepercentage bij patiënten met iMN in vergelijking 
met patiënten met iMN+FSGS. Bij de interpretatie van deze resultaten moet wel rekening 
worden gehouden met de grote mate van heterogeniteit tussen de verschillende studies. De 
voorspellende waarde van FSGS laesies in het nierbiopt bij patiënten met iMN is minder 
goed in vergelijking met andere voorspellende parameters  zoals ȕ2-microglobuline. 
Versmelting van de voeten van podocyten is kenmerkend voor nierziekten die gepaard gaan 
met eiwitverlies in de urine. De mate van voetjesversmelting is echter afhankelijk van de 
onderliggende aandoening. Bij minimal change nephrotic syndrome (MCNS) zijn de voetjes 
totaal versmolten, terwijl de mate van voetjesversmelting sterk wisselt bij idiopatische FSGS 
en FSGS secundair aan overbelasting van nefronen. In tegenstelling tot MCNS, is de mate 
van voetjesversmelting bij FSGS nooit door middel van een kwantitatieve meting 
geanalyseerd. Wij hebben bij 27 patiënten met FSGS de mate van voetjesversmelting  
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bepaald door middel van meting van de breedte van de podocytenvoetjes (PVB) (hoofdstuk 
6). De resultaten werden vergeleken met de PVB bij MCNS en normale nieren. Met behulp 
van vooraf opgestelde klinische criteria werd bij de patiënten met FSGS onderscheid 
gemaakt tussen idiopatische FSGS (n=13) en FSGS secundair aan overbelasting van 
nefronen (n=12). Bij 2 patiënten was het niet mogelijk om op grond van klinische criteria 
onderscheid te maken tussen idiopatische en secundaire FSGS. De mate van 
voetjesversmelting was het meest prominent bij patiënten met idiopatische FSGS en milder 
bij patiënten met MCNS. De voetjes waren redelijk normaal bij patiënten met FSGS 
secundair aan overbelasting van nefronen. De onderliggende aandoening bleek bij 
multivariate analyse de meest belangrijke voorspeller van de breedte van de 
podocytenvoetjes. Daarnaast bleek dat de breedte van podocytenvoetjes ook goed gebruikt 
kan worden om onderscheidt te maken tussen patiënten met idiopatische FSGS en FSGS 
secundair aan overbelasting van nefronen.  
FSGS kan na transplantatie terugkomen in de transplantaatnier. Afhankelijk van de 
onderliggende oorzaak, varieert de recidiefkans van 0% bij patiënten met secundaire FSGS 
tot 60% bij patiënten met idiopatische FSGS. Zonder adequate behandeling ontwikkelen 
deze patiënten uiteindelijk terminaal nierfalen. In een eerdere retrospectieve studiebij 
patiënten met een recidief FSGS na niertransplantatie, hebben wij de korte termijn resultaten 
laten zien na behandeling met plasmaferese. De resultaten van plasmaferese op de langere 
termijn  zijn echter onduidelijk. In hoofdstuk 7  beschrijven wij een langdurige follow-up 
(3,4 jaar) na behandeling met plasmaferese bij 13 patiënten met een recidief van FSGS in de 
transplantaatnier. De gegevens van deze patiënten werden vergeleken met een historische 
controlegroep van 10 patiënten met een recidief FSGS, die nooit zijn behandeld met 
plasmaferese. De uitgangskenmerken van de beide groepen waren niet verschillend. Van de 
13 met plasmaferese behandelde patiënten bereikten elf patiënten (85%) een remissie van de 
proteïnurie. Bij twee patiënten leidde het recidief tot volledig transplantaatfalen. Vanwege 
een recidief na de eerste plasmaferese behandeling, was bij vier patiënten  langdurige 
behandeling met plasmaferese noodzakelijk. Na een mediane behandeling met 58 
plasmaferesesessies, bereikten deze patiënten uiteindelijk ook een stabiele remissie. Deze 
vier patiënten werden gekenmerkt door een laat optredend recidief (> 30 dagen na de 
niertransplantatie). In de onbehandelde historische controlegroep persisteerde de proteïnurie  
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en uiteindelijk ging de functie van het transplantaat bij alle patiënten verloren. De 5-jaars 
overleving van de transplantaatnier was significant beter bij patiënten behandeld met 
plasmaferese (85% vs 30%). 
Plasmaferese is een effectieve behandeling bij een recidief van FSGS in de transplantaatnier. 
Echter na staken van de plasmaferese kan een nieuw recidief optreden. Bij deze patiënten is 
vaak langdurige behandeling met plasmaferese noodzakelijk om een remissie te handhaven. 
De rol van de immunosuppressieve behandeling in het voorkomen danwel behandelen van 
het recidief is onduidelijk. In hoofdstuk 8 beschrijven wij een 42 jarige patiënte met 
plasmaferese-afhankelijke FSGS na niertransplantatie. Het recidief ontstond 6 weken na de 
niertransplantatie. Wekelijkse behandeling met plasmaferese was noodzakelijk om een 
stabiele remissie te handhaven. De proteïnurie recidiveerde zodra de plasmaferese frequentie 
werd verlaagd. Vanwege ernstige osteoporose werd de  prednison vervangen door andere 
immunosuppressieve medicatie. Deze medicatie veroorzaakte echter ernstige bijwerkingen, 
waardoor opnieuw gestart moest worden met prednison.Vervolgens bleek de proteïnurie niet 
terug te komen na staken van de plasmaferese behandeling. Een tweede poging om de 
prednison te stoppen leidde opnieuw tot een recidief van de proteïnurie. Na starten met 
prednison verdween de proteïnurie weer. Deze observaties suggereren dat bij patiënten met 
een recidief FSGS na niertransplantatie behandeling met prednison essentieel is om een 
remissie te handhaven. 
Recent is bij een kind met een recidief FSGS na niertransplantatie, succesvolle behandeling 
gerapporteerd met rituximab, een chimerisch monoclonaal antilichaam gericht tegen het 
CD20 antigeen op B-lymfocyten. Rituximab kan mogelijk als alternatieve behandeling 
dienen bij patiënten met een recidief FSGS, met name in het geval van plasmaferese 
afhankelijkheid. In hoofdstuk 9 beschrijven wij succesvolle behandeling met rituximab bij 
een 24 jarige patiënte met een recidief FSGS na een tweede niertransplantatie. Hoewel 
behandeling met plasmaferese resulteerde in een remissie van de proteïnurie, lukte het niet 
om de plasmaferese te staken. De patiënte werd behandeld met rituximab, één keer per week 
gedurende 4 weken, aangezien zij gedurende meer dan 15 maanden afhankelijk bleef van 
plasmaferese. Na de behandeling met rituximab kon de plasmaferese worden gestaakt. Op dit 
moment heeft patiënte een partiële remissie.  
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In hoofdstuk 10 presenteren wij een diagnostische en therapeutische behandelstrategie voor 
bij patiënten met FSGS, gebaseerd op de studies gepubliceerd in dit proefschrift en een  
analyse van de literatuurgegevens 
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